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Abstract 
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
0DQDJHPHQW*XLGHOLQHVWKHGHILQLWLRQRI&23'LV³a disease state 
characterised by airflow limitation that is not fully reversible. The airflow is usually 
progressive and associated with inflammatory responses of the lungs to noxious 
particles and gases.´ It is becoming an increasing prevalent problem worldwide, with 
the incidences of morbidity and mortality continually increasing and promoting a 
lower quality of life in individuals that continue to suffer from it.  
To date, there is still an incomplete understanding of the pathogenesis of the disease 
resulting in poor diagnosis and treatment plans for COPD that are insufficient in 
preventing a decline in lung function. In recent years, research has focussed on 
discovering a set of biomarkers that could improve our understanding of pathogenesis 
of disease. The ability to measure a vast array of biomarkers simultaneously is highly 
desirable however the cost associated is somewhat prohibitive. Current methods 
centre on measuring the presence or absence of multiple biomarkers in patient 
samples compared to controls. 
As COPD is a multi-component disease which encompasses diseases such as 
emphysema and chronic bronchitis, it may be necessary to look at biomarker patterns 
within each disease category. A variety of immune effector cells are known to lead to 
the pathophysiology of COPD including neutrophils, macrophages and CD8 T-
lymphocytes that are all documented to be increased in number and contribute to the 
inflammatory process.  
Protein microarrays are used as a measurement tool to determine and quantify the 
presence or amount of proteins that exist in biological samples (i.e. blood, sputum, 
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urine etc). The wide use of protein microarray technology has advanced diagnosis and 
management of multifactorial diseases such as cancer, autoimmunity and allergy.  
At present, multiple microarray kits are available to researchers at a large cost which 
make it impractical for most research groups to investigate multiple biomarkers of 
interest simultaneously. Here we show development, validation and implementation of 
our bespoke in-house microarray platform enabling quantitative and simultaneous 
analysis of multiple protein biomarkers at a reasonable cost. The methodology is 
based on the traditional sandwich ELISA; antibodies are immobilised on poly-L-
lysine coated glass and signals amplified and quantified through fluorescence.  
The accuracy and reproducibility of the in-house microarray was investigated using 
the guidelines outlined by the Food and Drug Administration (FDA) for 
pharmacokinetic assay validation. The assay was shown to have high reproducibility 
with assay accuracy between 80-120% and precision within 20% coefficient of 
variation, except in very low abundant cytokines such as IL-10, where the CVs were 
higher due to the variation at the lowest concentrations in sera. Importantly there were 
no significant differences between ELISA and microarray. 
This microarray platform was then used to study a selection of healthy controls 
(n=12), healthy smoking controls (n=36) and COPD patients (n=60) to see if there 
was a difference in the expression of the 16 biomarkers tested. The overall analysis of 
the 16 biomarkers investigated in this study, a significant increase in expression of 
eotaxin-2 was observed in the sera those that have COPD compared to healthy 
controls and healthy smoking controls. This suggests that eoxtaxin-2 may potentially 
be responsible for the recruitment and activation of multiple cytokines which in turn 
lead to the inflammatory cascade observed in COPD.  
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COPD severity is divided into four categories according to international guidelines 
outlined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). This 
is often known as stage 1 (mild), stage 2 (moderate), stage 3 (severe) and stage 4 (very 
severe). This is based on the forced expiratory volume per second (FEV-1%). 
Interestingly when investigating the different severities of GOLD in COPD, it was 
observed that at the highest stage of GOLD (stage 4), the expression of 15 of the 16 
biomarkers had dropped significantly in comparison to the other stages. This may 
suggest that at this point of the disease process, the immune system may in fact be 
suppressed in alliance to hypoxia experienced by an individual.   
Additionally it has to be acknowledged that the medication that the COPD patients 
were on were not available prior to analysis. It has to be taken into account that 
patients at GOLD stages 3 and 4 could be likely to be on a high dose of inhaled 
corticosteroids, which are immunosuppressive which would lead to drop in the 15 
cytokines observed. However without the information available, it cannot be 
definitive to make such conclusions.  
Hence this work offers an understanding into the development of a bespoke 
microarray platform that is capable of investigating protein biomarkers in any disease 
setting.  
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Chapter 1: General Introduction 
1.1: Chronic Obstructive Pulmonary Disease 
1.1.1 COPD general introduction and definition 
&KURQLF REVWUXFWLYH SXOPRQDU\ GLVHDVH &23' FDQ EH GHILQHG DV ³D GLVHDVH VWDWH
characterised by airflow limitation that is not fully reversible. The airflow is usually 
progressive and associated with inflammatory responses of the lungs to noxious 
SDUWLFOHVDQGJDVHV´ [1, 2]. COPD has become a major worldwide problem with the 
incidences of morbidity and mortality continually increasing and promoting a lower 
quality of life of the individuals that continue to suffer from it. In the United States, 
COPD has become the 4th highest cause of mortality and morbidity [3-6]. Additionally 
in the United Kingdom, COPD is said to be the 3rd highest cause of mortality and 
morbidity [7, 8] . 
1.1.2: Pathophysiological symptoms 
The sub-phenotype of COPD include emphysema and chronic obstructive bronchitis 
(Figures 1 and 2). Bronchitis causes a narrowing of the airway lumen which limits 
airflow. Emphysema causes a reduction in elasticity recoil due to damage of lung 
alveoli, which cause small pockets of air being trapped in the lungs, which gives rise 
to symptoms such as shortness of breath [5]. Some of the hallmarks of COPD include 
ineffective tissue repair, and a mass influx of inflammatory cells which in turn leads to 
increased cell death (apoptosis) [9, 10].  
Two of the main symptoms observed in those that smoke and have COPD are 
breathlessness (during normal day activities) and a chronic cough. Additionally 
symptoms include reoccurring lung infections, weight loss and the use of accessory 
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muscles to breathe [11, 12]. The smaller airway diseases in smokers can persist for 
many years without exhibiting any clinical symptoms and can only be diagnosed 
through spirometry [13-15] 
 
 
Figure 1: COPD is a multiple component disease setting which is a combination of smaller 
diseases such as emphysema and chronic bronchitis. 
The symptoms that manifest from such diseases are used as possible indicators of the 
overall disease state. Asthma shares many of the clinical features of COPD such as 
wheezing and airflow obstruction. In many cases COPD is often misdiagnosed as 
asthma due to the close overlapping of clinical symptoms [16-18]. 
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Figure 2: The pathogenesis of COPD. 
Cigarette smoke leads to the activation of COPD (A) which in turn leads to the 
chemotactic recruitment and activation of neutrophils (B). This releases oxidants like 
NO which over time leads to tissue damage in the lungs (C) giving rise to 
emphysema. Activation of bronchial epithelial leads to fibroblast activity (D) leading 
to chronic bronchitis and bronchiolitis (E). Adapted from [19]. 
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1.1.3: Diagnosis 
In terms of diagnosis, spirometry is currently used to measure lung function. A key 
characteristic of COPD includes a reduced forced expiratory volume (FEV1) which is 
partly due to a combination of emphysema as well as other airway diseases [20]. 
Furthermore, FEV1 values are often used to grade the severity of COPD. If an 
individual has a FEV1 value of 80%, it is thought their pathogenesis of the disease can 
be classified as being mild whilst, if the percentage drops down to 30%, then the 
individual has severe COPD (Table 1) [21].  
Chest X-rays are used as possible indicators of those with emphysema but this 
technique is inconclusive as a predictor of the severity of COPD. An X-ray will point 
to pockets of trapped air which is associated with emphysema [22, 23]. Alternative 
tests for diagnosis include a normal exercise test (such as the 6 minute walk test), 
which indicate breathlessness and also there are questionnaires on the quality of life 
which indicates the states of mind with those that suffer from the disease [24, 25].     
As the disease is progressive, there is a continuous decrease in airflow which, over a 
period of time, leads to disability and premature death. Environmental factors 
LQIOXHQFH DQ LQGLYLGXDO¶V VXVFHSWLELOLW\ WR &23' LQFOXGLQJ GXVW JDVHV DQG LQ
particular cigarette smoke which is the leading cause of the disease [26].  
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Table 1: outlines the key stages of COPD progression in association with the characteristics 
of the disease with reference to FEV1/FVC1 values.  
COPD Diagnostic Stages: Characteristics of Disease 
1) Mild 
 
FEV1/FVC1<0.70 
FEV1 predicted 
 
 
2) Moderate COPD 
  
FEV1/FVC1<0.70 
)(91 predicted 
 
 
3) Severe COPD 
FEV1/FVC1<0.70 
30)(9150% predicted 
 
 
4) Very severe COPD 
FEV1/FVC1<0.70 
FEV1 predicted plus chronic 
respiratory failure 
FEV130% predicted 
 
 
Spirometric classification of COPD severity based on postbronchodilator 
FEV1 according to Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) Management Guidelines 2011.  
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1.1.4: Treatment 
Currently many of the treatments for COPD are insufficient in preventing a decline in 
lung function. The main treatment involves the cessation of smoking. In terms of 
pharmaceutical treatments, the leading drugs include nicotine inhibitors, 
bronchodilators and Bupropion which can relieve the craving symptoms associated 
with giving up smoking. Furthermore increasing the price of cigarettes as well as 
increased health warnings are being pursued in a bid to reduce the number of people 
smoking both nationally and worldwide [27] [28]. Treatment is often centred on 
treatment that is based primarily for asthmatics and hence not very specific for those 
with COPD [29-31]. 
Interestingly in terms of preventing chronic inflammation, anti-inflammatory drugs 
such as steroids are ineffective due to the resistance induced by macrophages 
producing peroxynitrate [32]. Additionally cytokines such as IL-8 and TNF-Į can also 
induce steroid resistance. Theophylline is currently used to treat individuals with a 
more severe spectrum of the disease, often in combination with bronchodilators [33]. 
It has been found to be successful as it can reduce the number of neutrophils and also 
reduce the overall concentration of IL-8 which is a key chemoattractant in the 
recruitment of these cells of the immune system. Also Theophylline is thought to 
increase the activity of histone deacetylases (HDACs) which can regulate the 
transcription of inflammatory cells [34] [35]. 
It has been shown that bronchodilators can increase FEV1 levels in those with COPD 
by up to 15-20% which is similarly observed in asthmatics. Those used specifically 
for COPD involve beta antagonists, anticholinergics and methylxanthines [36].  
As COPD is an irreversible airflow disease, whilst there is an improvement in FEV1 
levels in such cases, lung function will never return to normal. Alternatively, oral 
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corticosteroids have been used to treat COPD patients [37]. The net effects of these 
drugs show improved spirometry results and better clinical outcomes in those with 
acute exacerbations of the disease [38]. In patients with COPD who are at a higher 
stage of the disease will be more likely to be on a higher dose of inhaled 
corticosteroids or other medications which can affect the immune system. Hence this 
has to be taken into account when measuring biological samples from patients. 
1.1.5: Smoking Risk factors 
Smoking is the leading cause of development of COPD. Approximately 25% of heavy 
smokers will at some point in their lives develop symptomatic COPD [39, 40] [41]. A 
cigarette contains many thousands of chemicals (including nicotine, tar and carbon 
monoxide) that serve to alter the mechanisms that are responsible for protection and 
repair of tissues that are regularly damaged by inhalation [42, 43].  
Cigarette smoke in particular contains many oxidants and once inhaled into the lungs 
can cause an imbalance in the protective antioxidants that are present in lung tissue. 
Specifically reactive oxidative species include nitrogen oxide (NO) and peroxynitrate. 
NO can cause a dilatation of vascular and bronchiolar smooth muscle [44-46]. 
The primary antioxidant in the lungs is glutathione. Additionally there are superoxide 
dismutases (SODs) which are a group of enzymes whose function is to combat the 
threat of free radicals, which in this case would be from cigarette smoke [47, 48]. 
Specifically, manganese SOD is found in the alveoli, and in combination with other 
SODs, can convert highly reactive species, such as superoxide and nitrogen oxide, 
into less harmful substances that can be managed by the body. The activity of this 
enzyme is vastly increased in tissue samples of those who smoke and have COPD 
[49].  
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Individuals are encouraged to stop smoking as soon they are diagnosed with COPD. 
Many patients believe that once they have COPD the damage to the lungs has been 
done, that smoking cessation is not required. However as the Fletcher-Peto plot shows 
(Figure 3) the importance of smoking cessation could extend the number of years an 
individual can survive. However it has been noticed that despite the cessation of 
smoking, lung inflammation still persists in individuals, which could suggest that 
these reactive species may be present and or can be produced independent of cigarette 
smoke [50].   
 
Figure 3: The Fletcher-Peto Graph outlining the benefits of smoking cessation.  
The graph above clearly illustrates the importance of smoking cessation even at a late 
stage of COPD could extend the expected life span. Adapted from [51].  
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It is thought that histone deacetylase (HDACs) play a role in COPD. Multiple 
inflammatory genes are controlled by the acetylation of histones (to which DNA is 
wrapped around). Hence acetylation of key histones such as histone 4 allows 
transcription factors to become bound to the DNA and thus can begin transcription 
and eventually lead to the expression of inflammatory genes. This process is regulated 
by HDACs [52]. In those that smoke and have COPD, it is thought that this regulatory 
process is disrupted by the presence of peroxynitrate brought on by oxidative stress 
[53]. This in turn causes a decrease in HDAC activity which ultimately causes the 
release of inflammatory mediators in the lungs [54] [55].   
The lung epithelium provides a protective barrier between the lung tissue and the 
external environment. It also provides a large surface area for the exchange of gases 
and in COPD it allows the transfer of cigarette smoke into the body. This smoke can 
cause damage to the lung tissue and thus the body responds by repairing and 
remodelling the epithelium to protect itself from subsequent injury [56] [57]. The 
inflammatory process leads to bronchiolar constriction through the release of 
mediators such as cytokines which has a direct effect on the airway smooth muscle 
cells. In addition to the mass infiltration of cells, the T-lymphocytes and neutrophils in 
the lung tissue cause a thickening of the airway walls which could conversely lead to 
airway narrowing, limiting airflow. The mechanism of infiltration depends upon 
tachykinins which recruit neutrophils through a chemotactic gradient and adhesion of 
neutrophils to the walls. This situation is worsened in conjunction with cigarette 
smoke which can accelerate the process. Additionally it has been observed there is an 
increase of number of goblet cells. Neutrophils cause goblet cells to degranulate 
through the release of elastase and cathepsin G [58]. 
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1.1.6: Non-Smoking Risk factors 
Whilst smoking is an established risk factor in COPD, it has emerged recently that up 
to 45% of patients with COPD have never smoked [59, 60]. Other factors which may 
cause onset of COPD include exposure to indoor and outdoor air pollutants, 
workplace exposure to dust and fumes and poor socioeconomic status [61]. In less 
developed countries, approximately half of all households and the vast majority of 
rural households use biomass fuel (such as charcoal and animal excrement) with coal 
as their main source of domestic energy. Many billions of people are exposed to 
second hand smoke from biomass fuel which may contribute as an increased risk 
factor to a variety of irreversible lung diseases. With approximately 3 billion people 
exposed to smoke from biomass fuels, it is now thought that biomass smoke is a 
leading worldwide risk factor for COPD [62, 63]. 
Due to the rising cost of energy bills in developed countries such as Australia, Canada 
and certain parts of USA, households have switched to using a variety of biomass 
fuels including wood and charcoal for heating purposes. In countries like Nepal, 
Pakistan and India, women use biomass fuel for cooking and have reduced respiratory 
function to those who do not use such fuels [64] [65]. 
Biomass is a poorly combustible fuel which is derived from both plant and animal 
sources. Due to poor combustion of the materials, highly toxic concentrations are 
enclosed in domestic households that are harmful to the health of those who are 
exposed to them [66] [67]. Chemicals released as a consequence of burning biomass 
fuel include carbon monoxide, sulphur dioxide and a variety of carcinogens [68].  
Additionally it is suggested an increase in COPD is associated with occupational 
exposure to dust, fumes and toxic gases in the workplace [69]. It is thought that the 
effect of such exposure is worse than that of smoking [70-72]. Those who are 
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consistently exposed to such working conditions have a high prevalence for 
developing COPD than that of those who are sufficiently protected from such 
occupational hazards. For example railroad workers can inhale diesel exhaust fumes 
which once inhaled deep inside the lung leads to pulmonary inflammation [73]. 
Additionally chemical exposure as well as crop and animal farming are said to be risk 
factors associated with COPD [74]. 
Poor socioeconomic status is another risk factor that is associated with COPD. This 
often encompasses a variety of smaller factors, including poor nutrition whereby an 
individual is consuming insufficient antioxidants [75] [76].  
1.2. Immune Cells Involved in COPD 
A variety of immune effector cells are known to lead to the pathophysiology of 
COPD. There is a mass infiltration of cells like T-lymphocytes and neutrophils into 
the lung tissue that causes a thickening of the airway walls which could conversely 
lead to airway narrowing and limitation [77]. Additionally, macrophages and 
epithelial cells are thought to play a substantial role in the disease process (Figure 4).  
One of the main differences between smokers with COPD and those without COPD is 
the intensity of the immune response rather than the nature of the inflammatory 
responses [78]. The key chemokines involved in the recruitment of T-cells include IL-
ȕ0,3-ĮDQG ,/-8 [79]. Additionally the presence and activation of these T-cells 
can contribute to emphysema. It has been shown that CD8 T-cells have the capability 
to produce cytokines and chemokines such as IFN-Ȗ DQG IP-10 that upregulate 
metalloproteinases (such as MMP-12) that can effectively lead to emphysema [80]. 
Once the disease had been fully established the CD8+ subset of effector cells are 
selectively recruited, over neutrophils [81].   
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1.2.1: Macrophages 
 
Macrophages are part of the innate immune system and are often one of the first 
immune cells involved in airways defence against infection and are thought to play a 
prominent role in COPD. Macrophages have several roles in COPD including the 
recruitment of neutrophils and activation of CD8 T-lymphocytes as well as releasing a 
host of chemotactic factors such as IL-8, CXCR3 and CCL2 etc. Additionally 
macrophages release TGF-ȕ WKDW are involved in airway remodelling and also can 
release IL-6 that induces hepatocytes to produce acute phase proteins [45, 82, 83]. 
 
1.2.2: Neutrophils 
 
Neutrophils are documented to be increased in number and contribute to the 
inflammatory process in COPD. Additionally increased neutrophils levels have been 
oEVHUYHG LQ WKH VSXWXP RI WKRVH ZKRP DUH Į1-antitrypsin deficient compared to 
normal healthy subjects [84, 85]. A number of different chemotactic factors, such as 
IL-8, leukotriene B4 and CXCL5, are involved in the recruitment of neutrophils which 
contributes to acute exacerbations in COPD. Neutrophils can lead to the activation of 
proteases such as elastases and matrix-metalloproteinases that can lead to excess 
mucus hypersecretion, proteolysis and TGF-ȕDFWLYDWLRQ [86] [87] which in turn leads 
to inflammation and the release of proinflammatory cytokines and chemokines. 
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1.2.3: T-Lymphocytes 
 
In COPD it is thought that the different subsets of T-lymphocytes; CD8+ T-cells, 
CD4+ T-cells, T-regulatory cells (Tregs) and TH-17 cells all could contribute to the 
pathogenesis of the disease. 
In particular CD8+ T-cell lymphocytes are thought to participate in the inflammatory 
response in the airways of COPD patients of which there are two major mechanisms 
which contribute to CD8 T-cell cytotoxicity [88]. The first is dependent upon the 
release of cytotoxic proteins such as perforin and granzyme. These proteins cause cell 
lysis through the creation of pores in the lipid bilayer of target cells that disrupts their 
polarity and leads to immediate cell death. The second mechanism is through the 
expression of the Fas-ligand that is able to induce apoptosis by binding to the Fas 
receptor on target cells [89].   
CD8 T-cells are found in elevated numbers at various sites in patients with COPD, 
including the draining lymph nodes, lung parenchyma and many of the blood vessels 
that lead to the lungs [4, 90].  
An exacerbation of COPD could possibly occur due to infectious agents like bacteria 
and viruses that lead to lower respiratory tract infections. This could partly explain the 
reason for high numbers of CD8+ T-cells found in lung tissue. These T-cells cause 
alveolar damage and their homing to these sites are dependent upon cytokines, 
selectins and integrins. Even after infections, CD8 T-cells can still persist at these sites 
as memory cells [91] (Figure 4).  
CD4+ T-cells are responsible for controlling downstream immune processes by 
activating cytokines that are involved in the amplification of the immune response in 
COPD. CD4+ T-cells are responsible for eliciting the development of the adaptive 
immune response as well as promoting the survival of CD8 T-cells [92]. It has been 
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shown in various publications that the ratio of CD4+/CD8+ T-cells is lower in those 
that have an exacerbation in COPD compared to those with stable COPD [93] [94] 
[95]. Additionally a publication by Gupta et al have shown there to a lower ratio of 
CD4+/CD8+ T-cells in COPD patients compared to healthy controls [96].  
T-regulatory cells (Tregs) are a subset of CD4 lymphocytes have been thought to play 
a role in the immune regulation of COPD. There are two main lineages of CD4 + 
Tregs; natural Tregs (nTregs) and inducible Tregs (iTregs) [97].  
In particular Tregs serve to provide protection to the body against overactive immune 
responses through the production of immune-modulatory cytokines such as IL-10 that 
inhibit T-cell proliferation [98, 99]. Additionally IL-10 is thought to suppress the 
production and induction of Th1 cytokines such as TNF-ĮDQG,/-6 and chemokines 
such as IL-8 and MIP-1 which are responsible for neutrophilia in COPD [100]. Tregs 
can also produce novel anti-inflammatory markers such as IL-35. In rodents it has 
been shown that IL-35 can inhibit Th17 production however this has not been shown 
in humans [101].  
As COPD is an inflammatory disease, it was hypothesised that their numbers would 
be reduced in those with the disease. Interestingly, recent research has shown that 
increased levels of nTregs cells were found in patients who have an exacerbation in 
COPD and also those who have emphysema [102]. Overall there is growing evidence 
that whilst there is an increase in the number of Treg cells in those with COPD, 
however these cells are dysfunctional and are unable to alter the balance between pro- 
and anti-inflammatory cytokines. This is further justified where healthy smoking 
controls who do not have COPD, have elevated numbers of Tregs in their lungs but 
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the cells are more effective in regulating the level of inflammation in response to 
cigarette smoke [103].  
Th17 (T-helper-17) cells are another subset of CD4 T-lymphocytes. Th17 cells are 
suggested to induce strong pro-inflammatory cytokines and chemokines such as IL-6 
and IL-8 respectively. Cigarette smoke can directly lead to the upregulation of 
chemokines that are associated with Th17 cells which lead to the inflammation 
associated with COPD [104]. The main cytokine that is secreted by Th17 cells are IL-
17. The IL-17 cytokine family has 6 cytokines in its family from IL-17A-F which are 
secreted from a variety of immune effector cells including antigen presenting cells and 
B-cells [105]. 
Two additional cytokines that are produced from Th17 cells are IL-21 and IL-22. 
Whilst IL-21 is said to be involved in a positive feedback loop that aids the 
amplification of Th17 cells, IL-22 is said to be involved in many autoimmune diseases 
as well as COPD [106]. 
IL-23 may also plays a role in the maintenance of Th17 cell through the induction and 
release of both IL-17 and IL-22 [107]. IL-23 is expressed in chronic inflammation and 
shown by immunohistology in those with stable COPD [108].  Work with murine 
models have shown there to be increased level of expression of IL-17 in the lungs 
upon exposure of cigarette smoke [104]. 
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1.2.4: Epithelial Cells 
 
The surface of airway epithelial is a mixture of basal cells, ciliated cells, Clara cells as 
well as goblet cells. The airway epithelium forms a rigid barrier through intracellular 
epithelial junctions. These junctions serve to protect against pathogens and noxious 
particles which are inhaled through the lungs [109].  
When airway epithelial cells are exposed to cigarette smoke there is a reduction in the 
trans-epithelial electric resistance (TEER) [109]. This reduces the efficiency of the 
barrier function making it more prone to attack from pathogens.  Cigarette smoking 
induces the upregulation of growth receptor gene 1 (Egr-1) in epithelial cells [110]. 
This in turn leads to the activation of pro-inflammatory cytokines such as TNF-Į and 
IL-1 as well as leads to the production of IL-8 and mucins [111] (Figure 4). 
Recent publications have shown that pathogens such as rhinovirus (RV) and 
adenovirus (AV) cause injury to the epithelial cell lining in the airways which cause a 
deterioration in lung function which in turn exacerbate the effects of COPD [112, 
113]. 
The immune system responds to these viruses by producing a variety of different 
inflammatory chemokines and cytokines such as RANTES, GM-CSF and MCP-1. 
This leads further to the recruitment of other immune effector cells such as CD8+ T-
cells and NK-cells which amplify the existing inflammatory processes that leads to 
pulmonary and systemic inflammation in the lungs [114]. 
A key feature of COPD in the lung is mucus hypersecretion. Normally mucus acts as a 
physical barrier to trap pathogens in the lungs and is cleared by the immune system.  
Cigarette smoke causes the apoptosis of ciliary epithelial cells, the activation of 
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capases and the IL-5Į GHSHQGDQW SDWKZD\ ZKLFK UHVXOWV RQ WKH RYHUVHFUHWLRQ RI
mucus and the inability to clear the trapped pathogens [115]. This serves to exacerbate 
the symptoms of COPD with an increase in the level of inflammation and airway lung 
diseases.  
COPD is involved in the airway remodelling of epithelial cells, in particular squamous 
metaplasia and mucous hyperplasia [116]. It is this remodelling that contributes to 
irreversible airflow obstruction which is a key symptom in COPD. Cigarette smoke 
cause the injury to epithelial cells and also disrupts the ability of the cell to regenerate 
and repair itself. Both TGF-ȕDQGmatrix metalloproteinases (MMPs) are thought to be 
involved in the destruction and repair of epithelial cells [117]. In this process of 
regeneration, bacteria that exist in the lungs bind to cells that are undergoing repair. 
These bacteria release virulent factors which undermine the ability of the cell to 
regenerate, leaving it vulnerable to attack and unable to keep the epithelial barrier 
intact [118].  
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Overview of COPD: 
 
 
 
Figure 4: Cytokines and chemokines play a key role in the pathogenesis of COPD. 
These include IL-8, TNF-Į DV ZHOO DV ,/-ȕ 7*)-ȕ DQG ,/-17. Many of these 
cytokines serve to amplify the inflammatory process by recruiting key immune 
effector cells such as macrophages and neutrophils that contribute to the symptoms 
associated with COPD. 
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1.3 Biomarkers in COPD 
A biomarker is defined as a ³measurement of a molecule of interest which can 
indicate biological processes and thus can be used to predict disease process´[119]. 
The key characteristics of a biomarker could be to show the pathophysiological 
process of a given disease, responses to changes in disease and possibly to indicate the 
phenotype at different stages of the disease [120].  
FEV1 is the only accepted marker that meets the FDA criteria for COPD as it 
characterises the severity of the disease and is a known predictor of mortality and 
morbidity. Rosenberg and Kalhan, argue the problem of using FEV1 solely as a 
marker of COPD is that whilst is it both reproducible and easy to measure it, it doHVQ¶W
correlate with the health status or symptoms of the patient [121]. Specifically, FEV1 
GRHVQ¶W GLVWLQJXLVK EHWZHHQ WKH KHWHURJHQHLW\ RI WKH &23' ZLWK UHJDUG WR WZR
individuals who may have the same FEV1 %, but display two different sub-
phenotypes of COPD such as emphysema and small airways disease with varying 
levels of severity [122]. Hence the need to identify biomarkers in COPD that help 
improve the general understanding with regard to the complex nature of this disease. 
It is thought that certain biomarkers will be more useful in the prognosis of the 
disease. In the case of COPD, which is a multifaceted disease involving many immune 
cells, enzymes and mediators (Fig 4 & Fig 5), there will be many biomarkers which 
could prove to be good indicators of the disease process. With the development of 
novel assays, such as microarrays, there is a possibility for a greater number of 
biomarkers to be studied with greater reproducibility and enhanced sensitivity [123] 
[124]. 
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Frangogiannis, suggests at present there are two main approaches to identifying 
suitable biomarkers in disease setting. The first employs choosing a set of biomarkers 
based on the understanding of the pathophysiology of the disease. The second 
LQYROYHV XVLQJ DQ ³XQELDVHG´ SURWHRPLF DSSURDFK LQYHVWLJDWLQJ PXOWLSOH ELRPDUNHUV
which may be able to distinguish between the differential expression between normal 
and disease state individuals [125].   
A further advantage of examining a spectrum of biomarkers is in drug development. 
At present pharmaceutical companies are producing drugs that are targeting 
inflammation in COPD. Hence there is a need to identify reliable biomarkers which 
can indicate the clinical effectiveness of anti-inflammatory therapy in those with 
COPD [126] [127]. 
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Figure 5: A systemic view on the potential biomarkers of interest that could be investigated 
in COPD from those in the lungs to those in peripheral blood. 
Using one of the approaches Frangogiannis, used to described to identifying 
biomarkers according to the present understanding of the pathophysiology of COPD, 
the figure above illustrates a potential vast array of biomarkers that could be produced 
by cells of the immune system ranging from macrophages to neutrophils to T-
lymphocytes that could be investigated in the context of one another on a proteomic 
platform. Figure taken from [128]. 
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When looking for biomarkers in COPD, taking into consideration pathophysiology of 
the disease, biomarkers can be split broadly into four distinct categories namely; i) 
chemo-attractants, ii) inflammatory mediators, iii) immune-modulatory iv) those 
involved in destruction and repair, all of which could play a role in disease 
progression (Table 2). 
 
Table 2: A selection of potential biomarkers to which have been reportedly associated with 
COPD: 
Type of 
Biomarker: 
Chemo-attractants IL-8 Eot-1 MCP-1 Eotaxin-2 IP-10  
Inflammation IL-1ȕ TNF-Į IFN-G IL-4 IL-6  RAGE 
Destruction & Repair TGF-ȕ VEG-F     
Immunomodulatory IL-10      
Regulatory IL-23 IL-17     
 
 
(Adapted from Pinto-Plata et al.) 
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Over the last four or five years there has been an increased emphasis in discovering 
new biomarkers that could contribute to improving the overall understanding of 
COPD. In 2007, a major study by Pinto-Plata investigated the profiling of serum 
biomarkers in those that had COPD using a protein microarray platform [129]. From 
well over a hundred biomarkers investigated it was shown that a panel of 24 
biomarkers significantly correlated with FEV, BODE index as well as exacerbation 
frequency including IL-8, IL-17 and Eotaxin-2 (Table 3) [129]. 
In 2008, the ECLIPSE study was conducted to evaluate the phenotype and genetic 
parameters that would help define COPD as well as looking at potentially new 
biomarkers. This study was one of the biggest longitudinal studies in this research 
field looking at over 2000 COPD patients over a period of three years. Their research 
indicated that it was important to consider disease activity compared to disease 
severity when trying to investigate biomarkers in COPD. Their results showed that 
fibrinogen, serum surfactant protein D (SP-D) and CCL-18 could be considered 
potentially new biomarkers in COPD as they significantly correlated longitudinally 
with the disease as well with morality [130] [131]. However they emphasised the need 
to not only investigate one biomarker in COPD but look for a variety of biomarkers 
that could serve to contribute at different stages of the disease.   
A separate publication by Higashimoto et al, who also looked at serum biomarkers in 
COPD, found that CRP and MMP-9 were significantly correlated to lung function 
decline in those with COPD (Table 3) [127]. Interestingly their study showed that 
commonly sought biomarkers in COPD such as IL-8, IL-6 and TNF-Į RIWHQ
associated in the inflammatory stage of the disease) did not correlate with FEV-1 
levels [127]. However it was shown in this publication that concentrations of IL-8 and 
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TNF-ĮZHUHKLJKHULQWRWKRVHZKRVPRNHGFRPSDUHGWRQRQ-smoking healthy controls 
[127].  
In a more recent study by Garcia-Rio et al, looked at systemic biomarkers in COPD 
found that IL-8 and TNF-Į ZHUH VLJQLILFDQWO\ KLJKHU WKDQ KHDOWK\ FRQWUROV ZKLOVW
serum biomarker concentrations of IL-6 and albumin were linked to exercise tolerance 
[132]. Further studies by Rocke et al, [133] and Pinto-Plata et al, [134] have also 
shown a reoccurring theme whereby IL-6, TNF-A and CRP  are significantly shown 
to be increased in COPD patients compared to healthy controls (Table 3).   
Over the past four years, as there has become a clearer understanding of the role of 
regulatory T-cells in COPD, new investigations have looked at the role of cytokines 
that govern this subset of cells. Specifically studies conducted by Di Stefano et al,  
have shown there to be an increased expression of novel markers such as IL-17 and 
IL-23 in the sub-mucosa of those with COPD compared with healthy controls [135]. 
In addition, Gasse et al, have shown that IL-23 could be a key biomarker that could 
control part of the inflammatory pathway of COPD by inducing the production of IL-
17 that leads to pulmonary inflammation in the disease [136].  
)XUWKHUSXEOLFDWLRQVKDYHIRXQG³DOWHUQDWLYH´ELRPDUNHUVWKDWFRXOGFRQWULEXWHWRWKH
pathogenesis of COPD which include MCP-1 which is found to be higher in those 
with COPD than in healthy controls [137] whilst soluble receptor for advanced 
glycation endproducts (RAGE) were decreased in COPD [138, 139].  
At present no single biomarker in COPD demands worldwide acceptance mainly due 
to the conflicting reporting of specific biomarkers in publications. Therefore instead 
of looking at just one biomarker in a clinical setting it is far more beneficial to see 
whether a pattern could exist when looking at a variety of biomarkers in the same 
clinical setting as one another. This could improve the overall understanding of the 
Chapter 1: General Introduction 
 
 
~ 25 ~ 
 
disease to help differentiate the role each biomarker could play in the pathogenesis of 
the disease and also to ascertain whether one biomarker may be responsible for the 
increased or decreased expression of another biomarker. It would be interesting to see 
if there is a different biomarker pattern displayed by the three components that 
contribute to COPD (emphysema, chronic bronchitis and asthma) (Figure 1). 
Therefore the following section will outline the role of prominent cytokines that have 
been chosen from recent publications and we will examine the function of these 
cytokines in COPD. 
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Table 3: Shows all known information on COPD biomarkers and the tissue type analysed 
Type of Biomarker Cytokines References: Tissue type: 
Chemoattractants IL-8 [140] 
[141] 
[107] 
Epithelial Cells 
Plasma 
Sputum/Plasma 
 Eotaxin-1 [142] 
[143] 
Bronchoalveolar lavage 
(BAL) Fluid 
Sputum 
 MCP-1 [144] 
[134] 
Sputum 
Serum 
 Eotaxin-2 [145] 
[129] 
Plasma/Sputum 
Serum 
 IP-10 [146] 
[147] 
Serum 
Serum 
Inflammation IL-1-ɴ [148] 
[149] 
[150] 
[151] 
Epithelial Cells 
Epithelial Cells/Sputum 
Plasma 
Plasma 
 TNF-ɲ [152] 
[153] 
[154] 
[155] 
Plasma 
Serum 
Sputum/Plasma 
Serum/Sputum 
 IL-6 [156] 
[157] 
[158] 
Plasma 
Sputum 
Plasma 
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 IL-4 [159] 
[160] 
[161] 
Epithelial Cells 
Epithelial Cells 
Serum 
 IFN-ɶ [162] 
[163] 
[164] 
Epithelial Cells 
Epithelial Cells/Plasma 
Plasma 
 RAGE [165] 
[138] 
[139] 
Lung Tissue 
Serum 
Serum 
 IL-23 [136] 
[132] 
[166] 
Epithelial Cells 
Serum 
BAL Fluid 
 IL-17 [135] 
[108] 
[105] 
Endothelial Cells 
Plasma 
Plasma 
Immunomodulatory IL-10 [167] 
[168] 
[169] 
Serum/Sputum 
Plasma 
Sputum/Serum 
Destruction and 
Repair 
TGF-ɴ [127] 
[170] 
Serum 
Plasma 
 VEGF [171] 
[133] 
Serum 
BAL 
Fluid/Serum/Sputum 
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1.4 Cytokines as biomarkers 
Cytokines are small, extracellular signalling proteins (less than <75kDa) which are 
produced by a variety of cell types [172]. Cytokines are able to directly affect closely 
residing cells (paracrine) as well as target cells at a distance (endocrine/autocrine). 
Rarely are cytokines produced alone, often in association in one another. Hence when 
cytokines are produced together, patterns develop which can be used to characterize a 
type of disease.  
The pathology of COPD shows chronic inflammatory reaction whereby a cycle of 
tissue damage and repair takes place in association with a mass influx of inflammatory 
cells regulated by a group of cytokines [173]. The recruitment of cells such as 
neutrophils, macrophages, T-cells and eosinophils to the site of inflammation is 
governed by a type of chemoattractant cytokines called chemokines [144]. 
Chemokines are smaller than cytokines and are primarily responsible for recruiting 
leukocytes to tissues (Figure 6).   
Cytokines can be subdivided into the role they contribute to the pathology in COPD 
(Table 3 and 4) [172]. As can be seen there are a variety of cytokines such as IL-6, 
MCPs and RANTES that appear in more than one category indicating more than one 
role for this cytokines. Whilst the cytokines mentioned in Tables 3 and 4 all contribute 
to COPD, there is not a recognised pattern of cytokines that can be easily related to 
the disease.  
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Figure 6: Some of the inflammatory mediators involved in COPD. 
Cigarette smoke activates macrophages (A) which in turn secrete IL-6, TNF-ĮDQGD
variety of other cytokines (B) as well as proteases (C). TNF-ĮSURPRWHVIXUWKHUJHQH
transcription (D) that cause epithelial cells to release IL-8 (E) that leads to 
neutrophilic chemotaxis and further releases of proteases. Additionally epithelial cells 
produce TGF-beta (F) that is involved in tissue remodelling and repairs which 
eventually leads to fibrosis. Adapted from  [19]. 
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Table 4: Shows the subclasses of cytokines/chemokines involved in COPD. 
The overlapping nature of certain cytokines and chemokine indicate more than one 
role in the pathogenesis in COPD affecting more than one subset of immune effector 
cells. 
 
 
 
 
 
 
 
Family of 
Cytokine/Chemokine 
Cytokine/Chemokine 
Lymphokine IL-4, IL-5, IL-6, IL-10, IL-13 
Neutrophil Chemokine IL-8, GRO-Į, IL-1, TNF-Į 
Eosinophil Chemokine RANTES, GMCSF, MCP-3/4 
Macrophage Chemokine RANTES, MCP-1, MIP-Į
GRO-Į 
T-cells  MCP-1, RANTES, IL-16 
Proinflammatory IL-ȕ71)-ĮIL-6 
Anti-Inflammatory IL-10, IFN-Ȗ 
Growth Factors TGF-ȕ, PDGF, IGF 
Chapter 1: General Introduction 
 
 
~ 31 ~ 
 
1.4.1 Proinflammatory Cytokines 
Proinflammatory cytokines include IL-1, IL-6 and TNF-Į IL-6 is secreted by a 
variety of immune effector cells including macrophages, T-cells and B-cells. IL-6 has 
been recognised to be involved in exacerbation of COPD symptoms [153, 174, 175].  
Specifically IL-6 contributes to the proliferation, survival and activation of T-cells in 
COPD [156, 158, 176]. IL-6 levels are known to be elevated in not only serum but 
also BAL fluid and  sputum in the different stages of COPD [157]. IL-ȕ KDV DOVR
been reported to have a primary role when investigated in rodents [148]. High 
expression of this cytokine was found in rat lung epithelia that eventually manifests 
into emphysema and airway remodelling [177]. It is possible IL-ȕH[HUWV D VLPLODU
type of effect in humans. Finally TNF-Į LV NQRZQ WR EH DQ H[FHSWLRQDOO\ SRWHQW
mediator of inflammation. It is thought that the inhalation of cigarette smoke triggers 
the activation of TNF-ĮZKLFKLQWXUQFDQOHDG to a cascade of reactions that result in 
further activation of other inflammatory cytokines like IL-6, IL-ȕ *0&6) and 
GCSF [178, 179]. 
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1.4.2 Immunomodulatory Cytokines 
IL-10 and IFN-Ȗ DUH WZR VXFK H[DPSOHV RI DQWL-inflammatory cytokines that play a 
role in the inhibition of the production of inflammatory mediators mentioned above. 
Both IL-10 and IFN-ȖSOD\DUROHLQWKHLQKLELWLRQRI&'7-cell activity [180]. IFN-
Ȗ LV WKRXJKW WR SOD\ D UROH LQ WKH LQKLELWLRQ RI 003V LQ &23' DQG WKXV DFWLYDWLQJ
TIMPs which are inhibitors of MMPs [181]. In the sputum of those with COPD, the 
level of IL-10 was found to be reduced whereas proinflammatory cytokines such as 
TNF-alpha and IL-ȕZHUHXS-regulated, ultimately leading to tissue damage. IFN-ȖLV
a cytokine that plays a major role in COPD as it contributes to pulmonary emphysema 
[182, 183].  IFN-ȖLVWKRXJKWWRLnhibit CCR2 expression in human monocytes hence 
act as an inhibitor against the recruitment of macrophages [184].  
1.4.3 Eosinophil Chemokines 
Eosinophils are thought to play an inflammatory process in the lung mucosa through 
the release of highly toxic proteins such as eosinophil cationic protein (ECP) that have 
been found to be in peripheral blood as well as BAL fluid  in those with COPD [185]. 
Chemokines involved in this process include RANTES, eotaxin-1 & -2 as well as 
MCP-3 and MCP-4 [186] [142]. These cytokines are thought to be elevated in those 
with COPD compared to healthy controls and those with asthma indicating a role of 
cigarette smoke for inducing such changes [187]. These chemokines activate and 
attract eosinophils, in particular eotaxin-1 through the selective binding to the high 
affinity CCR3 receptor [187]. 
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1.4.4 Neutrophil Chemokines 
IL-8, IP-10 and MCP-1 are all but a few chemokines involved in the recruitment of 
neutrophils. They are expressed through either mesenchymal or inflammatory cells 
and can be stimulated by other cytokines including IL-6 and TNF-Į [188] [147] . 
Additionally cigarette smoke is thought stimulate the production of IL-8 from both 
macrophages and bronchial epithelial cells [189] [190].  
IL-8 is a potent neutrophilic chemokine that upregulates cell adhesion molecules such 
as ICAM-1 and e-selectin as well as increased production of LTB4 that all contributes 
to neutrophils leaving the blood and migrating to the site of inflammation [191]. In 
addition to elevated serum levels of IL-8, an increased amount has been also observed 
in COPD sputum samples [192].  
1.4.5 Lymphokines: 
Lymphokines are a subset of cytokines that are produced by lymphocytes; in 
particular CD4+ T cells and CD8+ cells. These T cells are responsible for the 
regulation of the immune response through the signalling between cells [193-195].  
Smoking can cause CD8 T-cells to release to IFN-ȖZKLFKLQWXUQXS-regulates IFN-Ȗ-
inducible protein (IP-10). IP-10 can induce the production of matrix metalloproteinase 
12 (MMP-12) that can lead to a reduction in elasticity recoil due to damage of lung 
alveoli [146]. Hence is its postulated IFN-Ȗ ,3-10 and MMP-12 can work by a 
positive feedback loop in emphysema [44] [196]. 
Over the years, publications have shown that plasma cells in the submucosal glands of 
the lungs that express IL-4 can also lead to goblet cell hyperplasia [197] [198] [199]. 
It is thought that T-lymphocytes can secrete IFN-Ȗ DQG WKH F\WRNLQH LWVHOI LV
responsible for the inhibition of cell proliferation and also contribute to the 
pathogenesis of the disease by augmenting the cytotoxic effects of TNF-Į[76]. 
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Research have shown that CD8 T-cells have the potential to be polarised towards a 
Tc2 profile; leading to production of cytokines such as IL-4 which lead to mucus 
hypersecretion [200].  
1.4.6 Macrophage Chemokines 
 Growth-regulated protein alpha (GRO-ĮDQGmonocyte chemotactic protein-1 (MCP-
1) play a similar role to IL-8 in the pathogenesis of COPD. Whilst both chemokines 
have been implicated as a potent neutrophilic chemoattractants, they have also been 
shown to be involved in a mass influx of macrophages that have been found in lung 
biopsies and sputum samples in COPD [144, 201]. Traditionally when there is 
saturated concentration of chemokine, the natural movement of cells is to bind to the 
cell surface slowing chemotaxis. However it has been noticed with GRO-Į that even 
at high concentrations macrophages continue to migrate leading to a greater burden of 
these monocytes at the site of inflammation (Fig 7) [144].  
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Figure 7: A modified representation of monocyte migration in response to a 
chemoattractant. 
 At low concentrations of chemoattractant there is a low gradient for cells to move 
efficiently (A). At the optimal concentration of chemoattractant the gradient is perfect 
for monocyte movement to the site of inflammation (B). As the concentration of 
chemoattractant increases, normally cells stick to the cell surface leading to reduced 
migration (C). However for chemokines like GRO-Į,/-8 and MCP-1 cell migration 
still continues leading to a greater number of macrophages observed in COPD (D). 
Figure originally adapted from [202]. 
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1.4.7: Growth Factors 
Growth factors such as TGF-ȕDQGplatelet-derived growth factor (PDGF) induce the 
proliferation of structural cells; specifically airways smooth muscle cells and 
fibroblasts. TGF-ȕ LV a cytokine that is involved in cell proliferation and cell 
differentiation [203]. Airway smooth muscle cells of those who have COPD have 
been shown to express large amounts of this cytokine. Due to airway remodelling that 
occurs with those that smoke and have COPD, TGF-ȕLVshown to be highly expressed 
[204]. Recent research has shown that TGF-ȕ DQG Lts receptor TGF-R can enhance 
apoptosis of peripheral T-lymphocytes by preventing the progression of growth of 
these cells from the G1-S transition phase [205] [206]. 
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1.5 Microarray Overview 
Protein microarrays can be used as a measurement tool to determine and quantify the 
presence or amount of proteins that exists in biological samples (i.e. blood, sputum, or 
urine etc). This is a fairly novel approach (since early 2000s) which has many benefits 
in proteomic research. The most common protein microarray that is used is an 
antibody microarray. This is whereby capture antibodies are printed onto a small chip 
or slide which can be then used to detect proteins of interest in a biological sample 
(Figure 8).  
 
 
 
 
Figure 8: An example of one type of protein microarray using a nitrocellulose slide. 
Antigens or proteins of interest can be detected using primary antibody and amplified 
further by the use of a secondary antibody which is tagged to biotin or alkaline 
phosphatase. The slide is subsequently scanned and standard curves are drawn to 
calculate the amount of protein present in a biological sample. (Figure courtesy of Dr 
Paddy Tighe).  
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Overall microarrays offer the potential to measure and evaluate a variety of 
inflammatory mediators including cytokines across a broad spectrum of 
concentrations, at a reduced overall cost compared to the traditional Enzyme-Linked 
Immuno-Sorbant Assay (ELISA). Despite the potential promise this technology brings 
to medical research; it is hindered by a lack of experience and reproducibility issues 
which require further validation and optimisation.  
At present ELISAs are WKH ³JROG VWDQGDUG´ IRU WKH PHDVXUHPHQW RI LQflammatory 
cytokines and is the best known method for measuring cytokines and other 
inflammatory mediators with both high levels of sensitivity and specificity. Recently 
there have been a lot of published studies that show the use of microarray technology 
in the quantification of cytokines in serum [207] [208] .  
Microarrays also allow for multiple repeats to be performed on the same chip 
enhancing the validity of subsequent results. 
The key advantages of microarrays over ELISAs involve: 
a) A smaller amount of sample required to run the assay 
b) The ability to detect and/or quantify more than one inflammatory mediator 
c) The ability to undertake multiple repeats of the same cytokine under the same 
experimental conditions 
d) The ability to detect a variety of proteins across a range of concentrations 
e) Reduced time and cost to run the assay 
Antibody microarrays are regarded as the future of biomarker detection of disease 
[209] [210] [211]. At present protein microarrays have evolved from DNA microarray 
technology, however they are not as robust and as reliable as the latter. Sandwich 
ELISA microarrays allow for the analysis and quantification of a large variety of 
proteins which require a small volume.  
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1.5.1 Microarray Slide Surfaces and Immobilisation 
One of the biggest obstacles to developing reproducible protein microarrays are slide 
surfaces. The surface chemistry of the slide dictates the immobilisation between the 
slide surface and the antibody or protein that is to be printed [212]. The physical 
interaction between proteins and the slide surface can occur by Van der Waals, 
covalent, ionic or hydrophobic interactions that need to be optimised depending on the 
nature of the protein of interest. In addition, the nature of the interaction should leave 
the protein functionally unaltered [213].  
The adsorption of proteins to the surface of the slide can be engineered by either a 
combination of a large number of weak contacts (which could alter the shape and 
functionality of the protein) or small number of strong bonds which leaves the protein 
unchanged except for at the point of contact.  
To enable this to occur, different types of slide surfaces have been developed. These 
can be divided into two broad classes. Firstly are 2D planar slides. These are coated 
by a variety of slide surface chemistries such as aminosilane, epoxysilane and poly-L-
lysine [214]. These slide surface chemistries interact with the proteins of interest 
through either the formation of covalent bonds or electrostatic interactions. However 
the disadvantage of using such 2D surfaces is evaporation of the liquid environment 
that the antibodies are printed, which in turn can affect the 3D structure of the protein 
[215]. 
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 Another approach is to use a 3D surface such as a nitrocellulose or hydrophobic 
surfaces that bind to the protein via physical adsorption. The advantages of using such 
slide surfaces are that they can preserve the protein in its original conformation over a 
period of time. On the other hand there are  large variations in signal intensities 
associated with using such slides [216]. More recently time has been invested 
developing slides with 3D surfaces such as hydrogels. It is thought that such a surface 
chemistry could provide a partially hydrated surface that would help maintain the 
functionality of the protein. Additionally the surface would allow a larger number of 
proteins to bind to the surface due to the increased surface area [217].  
Ultimately the slide surface and the way they interacts with the protein of interest will 
govern the spot morphology/size, spot intensity and amount of antibody that binds 
with the surface. Therefore the key aspect of choosing the best slide surface with 
respect to slide surface chemistry must consider the following: 
1) A high binding capacity 
2) A high signal to noise ratio 
3) The ability to bind to proteins securely whilst maintaining their functionality 
4) A reduced variability between slides of the same surface chemistry 
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1.5.2 Slide Noise and Spot Background 
6OLGHQRLVHFDQEHGHILQHGDV³WKHIOXRUHVFHQWVLJQDOWKDWDSSHDUVRQDUHDVRIWKHVOLGH
that have nRWEHHQSULQWHGZLWKDQWLERG\´ [214]. Spot background can be defined as 
the signal that appears on the spot when there is no antigen bound during the 
experimental procedure. Therefore an increase in either slide noise or spot background 
can reduce the sensitivity of the assay especially at the lower spectrum of detection 
[217].  
A possible reason for the increase in slide noise could be due to the denaturation of 
proteins used in the blocking phase of the procedure or alternatively non-specific 
binding of signal related proteins [218]. Spot background is due to non-specific 
binding of proteins to the slide which is influenced by the slide surface chemistry. 
Spot background may lead to the denaturation of the protein which can expose 
hydrophobic bonds which increases the likelihood of nonspecific binding.  
1.5.3 Spot Size and Morphology 
Often the spot size and morphology are dependent on either the slide surface 
chemistry or the printing buffer. Certain slide surfaces can prevent spot spreading, 
leading to a reduced spot diameter and better spot morphology [219]. The net result 
allows for more densely printed arrays. A poor slide composition can lead to poor spot 
morphology due to the inability of the surface to hold functionally active antibodies, 
which can ultimately lead to reduced signal intensities [214].  
Another important question is to look at the spot size and the number of spots that can 
be printed into a defined area on a slide. Currently spot size varies in diameter from as 
little as 25 microns to 150 microns [214]. If the spot diameter can be reduced but can 
still maintain the same intensity this could lead to a greater number of spots being 
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printed in the same space. Clearly this has the advantage of permitting more proteins 
of interests to be studied on one slide. 
1.5.4 Signal Detection and Generation 
The sensitivity and detection step of an assay are the key factor in microarray 
technology [220]. Signal detection can be achieved in two main ways; A) directly by 
molecules of interest or B) indirectly without any modifications to the molecules of 
interest [221]. Direct labelling can occur through the labelling of the protein of 
interest which can involve biotinylation (Figure 9) [222].  The advantage of direct 
labelling allows all proteins to be labelled in exactly the same way however, the 
potential disadvantage of using this method could lead to high background due to 
nonspecific adsorption of proteins such as albumin in serum that could affect the 
sensitivity of the assay [223]. Indirect labelling involves the addition of a detection 
antibody either biotin conjugated or with the use of a tertiary antibody.  
Fluorescent binding includes using Alexa, Oyster or Cyanine dyes. Fluorescence 
detection methods are currently the preferred choice in microarray detection as they 
are safe, have a high sensitivity limit as well as having a high resolution once scanned 
[224].  
A major limitation that occurs with antibody microarrays is possible cross reactivity 
especially in a mixed antibody arrays where more than one marker is measured at one 
time. An important element of the detection process has been the advent of signal 
amplification enzymatically. This can occur through the use of biotin, alkaline 
phosphatase or tyramide signal amplification [225].  
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Figure 9: Methods of detection and signal generation. 
The simplest way to generate a signal is to directly label the protein of interest through 
biotinylation (Fig A). The indirect approach involves the labelling of detection 
antibody (Fig B) or the labelling of tertiary antibody (Fig C). The latter approach takes 
away the need to chemically modify the nature of the detection antibody.  
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1.6 Introduction to Assay Validation 
Assay validation is an evaluation of an experimental method to determine how well it 
fits for its specific use. In the validation process multiple parameters are investigated. 
Most importantly the use of validation enables the one to understand the limitations of 
the method and where it might be improved. 
Validation is an on-going process where the design, development and establishment of 
a method, as well as optimisation and revalidation, are encompassed. However with 
many validatory procedures it is often limited by time constraints, resources and being 
able to have an assay that justifies the purpose of its needs [226].  
Assay development is a major part of quality control and at present there are multiple 
guidelines provided by professional bodies, such as the FDA [227]. These guidelines 
provide the model of boundaries and limitations in assay. 
Validation protocols have been published in recent literature with a variety of 
microarray concepts that have been developed by both major manufacturing 
companies (such as ThermoFisher and BIO-RAD) and in house microarray systems 
that have been used in research laboratories. The general definition of assay validation 
KDVEHHQDJUHHGWREHWKHIROORZLQJ³Assay validation involves documenting, through 
the use of specific laboratory investigations, that the performance characteristics of 
the method are suitable and reliable for the intended analytical applications. The 
acceptability of analytical data corresponds directly to the criteria used to validate the 
method.´[227].  
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A validation study can be described as a series of experiments that test the 
performance of an assay such as the accuracy, specificity and reproducibility of a 
system [228-230]. The major consideration taken in assay development is the intended 
purpose of the assay and how to construct a series of experiments that could answer 
the questions that could affect the assay [231].  
One of the aims of this thesis is the validation of a microarray assay. In the antibody 
microarray system developed here, the purpose is to address the absence/ presence of 
proteins in biological samples. Specifically this requires the quantification of these 
proteins in biological samples. Hence in the validation of this microarray system we 
ask the following questions: i) can this microarray system accurately measure the 
exact concentration of a sample?, ii) what is the dynamic range of the assay and what 
would be the lowest reproducible value? and iii) is the assay accurate and precise 
when measured multiple times on the same day and on multiple days? (Table 5)  
 
 
 
 
 
 
 
 
Chapter 1: General Introduction 
 
 
~ 46 ~ 
 
Table 5: To explore the validatory questions asked when developing an antibody 
microarray method. 
Test: Purpose of Assay: Questions asked 
of Assay: 
Validation 
parameters tested: 
Antibody 
Microarray 
Measure/ 
detect/quantify the 
presence of 
absence of proteins 
in biological 
samples 
a) Can assay 
accurately 
measure 
samples 
Accuracy and 
Reproducibility 
 
 b) What is the 
dynamic 
range? 
Standard Curve & 
Range 
 
 c) Can the 
assay be 
specific? 
Specificity/Cross 
Reactivity 
 
 d) Can assay 
be precise 
and 
accurate if 
repeated on 
the same 
day or 
multiple 
days? 
Accuracy, 
reproducibility and 
precision (CV%) 
 
The antibody microarray platform is used to measure and quantify proteins in 
biological samples. The key in being able to do this is to be accurate, precise and 
reproducible. A variety of different questions have to be answered by a variety of 
validatory tests.   
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Antibody microarrays can be used to be both qualitative (ie measuring the presence or 
absence of a protein in a sample) and quantitative (ie measuring the actual amount of a 
substance). Hence figure 10 illustrates the types of experiments and parameters that 
have to be tested when measuring a microarray system when deciding to run a 
qualitative or quantitative approach. As seen with a quantitative approach, as used 
here more validatory tests have to be performed to make sure the system is highly 
reproducible and accurate. 
 
Figure 10: The validatory experiments that have to be performed on an antibody 
microarray for both qualitative and quantitative approaches. 
The qualitative approach allows for less validatory experiments to be performed as the 
accuracy whilst needed is not as important as if a sample is to be quantified. In the 
quantitative approach multiple validatory approaches have to be performed and 
implemented to make the system highly reproducible for everyday use.  
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The accepted standard procedure in running a validatory process is to divide the 
nature of these experiments into different stages  [232].  These stages include, i) 
Method selection: choosing the best way to quantify proteins in biological samples 
and how and best way to run the microarray system, ii) Development of the 
microarray system; this involves most optimisation including trying a variety of 
reagents, slides and buffers to enable the best combination that allows validation to 
take place (see Chapter 3) and iii) Measuring performance of the microarray; working 
out accuracy and reproducibility which involves repeatability, robustness and 
improving precision [233] (Figure 11). Often optimisation and validation are a joint 
process whereby improving one concept has an impact on the other and vice versa.  
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Figure 11: The three key stages involved in validation. 
Stage 1 involves understanding the concept and choosing the right type of microarray 
procedure to run. Stage 2 involves the optimisation stage where the platform is built 
and initially tested with the biological samples to understand what is required from it. 
Thirdly, stage 3 is the main bulk of the validatory process where multiple 
experimental procedures are carried out to work out the accuracy and reproducibility 
of the platform and have a system in place that has no major issues which is ready to 
perform the initial hypothesis of the study. 
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If each stage is looked at in greater detail, one can understand why it is split into 3 
different stages; 
A) Method Selection; in this thesis the main aim was to build a methodology that is 
highly accurate and precise and allows for quantifiable detection of multiple 
biomarkers simultaneously across a variety of biological samples. For this reason the 
microarray approach was selected as the costs will be substantially reduced, requiring 
less sample and reagent than a traditional ELISA (which is limited to being able to 
measure one biomarker at one time). Furthermore microarrays have the capacity to 
deliver results quicker than an ELISA.  
B) Method Development: Here the best conditions to run the microarray must be 
optimised, for example, what is the best print buffer? The best blocking buffer? The 
best slide surface? All these variables have to be investigated in depth and the best 
combination of these factors are then chosen together to move the microarray process 
forward. At this stage normal biological samples are tested and unknown 
concentrations of proteins are detected. However the reliability of these proteins 
concentrations can only be checked in the performance stage. 
C) Method Performance: This is where most of the validatory tests are performed. 
Initially the limits of detection and quantification are defined. This will allow any 
further quantification work to fall within the boundaries of accurate quantification. 
Furthermore the performance of the assay can be tested by running a series of intra 
and inter assays over a period of days that show the accuracy and reproducibility of 
the system. In this investigation the guidelines for the parameters of the assay are 
EDVHGDURXQG WKH)'$*XLGDQFHRQ³%LRDQDO\WLFDO0HWKRG9DOLGDWLRQ´ [227]. Here 
we compare the microarray system to the traditional ELISA. Once the methodology 
has been validated with the ELISA, clinical samples can be used in the assay.   
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1.6.1: Assay Validation Parameters 
In all literature showing  validation of an analytical method, parameters such as 
accuracy and precision have been identified and established to characterize the 
performance of an assay [234]. 
1.6.2: Accuracy 
Accuracy can be defined as how exact the actual value obtained in an experiment is to 
the expected value [235]. This can be experimentally proven by applying the 
procedure to samples that can be prepared with a quantifiable accuracy (ie a series of 
³VSLNHV´6DPSOHVFDQEH³VSLNHG´WRDNQRZn concentration and the amount detected 
in the assay is determined. Accuracy is often expressed as the % error between the 
observed concentration and the expected concentration. Whilst accuracy is an 
important parameter in validatory testing, in certain examples such as qualitative 
measure accuracy cannot be required and instead can be replaced by sensitivity and 
specificity.  
1.6.3: Precision 
Precision is defined as the coefficient of variation (CV(%)) of multiple measurements 
or repeats [236, 237]. CV% is often calculated by dividing the standard deviation of 
multiple repeats by the mean of multiple repeats. Precision can be measured in a 
variety of ways, including repeatability of the same test, inter- and intra assays where 
experiments are performed multiple times on the same day or across multiple days.  
Accuracy and precision are often misinterpreted as being same but in fact they are 
completely different to one another. The diagram (figure 12) below illustrates these 
concepts in relation to one another. For an analytical method to be successful it needs 
to be both highly precise and accurate: 
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Figure 12: The relationship between accuracy and precision. 
It is possible to have a high degree of accuracy and yet be imprecise across multiple 
measurements (A).  Ultimately the aim of any assay is to be highly precise and highly 
accurate. This shows that from an experiment, the measured value is very close to the 
actual value (B).  It is possible to have a set of data that is highly inaccurate but 
consistent for that experiment. This is again highly undesirable (C). Finally in the 
worst case scenario of microarray validation it is possible to be both imprecise and 
inaccurate giving rises to questions about the validity of the method which will have 
to be readdressed (D) [238].  
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1.6.4: Intra assay 
Repeatability or the intra-assay can be defined as the precision obtained when the 
procedure or experiment is carried out under the same conditions within a short 
interval [239]. In the case of the microarray this is when the experiment is performed 
multiple times on the same slide. This serves as an indicator of how the precision is 
within the same day under normal working conditions.  
1.6.5: Inter Assay  
Inter assay where the experiment is carried out under the same experimental 
conditions across a few days. For example if a sample is taken and measured for any 
given protein  on day 1, day 2 and day 3, one would expect the result to be consistent 
across the three days [240]. The precision is calculated and again serves as an 
indicator of how the effects of precision vary in slightly different external 
environments (i.e. change in room temperature, light, buffers/reagents etc). Often the 
precision is expected to be lower than that obtained in the intra assay.  
1.6.6: Specificity  
The specificity of a method, with reference to a microarray platform, is the ability to 
measure the presence of an analyte in the context of multiple analytes [241]. It is 
important that the microarray platform can be specific for individual analytes and 
show no cross-reactivity with other analytes in the same experiment.  
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Within specificity, both selectivity and recovery are two further parameters to be 
considered. Selectivity is defined as the presence or absence of a particular analyte in 
the context of complex sample mixture [242]. Recovery of an analyte is the amount 
detected from the total amount of a sample that has been added to a biological sample 
mixture. Often in recovery experiments these are run at three different concentrations; 
low, medium and high. The closer the recovery is to 100% the greater the precision of 
the assay.  
1.6.7: Limit of Detection 
The lower limit of detection (LOD), is defined as the lowest level that an analyte that 
can be detected but not be truly quantified [243] [244]. This is often presented as a 
concentration. In terms of the microarray the LOD is defined as a point that is above 
the level of the blank. Often the LOD is calculated as three times the standard 
deviation of the blank + the blank [243] [245].  
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1.6.8: Limit of Quantification 
The limits of quantification are defined as the lowest (LLoQ) and highest (ULoQ) 
points in an assay that can be detected and quantified to an acceptable level of 
accuracy and precision [246-248]. Both the LLoQ and ULoQ, like the LOD, are 
expressed as a concentration. The LOD, LLoQ and ULoQ are all measured using 
standard curves. The LLoQ can be equal to the LOD but is often higher than the LOD. 
The LLoQ cannot however be lower than the LOD (Figure 13). 
 
Figure 13: The relationship between the LOD, LLoQ and ULoQ from a standard curve. 
The graph above illustrates the relationship of how the LOD, LLoQ and ULoQ can be 
determined from a standard curve. The LOD is often calculated to be 3 times the level 
of background intensity. Both the LLoQ and ULoQ are defined as the point in a 
standard curve which are an analyte can be detected and quantified to an acceptable 
level of accuracy and precision.   
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1.7 Aims and Hypothesis: 
The aim of this research is to develop a technique to enable a list of prominent 
biomarkers that allow for the early diagnosis of COPD. Additionally possible patterns 
of expression of biomarkers may help clinicians to categorise the severity of COPD. 
This would make it more beneficial and quicker to treat patients with this disease. 
The wide use of protein microarray technology has allowed for the diagnosis and 
management of numerous diseases, such as cancer and autoimmunity. This ability to 
measure a vast array of biomarkers simultaneously is highly desirable. In the case of 
multifaceted diseases such as COPD which involves many immune cells, enzymes 
and mediators, microarray technology could detect biomarkers which could prove to 
be good indicators of the disease process. Sixteen prominent biomarkers are to be 
investigated in this study. All have been implicated in the disease process yet all 16 
have yet to be investigated together. 
The main hypothesis of the thesis was thus to build an antibody microarray platform 
that can be used as a diagnostic tool for the simultaneous quantification of 
inflammatory biomarkers in the sera of COPD patients. This has to be both 
UHSURGXFLEOHDQGVHQVLWLYHDVFRPSDUHGWRDQ(/,6$ZKLFKLVFRQVLGHUHGWKH³*ROG
VWDQGDUG´ RI LQIODPPDWRU\ TXDQWLILFDWLRQ 2QFH WKLV LV DFKLHYHG WKH H[SUHVVLRQ RI
these biomarkers will be compared between COPD patients and smokers with and 
without COPD to determine whether there are significant differences between the 
groups with relation to FEV1, age or sex. Ultimately the aim is to use such a 
diagnostic tool to improve the prognosis, intervention and treatment of COPD.  
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Chapter 2: Materials and Methods 
2.1: Materials 
2.1.1: Chemicals and Reagents 
2.1.1.1 Printing Buffers 
A variety of inhouse coating buffers were made to identify the ideal buffer for printing 
antibody microarrays (Table 6): 
Table 6: The ingredients involved in the formulation of 8 different coating buffers tested.  
Printing Buffers: Ingredients: 
i) PBS x1 PBS (Sigma) (v/v) 
ii) PBS-Tween x1 PBS (Sigma), 0.01% Tween-20(Sigma) 
(v/v) 
iii) PBS-Glycerol x1 PBS (Sigma), 5% Glycerol (v/v) 
iv) PBS-Glycerol-Tween x1 PBS (Sigma), 5% Glycerol, 0.01% 
Tween-20 (Sigma) (v/v) 
v) PBS-Glycerol-Tween-
Trehalose 
x1 PBS (Sigma), 5% Glycerol, 0.01% 
Tween-20 (Sigma), 50mM Trehalose (v/v) 
vi) PBS-Trehalose x1 PBS (Sigma), 50mM Trehalose (v/v) 
vii) PBS-Trehalose-Tween x1 PBS (Sigma), 50mM Trehalose, 0.01% 
Tween-20 (Sigma) (v/v) 
viii) DMSO 70% DMSO, 25% 0.2M sodium acetate 
pH 4.5, 5% Glycerol (v/v) 
Abbreviations: i) PBS, ii) PBS-T, iii) PBS-GLYc iv) PBS-GLYc-Tw v) PBS-GLYc-
TwTre vi) PBS-Tre vii) PBS-Tre-Tw and viii) DMSO 
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2.1.1.2: Blocking Buffers 
 
A selection of blocking buffers were tested (Table 7): 
Table 7: The different blocking buffers tested. 
Blocking Buffers: Purchased from: Ingredients: 
I Block Tropix (Bedford, MA) 0.05g I Block in 25mL 
PBS-Tween-20 (0.05%) 
(Sigma) 
3% BSA Block Sigma, UK Diluting 30% BSA in x1 
PBS in 50mL 
3% Milk Block Marvel, UK Diluting 3g dried milk 
powder in 100mL PBST 
(0.05% Tween-20) 
NAP Block G-Biosciences, MO X2 Buffer diluted in 
50mL of PBS 
Smart Block Candor Bioscience GmbH 
(Germany) 
Used directly onto slides 
PVA Block Sigma, UK Diluting 2g in 50mL in 
destilled water and 
heated until dissolved 
Low Cross Block Candor Bioscience GmbH 
(Germany) 
Used directly onto slides 
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2.1.1.3: Wash Buffer (PBS-Tween 0.05%) 
PBS (x10): tablets where diluted in deionised water and mixed with 0.05% Tween-20. 
2.1.1.4: Reagent Diluent 
Reagent Concentrate (x10) of 10% BSA solution (R&D systems, MN, USA) was 
diluted in 1:10 in deionized water before use. 
2.1.1.5: Slide Surfaces 
A selection of slide surfaces were tested (Table 8) 
Table 8: The type of slide surface used and where they were purchased from. 
Slide Surface Purchased from: 
Epoxysilane Thermofisher, UK  
Schott, Germany 
Aminosilane Thermofisher, UK 
Poly-L-Lysine Thermofisher, UK 
Aldehyde Thermofisher, UK 
Nitrocellulose Grace Bio-Labs, OR, USA 
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2.1.2: Antibodies 
2.1.2.1: Antibodies for print testing 
The capture antibody used for the initial experiments was a monoclonal rat anti-mouse 
IgG1(Cambridge Biosciences, UK). Detection antibodies were Alexa Fluor 488 
labeled mouse IgG1, isotype control (BD Pharmingen, UK). 
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2.1.2.2 Antibodies for all ELISA and Microarray work 
All antibodies were purchased as duosets kits from R&D systems with product 
numbers (MN, USA) (table 9).  
Table 9: A list of all the antibodies used from optimisation to running patient samples. 
Antibody Product Number: 
IL-8 DY208 
IL-6 DY206 
IL-1ȕ DY201 
71)Į DY210 
VEGF DY293b 
Eotaxin-1 DY320 
IFN-Ȗ DY285 
IL-17 DY317 
Eotaxin-2 DY343 
IP-10 DY266 
RAGE DY1145 
MCP-1 DY279 
IL-4 DY204 
IL-10 DY217B 
7*)ȕ DY240 
IL-23 DY1290 
GCSF DY214 
GMCSF DY215 
MIP-ȕ DY271 
RANTES DY278 
MCSF DY216 
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2.2 Methods 
2.2.1: Biomarker Study Population 
Serum was obtained from 60 COPD patients, 37 healthy smoker volunteers and 13 
age and gender matched non-smoking healthy controls. The study was approved by 
the local reseach ethics committee (Leicestershire, Northamptonshire, Ruthland 
(LNR), REC 10/H0406/65. Samples were collected and stored at -70°C until use on 
the microarray to prevent repeated freeze-thaw cycles. 
Table 10 displays patient demographics and spirometric measurements of the study 
participants. 
Table 10: Demographic and Spirometric Data of the Study Participants.  
 
 
 
Age Mean 
(Range) 
Gender FEV-1% 
Mean (Range 
COPD (n=60): 67 (46-84) 35 Females 
25 Males 
72% (17-
80%) Gold Stage 1 (n=7) Gold Stage 2 (n=37) 
Gold Stage 3 (n=13) 
Gold Stage 4(n=3) 
Healthy 
Smokers 
(n=36) 
65 (42-80) 16 Females 
20 Males 
76% (30-
115%) 
Control Non 
Smokers 
(n=12) 
55 (41-65) 7 Females 
5 Males 
103.6% (87-
122%) 
 
Values are expressed as mean and (range). FEV1% - Percentage of Expected FEV1. 
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2.2.2: Slide Surfaces and Print Buffer 
The capture antibody for the initial experiments were diluted serially from 250µg/ml 
across 10 dilutions in 8 different coating buffers (Figure 14) and all detection 
antibodies were used at 1:500, 1:1000 and 1:5000 dilution (PBS containing 3% BSA). 
Slides outlined in Table 8 were purchased and were processed immediately and after 1 
week in storage in a vacuum. 
2.2.2.1 Protocol for Print Production for Slide Surface 
and Print Buffer testing 
Diluted capture antibody was loaded onto a 384 well plate (Genetix), and arrayed onto 
the different slides using a Biorobotics Microgrid II arrayer (Microgrid) and silicon 
contact pins (Parallel Synthesis Technologies, USA). The array chamber has a 
humidifier which was set at 58% humidity and run at room temperature during 
printing. The distance between spots was set to 315 microns and dwell time limited to 
0.400s and target height printed was -0.184mm. The average spot diameter varied 
between 50-150 microns.  
After printing slides were left overnight on the arrayer before being processed 
immediately or stored under vacuum or in air until use. Printed slides were blocked 
for 1 hour in 3% BSA, I-Block, 3% milk block or NAP block on a shaker. After 
blocking, slides were washed three times with PBST (containing 0.05% Tween-20) 
and incubated in solutions containing detection antibody conjugated with fluorescent 
dye for 1 hour at room temperature on a shaker.  
Slides were washed with PBST (as described above) and rinsed briefly in ultrapure 
water. Slides were dried by spinning at 1200 rpm for 5 min and scanned a 4200 AL 
microarray scanner (Axon GenePix®). 
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Figure 14: Illustrating the printing buffer /slide surface experiment overview. 
Antibodies were printed on a slide surface (A & B), blocked (C) and then probed by 
detection antibodies tagged with Alexa 488 (D) and scanned.  
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2.2.2.2 Data Analysis 
For a 16 pad slide, half of the slide is used for the construction of the standard curve. 
Often the top left well is used as a blank control well and the remainder of the left 
hand side of the slide is used to process the samples of interest. Each well on the 
microarray slide is equivalent to a well on an ELISA plate (Figure 15): 
 
Figure 15: This is an illustration which shows the distribution of how each 16 pad slide is set 
up. 
On the right hand side the standard curves are constructed with each concentration 
point in each well. On the top left hand slide is the negative control or blank. The 
remainder of the left hand of the slide is used for processing biological samples.  
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For the analysis undertaken in this thesis, the median value of the spot is considered as 
compared to the mean of the spot. When choosing between the median and mean of 
WKH VSRW WKH IROORZLQJ KDV WR EH FRQVLGHUHG ³7KH PHDQ LQWHQVLW\ LV GHILQHG DV WKH
DYHUDJH LQWHQVLW\RI WKH VLJQDOSL[HO´ZKHUH WKHPHGLDQ LVGHILQHGDV WKH³LQWHQVLW\
YDOXHWKDWVSOLWVWKHGLVWULEXWLRQRIWKHVLJQDOSL[HOVLQKDOI´[249] [250]. The number 
of pixels above the spot should be the same as the number of pixels below the spot. 
The advantage of choosing the median value over the mean value lies in the ability of 
the median to take into account the outliners of within the spot. Contamination is a 
major issue in the microarray printing and processing. Contamination occurs due to 
dust and impurities that are present on the spot result in brighter pixels present on the 
image. Hence contamination introduces outliers in spot that are processed. If the 
software is incapable of correctly identifying the signal of the spot, taking into 
account the background and removing contaminated pixels, the median is often the 
preferred choice over the mean. In the majority of the experiments contamination of 
spots were rarely seen and hence to overcome this issue replicate spots are printed 
taking the average median of all the spots to give a signal. The median-background 
was taken in all experiments to take into account potential irregular spots and maintain 
consistency in the data with regard to possible contamination that may occur in the 
spots. This was used to construct a standard curve for each cytokine tested. From the 
standard curve, unknown concentrations of cytokines were calculated.  
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2.2.3: ELISA protocol 
ELISA plates (96 wells) were purchased from Nunc-Immuno plate Maxisorp (Nunc, 
Denmark). ELISA duoset kits were purchased from R&D systems (Minneapolis, MN) 
and performed as described by the maQXIDFWXUHU¶VLQVWUXFWLRQV)LJXUH 
Briefly, plates were coated with 1-ȝJPORIFDSWXUHDQWLERG\DQGLQFXEDWHGRYHUQLJKW
at room temperature. The plates were washed 3 times with PBS-Tween 0.05% 
(Sigma) and blocked with Reagent Diluent (1% BSA in PBS) for 1 hour and washed 
three times. Standards were made in Reagent Diluent at the top concentration 
(according to kit instructions) and diluted 2 fold (across seven points) at 100µl per 
well in duplicates for 2 hrs. The plate was washed three times and 50µl of 
appropriately diluted biotinylated detection antibody was added to each well for 2hrs. 
After washing three times with washing buffer, 50µl of diluted streptavidin-HRP was 
added and incubated at room temperature for 30 mins in the dark. Wells were washed 
three times and the enzyme substrate peroxidase chromogen was added. After 
incubation for 30 mins at room temperature the reaction was stopped by adding 50µl 
of 0.18M H2SO4 per well and the absorbances were read at 450nm (See Figure 16). 
Graphs were plotted to show the absorbances against the varying concentrations of the 
standards. This was repeated three times and averaged to show reproducibility of the 
kits.  
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Figure 16: Illustrates the ELISA procedure. 
 Briefly, ELISA plates are coated with capture antibodies overnight. The plate is 
washed and blocked. The plate is washed and the standards and samples are added. 
After a period of 2 hrs the plate is washed again and detection antibodies are added for 
another 2 hrs. The plate is washed and streptavidin HRP is added for 30 mins and the 
plate is kept in the dark. The plate is washed three times and substrate peroxidase 
chromogen was added for 20 mins and finally stopped with 0.18M sulphuric acid. The 
absorbance is read on a plate reader at 450nm and graphs are plotted with the 
appropriate standard curve and samples. 
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2.2.4 Generating Microarray Standard Curves; Initial 
Protocol 
Microarray slides were purchased from Thermofisher (UK) with epoxysilane surface 
coatings. The protocol performed is similar to an ELISA. Briefly, diluted capture 
antibody was loaded onto a 384 well plate (Genetix), and arrayed onto slides at 
100µg/ml using a Biorobotics Microgrid II arrayer (Microgrid) and silicon contact 
pins (Parallel Synthesis Technologies, USA). Printed slides were blocked with either 
3% BSA (Sigma) or I-Block (Tropix) for one hour and washed three times with wash 
buffer (PBS-Tween 0.05%). Standards were made for each cytokine according to 
PDQXIDFWXUHU¶VLQVWUXFWLRQs and diluted two fold across seven dilutions and added at 
100µl per block in ten replicates for two hours. The slide was washed three times and 
100µl of appropriately diluted biotinylated detection antibody was added to each 
block for 90 mins. After washing three times with washing buffer, 100µl of 1:1000 
diluted streptavidin-conjugated cy5 (E-Biosciences, UK) was added and incubated at 
room temperature for 30 mins in the dark. The slide was washed three times and 
rinsed in ultra-pure water and centrifuged dry (Figure 17).  
Slides were spun dried and scanned with a 4200 AL microarray scanner at 635nm 
(Axon GenePix®). Fluorescence was quantified using the GenePix Pro Software 
(Axon GenePix®). The experiment was performed as an intra assay and repeated at 
least three times. As before the median fluorescence of each spot was measured 
(minus background) and the corrected fluorescence was used to calculate the average 
fluorescence signal across the standard detectable range (2000pg/ml-12.5pg/ml). 
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Figure 17: Illustrates the initial microarray method.  
Briefly, capture antibodies were mixed with PBS-Tre and printed on slides at 
100µg/ml. Slides were washed blocked with 3% BSA or I Block for one hour. Slides 
were then washed and standards/samples were added for 2 hrs. Slides were washed 
three times again and detection antibodies were added for 90mins. Slides were washed 
and streptavidin cy5 was added for 30 mins in the dark. The slide was finally washed 
and dried and scanned on the 4200 AL microarray scanner at 635nm. 
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2.2.5 Final Optimised Microarray Array Protocol 
Printed slides were blocked with I Block (Tropix) for one hour and washed three 
times with wash buffer (PBS-Tween 0.05%). A calibrated cocktail of standards were 
made for each cytokine according to manufacturer¶s instructions and diluted two-fold 
across eight dilutions and added at 50µl per block for 45mins. Additionally samples 
were added in corresponding wells on the slide. The slide was washed three times and 
50µl of appropriately diluted cocktail of biotinylated detection antibodies were added 
to each block for 45mins. After washing three times with washing buffer, 50µl of 
1:1000 diluted streptavidin-conjugated cy5 (E-Biosciences, UK) was added and 
incubated at room temperature for 15 mins in the dark. The slide was washed three 
times and rinsed in ultra-pure water and centrifuged dry.  
Slides were spun dried and scanned with a 4200 AL microarray scanner at 635nm 
(Axon GenePix®). Fluorescence was quantified using the GenePix Pro Software 
(Axon GenePix®). The experiment was repeated at least twice. As before the median 
fluorescence of each spot was measured (minus background) and the corrected 
fluorescence was used to calculate the average fluorescence signal across the standard 
detectable range. 
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2.2.6: Amplification 
Amplification was performed after the detection stage of the microarray process 
described above with the addition of 50µl of 1:1000 diluted streptavidin-HRP (Bio-
RAD, USA) and incubated at room temperature for 15 mins in the dark. The slide was 
washed and 50µl of Bio-Rad Amplification Reagent was added for 10 mins in the 
dark. The slides were washed three times with 20% DMSO-PBST and subsequently 
washed three times with wash buffer (see Figure 18). After washing, 50µl of 1:1000 
diluted streptavidin-conjugated cy5 (E-Biosciences, UK) was added and incubated at 
room temperature for 15 mins in the dark. The slide was washed three times and 
rinsed in ultra-pure water and centrifuged dry and analysed as mentioned above. 
 
Figure 18: The amplification procedure and the effect it has on a standard curve  
The HCN method is used to amplify the standard curve (A). As can be seen on the 
slide shot the effect of amplification increases the signal intensities of the spots (B). 
The effect of amplification is beneficial to the microarray platform as it is able to 
substantially increase the performance and range of the standard curve (C). 
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2.3 Printing 
Slides were used to investigate the effects of dwell time, target height and humidity on 
spot shape, size and intensity. A slide was taken and was split for print into two. The 
top half of the slide was kept constant for the slide target height at -0.18mm and the 
dwell time was varied between 0.00 sec to 4.00 sec. In the second half of the slide the 
dwell time was kept constant at 0.40sec and the target height was changed between 
0.0mm to -0.5mm (Figure 19). This was initially run without humidity (25-30% 
humidity) and repeated with humidity (60%). Each pad of the 16 pad slide was set to 
print up to 120 spots. The slide was processed as mentioned in 2.2.5 and signal 
intensity was measured as well as the number of spots printed per pad. 
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Figure 19: The layout of the print experiment. 
In the top half of the slide the target height was kept constant at -0.18mm and the 
dwell time was varied (A). In the bottom half of the slide the dwell time was kept 
constant at 0.40sec and the target height was varied (B). Additionally the experiment 
was run without humidity and then with humidity set at 60%. Note per pad up to 120 
spots were expected to be printed.  
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2.4: Microarray Validation 
Due to the lack of guidelines for protein microarray assays the accuracy and 
reproducibility of the methodology was established based on the guidelines outlined 
by the Food and Drug Administration (FDA) for pharmacokinetic assay validation 
where multiple validation experiments were performed including intra- and inter 
DVVD\V$VHULHVRI³VSLNH UHFRYHU\´H[SHULPHQWVZHUHDOVRSHUIRUPHG$GGLWLRQDOO\
healthy donors were quantified by both ELISAs and microarrays to see the 
comparison between techniques.  The accepted criteria for this assay for accuracy was 
between 80-120% and precision at <20% [227].  
2.4.1 Intra and Inter-Assay 
To determine the precision of the microarray platform, intra-assays and inter-assays 
were performed. Intra-assays were performed repeatedly over the same slide on the 
same day and inter-assays performed over a period of three consecutive days.  Up to 
30 sera from healthy donors were collected and quantified for 16 biomarkers. The 
mean of the replicates and standard deviation was used to calculate the precision of 
the microarray methodology.  
2.4.2: PBS Spikes and Serum Spikes 
PBS was spiked to three known concentrations at 750pg/ml, 188pg/ml and 24pg/ml 
using recombinant protein standards for each of the 16 biomarkers and quantified 
using the standard curves generated from the microarrays. These three spikes were set 
to be above and below the limits of quantification. Accuracy was calculated based on 
the observed concentration measured against the expected concentration that was 
spiked (%).  
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Additionally sera from healthy donors were taken and cytokine levels were quantified 
for all 16 biomarkers. This serum was then spiked to three known concentration 
points. The observed concentration was subtracted from background levels to 
calculate accuracy and precision. 
 
2.4.3 ELISA Vs Microarray Comparison 
The microarray technology was compared to a traditional ELISA. 30 sera from 
healthy donors were obtained and quantified for all 16 biomarkers through microarray 
and ELISAs. Direct correlations were made between the quantified values between 
techniques. Additionally Bland-Altmann plots were drawn as a means to understand 
the sensitivity between techniques. 
 
2.4.4: Lower Limit of Detection, Lower Limit of 
Quantification (LLoQ) and Upper Limit of 
Quantification (ULoQ) 
The lower limit of detection was calculated as the concentration of biomarker required 
to give a signal that was equal to the background (blank) plus three times the standard 
deviation of the blank. This was calculated from the average of 3 standard curves for 
all 16 biomarkers. Additionally the lower limit of quantification (LLOQ) can be 
calculated to be twice the level of the LOD [243]. However for the limits of 
quantification, these were the lowest and highest points that could be detected at an 
DFFHSWDEOHOHYHORIDFFXUDF\DQGSUHFLVLRQ+HQFHDVHULHVRI³VSLNHV´ZHUHUXQDWWKH
either end of the standard curves of the 16 biomarkers. The point where the precision 
fell below 20% was deemed to be LLoQ and 15% for the ULoQ as in line with FDA 
regulations for assay development. 
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2.5 Statistical Analysis  
For the comparison between ELISA and microarray techniques, paired t-tests were 
performed (Chapter 4). For the COPD samples where there were three or more 
groups, Kruskal-Wallis tests were performed DQGVXEVHTXHQWO\'XQQ¶VSRVWPXOWLSOH
comparisons tests between each subgroup. Where the software indicated there were 
significant differences between two groups, Mann-Whitney U tests were performed. 
For the correlation studies with age and FEV-1 predicted with cytokine concentrations 
6SHDUPDQ¶V U FRHIILFLHQW ZDV SHUIRUPHG &KDSWHU  $ ³S´ YDOXH RI  ZDV
considered to be statistically significant. Statistics and the generation of graphs were 
performed using Graphpad Prism 5.01.  
Undertaking multiple Kruskal-Wallis tests and correlations also constitutes for 
multiple testing and therefore needs controlling to avoid the rise in false positive data. 
Hence this was performed through J-Express Pro 2012 ± Build 119 which allows for 
IXUWKHUSURWHRPLFH[SUHVVLRQDQDO\VLV8VLQJWKLVVRIWZDUHWKH³VLJQLILFDQWDQDO\VLVRI
PLFURDUUD\V´RU³6$0´ZDVDPHWKRGFKRVHQWRFDOFXODWH WKHQXPEHURIJHQHV WKDW
are false positive. This was used on the data to see if any of the significant cytokines 
that were positively expressed were indeed showing as false-positive.   
All heatmaps and hierarchical clustering was performed using 
MultiExperimentViewer (MEV) version 4.7.4.  
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Chapter 3: Optimisation of an Antibody 
Microarray Platform  
3.1: Introduction 
The ability to measure an array of biomarkers systematically in the same experimental 
setting is highly desirable. As such, antibody microarrays are regarded as the future of 
biomarker detection in disease. In the case of multifaceted diseases such as COPD, 
which involves many immune cells, enzymes and mediators, microarray technology 
could detect biomarkers which could prove to be useful indicators of the disease 
process [129, 251-253].  
One of the biggest obstacles to this system is the slide surface. The surface chemistry 
of the slide dictates the mobilisation between the slide surface and the antibody or 
protein that is to be printed. The physical interaction between proteins and the slide 
surface by van der Waals, covalent, ionic or hydrophobic interaction needs to be 
optimised depending on the nature of the protein of interest [218].  
Commercially there is a large variety of slide surfaces. These can be split into two 
main categories; firstly 2D plain slides, which include aminosilane, epoxysilane or 
poly-L-lysine surfaces that interact by electrostatic or covalent bonds. Secondly, 3D 
slides that are gel or membrane coated surfaces and include nitrocellulose and agarose 
slides that interact by physical adsorption [254-257]. 
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Hence there are some important factors that should be considered when choosing the 
slide surface. These include a binding capacity, a signal-to-noise ratio, the ability to 
maintain the conformation of the protein that is once bound as well as the 
reproducibility between slides. The ideal slide would be a combination that enables 
maximal immobilisation and as well as maintaining the functionality of the antibody.  
The spot morphology is often dependant on factors such as the slide surface and the 
way the capture antibody interacts with the surface chemistry. Poor spot morphology 
is indicative of low antibody activity and in turn will lead to poor signal intensities 
[219, 258]. Hence it is important to distinguish which slide surface will provide the 
best spot morphology but more importantly give higher levels of intensity. 
Often the spot size and morphology are dependent on either the slide surface 
chemistry or the printing buffer. Certain slides surfaces can prevent spot spreading, 
leading to a reduced spot diameter and better spot morphology [219] [258]. The net 
result allows for more densely printed arrays. 
Prior work in the field has investigated individual parameters such a printing buffers 
or slides surfaces or blocking buffers across numerous publications. Work conducted 
by Olle W et al, has shown that glycerol to be an efficient printing buffer for printing 
antibodies [219]. Additionally work by Seurynck-Servoss et al investigated different 
slides surfaces which showed that both aminosilane and poly-L-lysine surfaces are 
preferable for antibody microarrays [218]. Finally work by Rimini et al investigated 
different types of blocking buffers onto antibody microarray surfaces which showed 
that BSA block was effective to in preventing non-specific adsorption [259].  
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Here we investigate for the first time multiple parameters simultaneously including 
variety of coating/blocking buffers using four different slide surfaces to investigate the 
impact on intensity (short and long-term) and spot morphology which provides an 
more in-depth understanding what is required to build a successful antibody 
microarray platform.  
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3.2: Materials and Methods 
Briefly slides were purchased from Thermofisher (UK). For the optimisation of slides 
surfaces, blocking buffers and investigating intensity levels poly-L-lysine, 
epoxysilane, aldehyde, aminosilane and nitrocellulose slides were used respectively. 
A variety of 8 in-house coating buffers were used to print on the slide surfaces (see 
Table 5) and the experiment was run either immediately or one week later. On the day 
of processing the slides were taken and blocked for an hour with a variety of blocking 
buffers including I Block, 3% BSA Block, 3% Milk and NAP blocking buffer. The 
slides were washed and incubated in solutions containing detection antibody 
conjugated with fluorescent dye for one hour. The slides were washed and spun dry 
and scanned at 488mm wavelength on the 4200 AL scanner. The intensity levels of 
these slides were compared against one another to distinguish which would represent 
the best slide surface for both short and long term use.  
For the remainder of the Chapter, poly-lysine slides were used. Due to the low level of 
sensitivity obtained, these slides were subject to amplification. Briefly, antibody 
duoset kits were purchased (R&D Systems, MN, USA) and printed on the slide. Slides 
were processed immediately or after one week. Slides on the day of processing were 
taken from the vacuum and blocked for an hour with either I Block or 3% BSA block 
buffer. Standards were made for all 16 cytokines (IL-8, IL-6, IL-1ȕ71)-Į([RWD[LQ-
1, Eotaxin-2, IFN-Ȗ 5$*( ,/-10, IL-4, IL-17, IL-23, MCP-1, VEGF and IP-10) 
DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV DQG GLOXWHG  IROG DFURVV  GLOXWLRQV DQG 
added at 100µl per block in 10 replicates for two hrs. The slide was washed three 
times and 100µl of appropriately diluted biotinylated detection antibody was added to 
each block for 90 mins. After washing three times with washing buffer, 100µl of 
1:1000 diluted streptavidin-conjugated cy5 (E-Biosciences, UK) was added and 
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incubated at room temperature for 30 mins in the dark. Slides were spun dried and 
scanned with 4200 AL microarray scanner at 635nm (Axon GenePix®).  
For the latter part of this Chapter, and the printing conditions as well as the role Cy5 
plays in the detection of antibodies and the detection of cytokines in both plasma and 
serum were investigated. Slides initially showed a lack of sensitivity at the lowest 
concentrations of standard curves, hence were subject to tyramide amplification. 
Briefly, this was performed after the detection stage of the microarray process 
described above with the additional of 50µl of 1:1000 diluted streptavidin-HRP (Bio-
Rad, USA) in the dark. The slide was washed and 50µl of Bio-Rad Amplification 
Reagent was added for 10 mins in the dark. The slides were washed three times with 
20% DMSO-PBST and subsequently washed thrice with wash buffer. After washing, 
50µl of 1:1000 diluted streptavidin-conjugated cy5 (E-Biosciences, UK) was added 
and incubated at room temperature for 15 mins in the dark. The slide was washed 
three times and rinsed in ultra-pure water and centrifuged dry and analysed as 
mentioned above. 
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3.3: Results 
To compare printing buffers, 8 commercially available print buffers were tested across 
different slide surfaces. Capture antibodies (moclonal rat anti-mouse IgG1) were 
mixed with 8 different print buffers (PBS, PBS-T, PBS-GLYc, PBS-GLYc-Tw, PBS-
GLYc-TwTre, PBS-Tre, PBS-Tre-Tw and DMSO) and detected with an Alexa Fluor 
488 labeled mouse IgG1, isotype control. 
The median signal intensities of the spots were calculated. In addition the spot 
morphology and size were also considered. The final aspect of this investigation was 
to examine the effect of storage. It is important to find a surface that when stored 
would produce the same level of intensity when printed freshly and analysed 
immediately. Hence the correct combination of print buffer and slide surface is 
sought. 
3.3.1 Epoxysilane 
Epoxysilane slides provide an epoxy ring that reacts with the amine group on 
antibodies and proteins that are spotted. 
3.3.1.1 Slides surface and coating buffer 
The average intensity of 8 printing buffers across concentration of primary antibody 
ranging from 250µg/ml to 0.49µg/ml on epoxysilane slides was measured (Figure 
3.1.). The average intensity falls quite dramatically after 125µg/ml for most buffers. In 
these conditions on this slide surface PBS-GLYc, PBS-TRE and to a lesser degree 
PBS perform the best at with the highest intensities measured at over 16000 AU for 
PBS-Tre and over 12000 AU for both PBSGLY and PBS (Figure 20). PBS-Tre 
performs the best with both blocking buffers used and is the most consistent printing 
buffer on this particular slide surface.  
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Intensity levels could not be maintained at low concentrations in all 8 printing buffers. 
With both blocking buffers most signal intensities dropped to almost non-recordable 
levels below 31.25µg/ml.  
Epoxysilane slides exposed to air lost intensity as the slide surface would interact with 
the atmosphere and lose reactivity. PBS-Tre could be suggested as a best printing 
buffer as the average intensity was the highest but subsided sharply with decreasing 
concentrations of capture antibody printed (at 31.25µg/ml). 
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Figure 20: Signal intensity of 8 printing buffers on epoxysilane slides. 
The average intensity of 8 printing buffers across monoclonal rat anti-mouse IgG1 
serially diluted, ranging from 250µg/ml to 0µg/ml with the addition of mouse IgG1 
secondary antibody diluted 1:500, then blocked in 3% BSA (A) and I Block (B) on 
epoxysilane slides was measured. On this slide surface PBS-Tre showed to be the best 
coating buffer with the highest level of intensity and had the best dynamic range with 
signals detectable as low as 15.6µg/ml. Interestingly PBS-Tre performs the best with 
either blocking reagent where the other 7 buffers are not so consistent (n=3). 
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3.3.1.2 Epoxysilane Spot Morphology and Size 
Spot morphology is dependent on a variety of factors including the choice of slide 
surface and coating buffers. In the case of PBS, the comet like spotting that occurs at 
the highest concentration indicates there is too much capture antibody loaded onto the 
spot (Figure 21). As there is so much capture antibody it cannot be sufficiently 
contained within the coating buffer, DQGKHQFHWDLOVRIIDVLWLV³ORRVHO\´ERXQGWRWKH
surface potentially leading to falsely interpreted results.  
The spot morphology for PBSTre was good, so in conjunction with figure 20, PBSTre 
seemed the most suitable coating buffer for epoxysilane slide surfaces. The next step 
was to establish the optimum capture antibody concentration to coat a variety of 
cytokines/antibodies.  
 
 
Figure 21: Spot morphology epoxysilane slides when tested with 8 coating buffers. 
Of the 8 coating buffers tested only PBS, PBS-GLYc and PBS-Tre and to a lesser 
degree PBSTreTw produced any signals that could be quantified as shown graphically 
in Figure 20 showing the suitability of these coating buffers on epoxysilane slide 
surfaces. 
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3.3.1.3 Epoxysilane Short vs Long-Term effects of 
Printing 
Antibodies were printed on epoxysilane slide surface. These were processed 
immediately or one week later once left in dessciated vacuum. 
 As can be seen there is a big drop in intensities when the slides are processed after 
one week indicating the slide surface chemistry does not efficiently hold the antibody 
over a period of time. Specifically, buffers such as PBS, PBS-GLYc, PBS-Tre 
(starting at 15000 AU immediately and dropping to less than 1000 AU after 1 week) 
and PBS-Tre-Tw that produced high levels of intensities when processed and analysed 
immediately all experienced a sharp drop in intensity 1 week later. This shows that 
this type of slide surface is not ideal when investigating the utility for long-term 
measurement of biomarkers (Figure 22). 
The epoxy slides were tested with I Block to see if a different blocking buffer could 
produce a higher intensity than 3% BSA. However there were no discernible 
difference between I Block and 3% BSA block irrespective of spot intensity, 
morphology or short vs long-term use. 
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Figure 22: Signal intensity of epoxysilane slides processed immediately or delayed. 
The signal intensities between the coating buffers when analysed fresh and analysed 
after a week once printed. The average intensities were measured at the top end range 
of 250 µg/ml of capture antibody when blocked with 3 % BSA Block (A) or I Block 
(B). Buffers such as PBS,  PBS-Tre and PBS-Tre-Tw consistently produced high 
levels of intensities when processed and analysed immediately (with either blocking 
buffer) but all experienced a sharp drop in intensity when processed one week later. 
This indicates this is not the best surface for the long-term use of an antibody 
microarray platform (n=3). 
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3.3.2 Aminosilane 
The aminosilane slide surface provides available amines groups that provide a solid 
covalent bond between the slide surface and the protein. The composition of the slide 
surface chemistry provides a high signal to noise ratio [260]. 
3.3.2.1 Slides surface and coating buffer 
The average intensity of 8 printing buffers across concentrations of capture antibody 
ranging from 250µg/ml to 0µg/ml with the addition of secondary antibody diluted 
1:500, then blocked in 3% BSA on aminosilane slides was measured (Figure 23). The 
coating buffers, in particular PBS-Tre-Tw and PBS-Glyc produced the best curves. 
PBS-Tre-Tw had the highest intensity with a peak of 25000 AU (at 250µg/ml) and 
had the most consistent curve with intensities detectable as low as 15.5µg/ml. When I 
Block was used as a blocking buffer, PBS and PBS-Tre-Tw produced the best curves. 
PBS had the highest intensity at 15000AU (at 250µg/ml) and was the most consistent 
curve. Note that the overall levels of intensity of the 8 printing buffers were lower 
when blocked with I-Block compared to 3% BSA.  
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Figure 23: Signal intensities of 8 printing buffers on aminosilane slides. 
The average intensity of 8 printing buffers across monoclonal rat anti-mouse IgG1 
serially diluted, ranging from 250µg/ml to 0µg/ml with the addition of mouse IgG1 
secondary antibody diluted 1:500, then blocked in 3% BSA (A) and I Block (B) on 
aminosilane slides was measured. On this slide surface PBS-Tre-Tw (A) showed to be 
the ideal coating buffer with the highest level of intensity and had the best dynamic 
range with signals detectable as low as 15.6µg/ml. Interestingly PBS performs 
marginally better than PBSTreTw in I-Block (n=3). 
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3.3.2.2 Aminosilane Spot Morphology and Size 
Aminosilane slides produce nice spot morphology for all printing buffers (Figure 24).  
The shape of the spots are round-doughnut and fairly consistent. Note with PBS-Tre 
the shape of the spot decreases in diameter as the concentration decreases of capture 
antibody. However DMSO does not spot after 250µg/ml, whilst the PBS-T, PBS-
Glyc-Tw and PBS-Glyc-Tw-Tre show autoflourescence at the lowest concentration. 
 
Figure 24: Spot morphology aminosilane slides when tested with 8 coating buffers and 
blocked with 3% BSA. 
Of the 8 coating buffers tested only PBS-Tre-Tw stood out as the print buffer that 
produced any signals which could be quantified as shown graphically in Figure 23 
showing the suitability of these coating buffers on aminosilane slide surfaces. 
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3.3.2.3 Aminosilane Short vs Long-Term effects of 
Printing 
The short-term vs long-term effects of aminosilane was investigated as described with 
epoxysilane slides. Aminosilane, like epoxysilane provides a surface chemistry that 
performs well when processed immediately. Short-term using both 3% BSA block and 
I Block, aminosilane produce moderate levels of intensity but with high variability, 
whilst long term the intensity drops dramatically but the variability is reduced with 
both blocking buffers (Figure 25). This once again indicates whilst short term the slide 
surface chemistry provides good intensities and spot morphologies, long term it may 
not be the ideal surface moving forward. Interestingly, PBS-Tre-Tw in I-Block 
produced a high level of variation indicating this combination of print buffer, slide 
surface and blocking buffer is unsuitable. 
The poor spotting nature of DMSO print buffer on slide surfaces resulted in this buffer 
being removed in future analysis of the short and long-term effects of printing (Figure 
25). 
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Figure 25: Signal intensity of aminosilane slides processed immediately or delayed 
The signal intensities between the coating buffers when analysed fresh and analysed 
after a week once printed. The average intensities were measured at the top end range 
of 250 µg/ml of capture antibody when blocked with 3 % BSA Block (A) or I Block 
(B). The aminosilane surface is not conducive to preserving the formation of the 
antibodies as shown by a drop of intensity after one week when processed. In all the 
buffers the intensities have dropped indicating that this slide surface chemistry is 
unsuitable when used long term when preserving the functionality of the antibody 
(n=3). 
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3.3.3 Poly-L-Lysine 
Like aminosilane slides, poly-L-lysine slides provide a dense layer of amine groups 
which are ideal for binding a variety of molecules such as proteins, DNA and 
oligonucleotides [261]. 
3.3.3.1 Slides surface and coating buffer 
The average intensity of 8 printing buffers across concentrations of primary antibody 
ranging from 250µg/ml to 0.49µg/ml with the additional of secondary antibody 
diluted 1:500 in I-Block on poly-L-lysine slides were measured.  
As can be seen PBS-Tre and PBS-Tre-Tw produce the best curve. The consistency of 
both buffers across the 3 slides surfaces investigated thus far shows their adaptability. 
The intensity is moderate to high and is detectable as low as 7.8µg/ml showing its 
effectiveness at the lower range (Figure 26). Interestingly, most coating buffers apart 
from PBS-Tre and PBS-Tre-Tw produced intensities that were too low for detection. 
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Figure 26: Signal intensities of 8 printing buffers on poly-L-lysine slides. 
The average intensity of 8 printing buffers across monoclonal rat anti-mouse IgG1 
serially diluted, ranging from 250µg/ml to 0µg/ml with the addition of mouse IgG1 
secondary antibody diluted 1:500, then blocked in 3% BSA (A) and I Block (B) on 
poly-L-lysine slides was measured. The level of intensity did not vary greatly between 
3% BSA Block and I Block. Both PBS-Tre and PBS-Tre-Tw produced the greatest 
intensities of the buffers (n=3). The shape of both curves are smooth and detectable at 
the lower range of capture antibody showing both coating buffer has the capacity to 
work to a broad dynamic range. The intensities for both peaked at approximately 1375 
AU (PBS-Tre-Tw) and 15000 AU (PBS-Tre) which is moderate to high in comparison 
to aminosilane and epoxysilane slides from Thermofisher. Both PBS-Tre and PBS-
Tre-Tw have been the most consistent print buffers across the 3 slide surfaces 
investigated so far showing their efficiency despite changes in slide surface chemistry 
(n=3). 
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3.3.3.2 Poly-L-lysine Spot Morphology and Size 
The spot morphology did not vary between blocking buffers. Interestingly auto-
fluorescence was observed using both block buffers at the lowest capture antibodies 
concentrations indicating the problem is due to the nature of the slide surface 
chemistry especially at the lowest concentrations (Figure 27). Additionally for PBS-
Tre-Tw the diameter of the spots were approximately 100 microns in size. 
 
Figure 27: Spot morphology aminosilane slides when tested with 8 coating buffers and 
blocked with 3% BSA. 
Spot morphology poly-L-lysine slides when tested with 8 coating buffers.  All 8 
printing buffers produced any signals that could be quantified as shown graphically in 
figure 26 especially PBS, PBS-Tre and PBS-Tre-Tw showing the suitability of these 
coating buffers on poly-L-lysine slide surfaces. 
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3.3.3.3 Poly-L-Lysine Short vs Long-Term effects of 
printing 
Antibodies were printed on poly-L-lysine slide surfaces. These were processed 
immediately or one week later once left in dessciated vacuum. As can be seen with I-
Block, the intensity of the slide increased across all 7 buffers, when the slides were 
printed, stored then analysed one week later. Apart from PBS, the remaining 6 buffers 
showed an increase in intensity with time. A possible explanation is due to the 
proteins having sufficient time (7 days) from printing to adsorb to the surface of the 
slide allowing a greater level of intensity when analysed (Figure 28). Interestingly, 
when blocked with I Block there is also less variation amongst all 7 buffers suggesting 
a mixture of I Block and poly-L-lysine could potentially be the optimum combination 
for printing, storing and maintaining functionally active antibodies.   
In the case of PBS, there was a high level of variability over three repetitions leading 
to high standard deviations and combined with low levels of intensities both 
immediately processed and delayed, show that this buffer is unsuitable for coating of 
desired proteins or antibodies. Both PBS-Tre and PBS-Tre-Tw stand out, in particular 
the latter (with small deviations and high reproducibility) show promise when 
considering a printing buffer to use long-term (Figure 28). 
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Figure 28: Signal intensity of poly-L-lysine slides processed immediately or delayed. 
The signal intensities between the coating buffers when analysed fresh and analysed 
after a week once printed with 3 % BSA (A) or I Block (B). The average intensities 
were measured at the top end range of 250 µg/ml of capture antibody. All 7 buffers 
showed an increase in intensity when processed a week later except in the case of PBS 
which decreased in intensity. This indicates with the correct print buffer this surface is 
conducive to long-term storage of slides and can functionally maintain antibodies until 
processing. Note DMSO was not included in the final analysis due to the variability in 
print pattern (n=3). 
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3.3.4 Nitrocellulose 
Nitrocellulose slides offer an alternative surface to the slide surfaces described 
previously. A thin nitrocellulose coating provides a suitable surface that allows for a 
non-covalent surface for the adhesion of molecules of interest [262]. As this is a 
coating that does not react with moisture in the atmosphere compared to certain silane 
surfaces it offers possibly the best alternative to printing the desired capture antibodies 
which can then be stored over an indefinite time and processed when required. 
Additionally it has been reported that nitrocellulose slides can offer the lower levels of 
background and enhanced signal to noise ratios compared to three slides surfaces 
discussed above. 
3.3.4.1 Slides surface and coating buffer 
The average intensity of 7 printing buffers across moclonal rat anti-mouse IgG1 
serially diluted, ranging from 250µg/ml to 0µg/ml with the addition of mouse IgG1 
secondary antibody diluted 1:500, then blocked in 3% BSA, I-Block and 3% Milk 
Block respective on nitrocellulose (Gentel Biosciences) slides were measured. As can 
be seen from figure 29, irrespective of the blocking buffer used, the vast majority of 
the printing buffers did not react well with the nitrocellulose surface. In particular 
buffers that contained glycerol had very low levels of intensity across the three 
blocking buffers. Additionally the better buffers (PBS and PBS-Tre-Tw) were both 
inconsistent in shape of their standard curves with neither buffer being smooth. With 
the shape of the curves being so poor, it was hard to be conclusive about the exact 
point where the intensity levels dropped beyond measureable levels with certain 
buffers increasing sporadically as the capture antibody concentration decreased 
(Figure 29).  
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Figure 29: Signal intensity of 8 printing buffers on nitrocellulose slides. 
The average intensity of 8 printing buffers across monoclonal rat anti-mouse IgG1 
serially diluted, ranging from 250µg/ml to 0µg/ml with the addition of mouse IgG1 
secondary antibody diluted 1:500, then blocked in 3% BSA (A), I Block (B) and Milk 
Buffer (C) on nitrocellulose slides were measured. As seen in all three graphs, the 
most consistent print buffers were PBS, PBS-Tw and PBS-Tre-Tw. However most of 
the printing buffers reacted poorly with the slide surface which coincided with 
inconsistent graphs, across the three different blocking buffers (n=3). Additionally as 
noticed on the slide shots, at the highest concentration there was comet like 
formations, suggesting the problem lies with the amount of capture antibody printed 
(Figure 30).  
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3.3.4.2 Nitrocellulose Spot Morphology and Size 
With all blocking buffers at the highest concentration of capture antibody, there 
appears to a combination of poor spotting or comet like formation indicating at 
250µg/ml there is an overload of antibody which is not bound to the surface leading to 
lower than expected signal intensities. It can be noted compared to the poly-L-lysine 
the spotting is not as distinguished suggesting the coating buffers interacts differently 
with the 4 slide surfaces investigated (Figure 30).  
 
 
 
Figure 30:  Image to show irregular spotting and smearing of print buffers on nitrocellulose 
slides when blocked with 3% BSA.  
At the top concentration of 250µg/ml there was a lot of comet like formations within 
the spots leading to falsely low intensities indicating at this concentration the 
antibodies are loosely bound or are too high for the slide surface to hold. Additionally 
the size and shape of the spots are inconsistent when they are printed and at the lowest 
concentration signals are not being detected suggesting potential this type of 
nitrocellulose slide surface may be unsuitable for antibody microarray work. 
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Smears and comet like formations at top dilution when printed. 
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3.3.4.3 Nitrocellulose Short vs Long-Term effect of 
Printing 
The strength of the intensities produced from nitrocellulose slides using the above 
procedures increases when the slide is analysed after a week compared to when it is 
processed immediately (Figure 31). When proteins were not given the adequate time 
to bind to the surface when printed and processed immediately, a large majority of 
these antibodies are removed duULQJ WKH ³ZDVK´ SKDVH DQG WKXV OHDGV WR D ORZHU
intensity signals. As shown in Figure 30, DMSO poor spotting pattern led to its 
exclusion when investigating short versus long-term storage study.  
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Figure 31: Signal Intensity of nitrocellulose slides processed immediately or delayed. 
The average intensity of 7 printing buffers at 125µg/ml of capture antibody when 
processed and analysed immediately with the additional of secondary antibody diluted 
1:500 and stored and analysed 1 week later in 3% BSA blocking buffer (A), I Block 
(B) and 5% Milk Block (C) (n=3). As can be seen in PBS-Tre-Tw and PBS-Tre there 
is an increase in intensity when analysed a week later showing that these buffers have 
the capacity to hold an antibody functionally active over a course of a week. In 
general the errors bars are much higher than those observed in poly-L-lysine 
suggesting that this surface despite the ability to hold antibodies better than 
aminosilane or epoxysilane over a period of a week is not as reproducible as poly-L-
lysine. 
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3.3.5: Milk and NAP Blocking Buffer 
NAP Block buffer is a non-animal protein blocking agent used in a vast array of 
immunodetection assays such as western blots and ELISAs [263, 264]. 5% Milk 
buffer is a type of casein blocking buffer that is made fresh prior to use. However 
NAP and 5% milk block buffers led to high background and in certain cases smearing 
of the slides were noticed when scanned (data not shown). This indicates insufficient 
blocking. This may indicate that potentially these blocking buffers may be more 
suitable for 3D planar surfaces such as nitrocellulose compared to the 2D surfaces of 
epoxysilane, aminosilane or poly-L-lysine. These two blocking buffers subsequently 
were excluded from future work and not shown in conjunction with the results shown 
above. 
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The following table shows a summary of all the four slide surfaces tested. As seen, in 
terms of consistency and reproducibility, poly-L-lysine slides were the best overall. 
Despite a better reproducibility in both aminosilane and epoxysilane a week later a 
dramatic drop in intensity was seen. Only in poly-L-lysine and nitrocellulose slides 
were there an increase in the level of intensity over time suggesting this slide surfaces 
is conducive to both short and long term processing. However there was a greater 
variation in nitrocellulose slides compared to poly-L-lysine slides. Interestingly 
aldehyde slides were printed with the 8 coating buffers however once processed no 
spots appeared suggesting that this type of slide surface is not suited for antibody 
microarray work. Epoxysilane slides offered the highest levels of intensity of all the 
slide types (Table 11). Hence moving forward to complete the remainder of the 
antibody microarray work, poly-L-lysine slides were used unless stated otherwise: 
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Table 11: Summary of the optimisation tests performed across the 5 slide surfaces. 
Overall poly-L-lysine slides were the best type of slides surfaces which offered the 
highest level of consistency. Most encouraging was the increase in intensity levels that 
was observed in poly-lysine slides over time making them very desirable for future 
antibody microarray work. Both aminosilane and epoxysilane dropped in intensity 
when slides were printed after one week making them undesirable for long term use. 
Nitrocellulose slides produced inconsistent spot morphology with moderate signal 
intensities which made them undesirable. Hence moving forward poly-L-Lysine slides 
would be used in future experiments 
 
. 
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3.3.6 Establishing the optimum capture antibody 
concentration for printing on poly-L-lysine slides  
Poly-L-lysine slides in conjunction with PBS-Tre as the print buffer will be used for 
future antibody microarray work. The next stage of the investigation was to consider 
the concentration of capture antibody that is printed on this slide surface that would 
allow for best signal intensity whilst being consistent in both spot size and 
morphology. The RANTES duoset kit was used and slides were processed at three 
capture antibody concentrations (200µg/ml, 100µg/ml and 50µg/ml respectively) 
Printed slides were blocked for 1 hour in 3% BSA and I-Block. After blocking, slides 
were washed three times with PBST (containing 0.05% Tween-20) and incubated in 
solutions containing detection antibody conjugated with fluorescent dye for 1 hour at 
room temperature on a shaker. Slides were washed with PBST (as described above) 
and rinsed briefly in ultrapure water. Slides were dried by spinning at 1200 rpm for 5 
min and scanned a 4200 AL microarray scanner (Axon GenePix®). Standard curves 
were drawn to compare the three concentrations of capture antibodies. 
As seen from Figure 32 there is little difference in the strength of the standard curves 
with capture antibody concentrations printed at 200µg/ml compared to 100µg/ml. 
However it was observed that at 50µg/ml there is a sharp drop in intensity suggesting 
at this concentration is would be inappropriate to print capture antibodies. 
Additionally at the lower end of the standard curve (from 100pg/ml) there is no 
difference between the standard curve printed at 200µg/ml and that printed at 
100µg/ml. Additionally the choice of blocking buffer did not have an effect on the 
signal intensity as the results with I Block were similar to those produced by 3% BSA 
block (results not shown).  
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Hence from Figure 32 it was established that printing at 100µg/ml would be the 
optimum concentrations for all future antibodies that are printed on the microarray 
platform. 
 
Figure 32: Choosing the optimal concentration of capture antibody that was printed on a 
poly-L-lysine slide surface and blocked with 3 % BSA. 
A substantial drop in intensity was not observed between standard curves printed at 
200µg/ml and that printed at 100µg/ml. However at 50µg/ml the standard curve 
dipped to near undetectable levels at 100pg/ml. The experiment was repeated using I-
Block which produced similar trends in the standard curve. This suggested at 
100µg/ml is the optimal capture antibody concentration for printing antibodies on 
poly-L-lysine slides.  
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3.3.7 Poly-L-Lysine Standard Curve Reproducibility 
In section 3.3.3.3 we have shown that poly-L-lysine is the ideal surface for both short 
and long term printing and processing. However this was only applied to capture 
antibody that was serially diluted. We therefore tested whether the impact of an 
increase in signal intensity is recorded when standard curves are drawn for TNF-Į
Rantes, GMCSF, MCSF, IL-2 and IFN-Ȗ respectively.  
These six cytokines were taken and processed as outlined in section 2.2.4. Briefly, 
standard curves were drawn using poly-L-lysine slides that were processed 
immediately and delayed without amplification. As can be seen in Figure 33 the 
highest intensities in the standard curves were spotted when poly-L-lysine slides were 
processed after a week (delayed). Interestingly the standard curves were higher in 
poly-L-lysine slides that were processed a week later. This is in-line with the 
observations noted from Figure 33 where an increase in signal intensity was observed 
with PBS-Tre when processed a week later. Also it can be seen in figure 33 that there 
is no major difference between the signal intensities between poly-L-lysine slides 
processed immediately and those delayed. This shows that poly-L-lysine is a surface 
that can allow slides to be processed at any given time point which is extremely useful 
moving forward. So in future for further experiments poly-L-lysine slides were 
processed immediately unless stated otherwise.  
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Figure 33: Showing the effect of processing poly-L-lysine slides immediately and delayed on 
standard curves using six cytokines: (A) TNF-ɲ ? ? ?ZĂŶƚĞƐ ? ? ?'D^& ?(D) MCSF, (E) IL-2 and 
(F) IFN-ɶ respectively. 
 When poly-L-lysine slides are printed and processed a week later they produce the 
highest levels of intensities compared to the same slides that are printed and processed 
immediately (red vs. black lines). However there is not a big difference between the 
signal intensities when they are printed immediately or delayed suggesting this surface 
is suitable for all types of printing and storage.  
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3.3.8 Sensitivity at the lower end of a standard curve 
A key aim of this thesis is the ability to measure multiple biomarkers at very low 
concentrations. However using the protocol outlined in section 2.2.4, there was a lack 
of signal intensity at the lowest concentrations of the standard curves (Figure 34). At 
the lowest concentrations of the 6 cytokines standard curves there is a minimal signal 
which could cause a problem when measuring low abundant cytokines in serum. This 
indicates that the poly-L-lysine surface may be incapable of detecting proteins at the 
lowest concentration. Hence the use of amplification was considered to improve the 
sensitivity of the lower end of the standard curve. 
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Figure 34: Standard curves for 6 cytokines at the lower end of the standard curve. 
As can be seen in all 6 cytokines there is a lack of signal at the lower end of the 
standard curve. In the case of most cytokines, below 100pg/ml there is very little 
signal. It is known that most healthy individuals and COPD patients have cytokines 
concentrations that are equal to or below 100pg/ml, these standard curves will have to 
be improved through amplification in the future.  
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3.3.9 Amplification 
Amplification was used to improve the sensitivity of the lower range of the standard 
curves of low abundant cytokines. Figure 35 gives an example of one low abundant 
cytokine that was investigated (GCSF). Signals were amplified using the BIO-RAD 
amplification system. Upon amplification the signal intensity is multiplied almost 10 
times (Figure 35A). Furthermore with amplification signals can be detected as low as 
6pg/ml for GCSF (Figure 35B). Interestingly, the level of background on the slide 
dropped from an average of 120 AU to 60 AU, which helps enhance the sensitivity of 
the assay (Figure 35C). The signal to noise ratio was again enhanced upon 
amplification when the slide is processed normally (Figure 35D). This was found to 
be the case in all cytokines tested. 
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Figure 35: The effect of Bio-Rad amplification is three fold; it allows the raising of the 
standard curve in general enabling greater sensitivity at the lower concentration. 
The difference between a non-amplified and amplified standard curve is shown (A). 
There is a marked difference at the lowest end of the standard curve with a higher 
level of intensity observed with the amplified curved compared to the normal curve 
(B). Additionally the background levels that were previously noticed were reduced 
(C) and as a result the signal-to-noise ratio of the spots were improved allowing for 
better detection at the lower concentration (D).  
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3.3.10: Time Course Experiment to Optimise Cytokine 
Standard Curves 
An important aspect oI WKH PLFURDUUD\ SURWRFRO ZDV WR EH TXLFNHU WKDQ WKH ³JROG
VWDQGDUG´ (/,6$ 2IWHQ (/,6$V KDYH  KU LQFXEDWLRQV ZKHQ VWDQGDUGVVDPSOHV DUH
added and also after detection antibodies are added, so the process could take up to 8 
hours from start to finish. However with the multiplexing nature of the microarray it 
was important not only to develop a platform that could measure multiple biomarkers 
but also one that could be fast and deliver a quick turnaround. Subsequently from the 
original protocol 2.2.4 each procedural step i.e. blocking, adding of standards and 
detection were continually halved and the signal intensity was measured. It was 
important to maintain a high level of intensity and also work out the optimal time for 
each stage of the microarray process. As seen in Figure 36, when the assay was run at 
half the intended time, the strength of the standard curves were superior than when the 
assay was run according to the original devised protocol. This may be due to reagents 
working best within a limited time frame across the slide surface and if left on for 
longer than required reduces the efficiency of the performance. Additionally, 
alternative factors like evaporation and exposure to the external environment when 
running the array are halved which could also have a bearing on the signal intensity.  
Subsequently from the data analysed from Figure 36, including previous knowledge 
gained from understanding both blocking and amplification steps, the protocol was 
modified and outlined as written in section 2.2.5. This protocol was used for all 
experiments described hereafter. 
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Figure 36: Time course experiment to optimise microarray protocol: 
With IL-8 (A), IL-6 (B) and TGF-ȕ 'ZKHQ WKHSURWRFRO OHQJWKZDVKDOYHGIURP
the original time (to 5.5 hours), the strength of the signal is increased whereas in TNF-
Į&WKLVLVIDLUO\FRPSDUDEOHWRWKHRULJLQDOWLPH+DOYLQJWKHRULJLQDOWLPHPD\EH
the optimal time required for most of the reagents to work at their best. Additionally 
halving the original time of the protocol maybe what is required to reduce the effect of 
external environmental factors such as evaporation.  
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3.3.11 Printing Conditions on Poly-L-Lysine slides 
Printing, along with the slide surface, is a crucial step in the microarray process. It is 
important to get the settings correct for printing as it will allow the optimal size and 
shape of a spot to be printed. Experiments were subsequently undertaken to 
investigate the different factors that are involved in the printing procedure. This 
includes the dwell time (the amount of time the pin spends on each spot) from 0.0 sec 
to 3 sec and the target height (the distance at which the pin comes from to print on the 
surface of the slide) from 0.0mm to -0.60mm and also the number of spots the pin can 
print in the absence or presence of humidity. The number of spots were counted per 
well and the average calculated upon the experiment being repeated three times.   
As seen in Figure 37, there is a major difference between printing with (58%) and 
without humidity (30%). Firstly when investigating dwell time and the number of 
spots printed, it can be seen that as the dwell time increases there is a decrease in the 
number of spots which are printed. This is the general trend observed with/out 
humidity. However one can see clearly in Figure 37A where there is no humidity there 
are less spots printed. This is because without humidity the rate of evaporation in the 
microarray chamber is increased. Therefore capture antibody that is picked up in the 
pin is more prone to evaporation resulting in less capture antibody that is available to 
be printed on the slide surface and hence less spots being printed. Additionally when 
the dwell time is increased, the time between spotting is increased allowing 
evaporation to take greater effect.  
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Secondly, when investigating target height a similar trend is observed where humidity 
aids more spots to be printed; however the effects are not as great as that observed 
with dwell time. In general, as the target height increases there is not a big difference 
in the number of spots that were printed. However it has to be noted that at a target 
height of -0.60mm, the pin did not touch the slide surface enough to allow spots to be 
printed and were not included in Figure 37 B. 
Interestingly when the spot size, shape and diameter were investigated there was no 
difference in increasing dwell time or target height.  
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Figure 37: The effect of dwell time and target height on spot printing. 
The effect of printing on poly-L-lysine slides was investigated in further depth. 
Initially the effect of humidity was investigated to see the number of spots that could 
be printed with humidity (58%) and without humidity (30%). The number of spots are 
counted per well and the average calculated as the experiment is repeated. As seen 
humidity enables more spots to be printed irrespective of changes in dwell time or 
target height. Additionally as dwell time increased there were less spots printed due to 
evaporation that occurred in the microarray chamber (A). Target height does not affect 
the number of spots printed except in the case where humidity allows slightly more 
spots to be printed (B). 
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Figure 38: The effect of dwell time and target height on spot diameter/size. 
The effect spot diameter was investigated with by varying both the dwell time and 
target height. The spot diameter was calculated using the 4200AL scanner measuring 
tool for all spots. The average spot diameter was calculated and plotted above. As 
seen above, the increase of dwell time or target height does not have an effect of spot 
diameter or size (A/B) with (58%) or without humidity (30%)  
 
Chapter 3: Optimisation of an Antibody Microarray Platform 
 
 
~ 124 ~ 
 
From the data gathered from these experiments, the optimal printing conditions were 
as follows: dwell time: 0.40sec, target height -0.184mm and the humidity was set to 
58%. This is used for all subsequent experiments in thesis. 
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Figure 39: The effect of dwell time and target height on signal intensity. 
As seen without humidity, the signal intensity is decreased irrespective of increases in 
dwell time and target height (A & B). Interestingly, the increase in dwell height and 
target height does not cause major changes in signal intensities. Humidity causes 
evaporation which may affect the signal intensity irrespective of the spot size and 
shape. 
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3.3.12: Cy5 and the Long terms effects on the slide 
surface 
Here we examined the use of Cy5 for detection on microarray. A major consideration 
in using cy5 is the possible effect of signal detection over time. Hence the long term 
effects of cy5 on poly-L-lysine slides were investigated.  
Briefly printed slides were blocked with I Block (Tropix) for one hour and washed 
three times with wash buffer (PBS-Tween 0.05%). A calibrated cocktail of standards 
(IL-6, IL-17, IP-10 and MCP-1) were made for each cytokine according to 
manufacturer¶s instructions and diluted two-fold across eight dilutions and added at 
50µl per block for 45mins. The slide was washed three times and 50µl of 
appropriately diluted cocktail of biotinylated detection antibodies were added to each 
block for 45mins. After washing three times with washing buffer, 50µl of 1:1000 
diluted streptavidin-conjugated cy5 (E-Biosciences, UK) was added and incubated at 
room temperature for 15 mins in the dark. The slide was washed three times and 
rinsed in ultra-pure water and centrifuged dry. Slides were spun dried and scanned 
with a 4200 AL microarray scanner at 635nm. 
Subsequently, the processed slide was preserved, protected from light and kept in a 
vacuum and analysed at repeated intervals over a period of weeks and months. The 
graphs in figure 40 show that cy5 fluorescence intensity does not drop over time and 
is consistent over a period of 2 months.  This is important in the long term analysis of 
patient samples, as the slides can be preserved for up to 2 months or more, these 
samples can be taken re-scanned and recalculated if required. The key to the 
effectiveness of the cy5 is due to a combination of slide surface and also the print 
buffer that does not change over time. 
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Figure 40: The long terms effects of cy5 on signal intensity. 
 The durability of cy5 was tested over a period of two months. Processed slides was 
preserved, protected from light and kept in a vacuum and analysed at repeated 
intervals over a period of weeks and months. Slides were scanned for 4 cytokines (A-
D) and as seen there is no major drop in the strength of the signal over time. This 
shows the strength of cy5 when stored correctly remain very consistent over a 
prolonged period of time and can be stored and rescanned if required.  
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3.3.13: The Effects of Blocking Buffers in 
Serum/Plasma 
Before the validation phase is conducted with serum or plasma, it is important to 
define the optimum blocking buffer that is to be used on both serum and plasma that 
contain a variety of proteins that could interfere with the microarray. Initially three 
serum and plasma were taken from healthy donors and processed. 
Serum and plasma was obtained from the sample healthy individuals and the slides 
were processed and blocked with 3% BSA as described in 2.2.5. Briefly, printed 
slides were blocked with a blocking buffer for one hour and washed three times with 
wash buffer (PBS-Tween 0.05%). A calibrated cocktail of standards were made for 
each cytokine according to manufacturer¶s instructions and diluted two-fold across 
eight dilutions and added at 50µl per block for 45mins. Additionally samples were 
added in corresponding wells on the slide. The slide was washed three times and 50µl 
of appropriately diluted cocktail of biotinylated detection antibodies were added to 
each block for 45mins. After washing three times with washing buffer, 50µl of 1:1000 
diluted streptavidin-conjugated cy5 (E-Biosciences, UK) was added and incubated at 
room temperature for 15 mins in the dark. The slide was washed three times and 
rinsed in ultra-pure water and centrifuged dry. Slides scanned with a 4200 AL 
microarray scanner at 635nm   
Subsequently, the difference in S/N ratio was calculated between serum and plasma in 
IL-8, TNF-Į,/-ȕ,/-6, TGF-ȕ0&3-1, VEGF and Eotaxin-1 respectively.  Finally 
7 different blocking buffers were used to explore the impact on backgrounds levels 
and S/N in both serum and plasma.  
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From Figure 41, plasma samples produce higher background levels compared to the 
sera samples. The biggest problem with this is that low abundance cytokines in 
plasma are unable to be quantified. Additionally when the signal to noise (S/N) was 
analysed (see Figure 42), plasma had a much more reduced S/N ratio than serum. In 
higher abundant cytokines such as MCP-1 and VEGF this may not be a problem as 
these can be detected much more easily than low abundant markers such as IL-1ȕDQG
IL-6 respectively. Hence a variety of factors could contribute to this high background 
including the slide surface and the type of blocking buffer that is used. Ultimately 
only one blocking buffer can be used on this microarray system. At present most 
experiments so far have centred on using either 3% BSA block or I-Block. We shall 
first look at the effect of using a variety of different blocking buffers on serum then 
secondly look at plasma to determine which blocking buffer contributes to the least 
background and produces the highest signal to noise intensity. 
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Figure 41: Visual difference between serum and plasma when blocked with 3% BSA. 
Serum and plasma was obtained from the sample healthy individuals and the slides 
were processed to investigate the difference in background levels. From the figure, it 
can be seen that plasma samples (right) have higher level of background than serum 
samples (left). There is a greater degree of non-specific binding that occurs in plasma 
samples leading to higher background levels than in serum. Hence this would make it 
harder to measure and quantify very low abundance cytokines in plasma than serum 
samples.   
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Figure 42: The overall S/N ratio between plasma and serum samples for the 8 cytokines 
analysed. 
The S/N was calculated for 8 cytokines (IL-8, TNF-Į ,/-ȕ ,/-6, TGF-ȕ0&3-1, 
VEGF and MCP-1) between serum and plasma samples. It can be seen that serum has 
a higher S/N than plasma samples across all 8 cytokines. The superior S/N in serum 
compared to plasma is especially advantageous in being able to detect low abundance 
cytokines, such as TNF-ĮDQG,/-ȕ   
 
 
 
 
 
 
Chapter 3: Optimisation of an Antibody Microarray Platform 
 
 
~ 132 ~ 
 
Serum was blocking with 7 different blocking buffers and the S/N and background 
levels were determined. As can be seen from Figure 43 A, the optimal background 
levels were produced by 3% BSA, I-Block and also milk blocking buffers and 
additionally these three buffers also produced the best S/N ratios (B). Interestingly, 
Smart block and also PVA had some of the highest backgrounds and lowest S/N ratio. 
3% BSA Block is slightly better than both I-Block and milk block as it is consistent 
across all 8 cytokines investigated, especially with low abundant cytokines such as IL-
6, IL-1ȕ and TNF-Į, 3% BSA produces a higher S/N ratio than I-Block making this 
the preferred choice of blocking buffer when investigating serum samples in the 
future. It has to be noted that milk blocking buffer leaves grain like deposits after the 
processing of microarray slides making it inconsistent in scanning certain areas of the 
slide making it less desirable for use than 3% Block or I-Block 
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Figure 43: A/B: Investigating the best blocking buffer in serum. 
Seven blocking buffers were tested across 8 cytokines in serum. 3% BSA, I Block and 
milk block produced the best background whereas PVA and Smart block were the 
highest. Additionally 3% BSA produced the best S/N ratio across all 8 cytokines, 
especially in low abundant ones such as IL-6 and IL-ȕ VXJJHVWLQJ WKLV LV WKH
optimum blocking block for serum in this microarray platform. Note in comparison I 
Block and 3% Milk block has signal intensities that are undetectable.  
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The same experiment was repeated in plasma to see if the level of background could 
be reduced. As seen in Figure 44, I-Block had low background levels when tested on 
plasma and also had the best signal to noise ratios of all the blocking buffers across all 
the cytokines. However both the background levels and S/N in plasma were far 
inferior to that produced in serum. This indicates plasma has some components that 
cause unspecific binding and this contribute to a higher background and poorer signal. 
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Figure 44: A/B: Investigating the best blocking buffer in plasma. 
Plasma was taken and blocked with 6 blocking buffers. As can be seen serum still has 
the highest S/N ratio and lowest background despite multiple blocking buffers used. 
Overall I Block has the best combination of lowest background and highest S/N ratio. 
However the blocking of plasma is not as effective as serum suggesting there are 
proteins that can contribute to unspecific binding on the microarray platform. 
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3.3.14: Large and low abundance cytokines 
When developing a microarray platform it is desirable to have a platform that is able 
to measure low (<200pg/ml) and high abundance (µg/ml-mg/ml) cytokines. At present 
commercial antibody companies such as R&D Systems are able to provide such a 
platform using chemiluminescence microarrays. Therefore we tested this principal on 
our microarray system using five cytokines (CRP, MMP-9, RAGE, TIMP-1 and IP-
10).  These included high abundance cytokines, sera were diluted 1 in 250 and added 
to the microarray platform and processed with amplification. As seen in Figure 45, by 
diluting the high abundance cytokines, the low abundance  cytokines were too dilute 
and could barely be detected, in particular IP-10 and RAGE. Hence for it was decided 
to maintain a platform that could measure cytokines without the need for dilution. 
Hence the remainder of the chapters; the validation and analysis of COPD samples 
(Chapter 4 and 5) focusses on the measurement of low abundance to mid-range 
cytokines. 
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Figure 45: Image to show the microarray incorporating high and small abundance cytokines. 
The above image shows illustrates the problems to incorporating high abundance 
cytokines with low abundance cytokines. CRP required a dilution of 1 in 250 to be 
used on the microarray platform. However this required diluting all 5 cytokines, 1 in 
250 within the same sample and detecting them together, resulting low abundance 
cytokines being lost into the background which makes it unquantifiable. This suggests 
the microarray platform can be used to measure low abundance cytokines. Hence for 
future work only low to mid-range abundance cytokines would be investigated with 
regards to validation and the screening of COPD patients.  
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3.4 Discussion 
The key aim of the initial part of this project was to establish a print buffer that would 
provide a platform for capture antibodies to maintain their structure and reactivity 
both short and long-term. Furthermore it was to compare slide surfaces, working out 
the best blocking buffer and also to see how the microarray platform performs on 
biological samples such as serum and plasma.  
3.4.1: Printing Buffers 
We have shown consistently that PBS-Tre-Tw and PBS-Tre were the best coating 
buffers. Trehalose in particular is a naturally linked alpha disaccharide that forms a 
gel like surface on the slide and prevents the antibody from drying out and effectively 
holds them in position [265-267]. Subsequent rehydration that occurs upon processing 
the slides allows the antibody to resume its reactivity when it binds to the detection 
antibody or protein of interest. Tween-20, which is a detergent, also provides 
additional stability. Hence we can conclude from the evidence gained thus far that 
PBS-Tre-Tw has the best dynamic standard curve range of all the coating buffers 
tested. Additionally when this coating buffer was tested across the 4 slide surfaces, it 
consistently produced the best intensities showing its adaptability across the different 
slide chemistries. 
The second most consistent buffer was PBS-Tre. A combination between PBS and 
WUHKDORVHHQDEOHGWKHDQWLERG\WRPDLQWDLQLWV¶IXQFWLRQDOLW\HVSHFLDOO\DWWKHWRSUDQJH
of concentrations. However unlike PBS-Tre-Tw, the intensity tended to subside at the 
lowest concentrations of capture antibody with PBS-Tre.  
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Looking at all 8 coating buffers, it is possible to say that PBS-Tre-Tw and PBS-Tre 
were the most consistent buffers which had the highest intensities and could also be 
detectable at the low range of capture antibody. Thus, PBS-Tre will be used as the 
preferred print buffer for the remainder of this project.  
3.4.2: Slide Surfaces  
From the four slides that were used (aminosilane, epoxysilane, poly-L-lysine and 
nitrocellulose) there are questions regarding reproducibility and storage. Each slide 
has its own strengths and weaknesses. 
3.4.2.1: Epoxysilane 
Epoxysilane slides have been very successful in multiplex PCR and DNA microarrays 
[268-271]. This choice of slide provided the highest level of intensity of all when used 
fresh and processed almost immediately. However exposure to the moisture in the air 
results in the surface losing this reactivity and producing very low levels of intensities 
especially at the lowest concentrations of capture antibody. For this slide to be used 
consistently over a longer frame of time, it is vital it is stored in a vacuum to prevent 
exposure to air. Additionally the choice of manufacturer is important as the spot 
morphology can vary depending on the way the slide is prepared.  
As seen previously, when the ThermoFisher slides were stored at room temperature 
under no vacuum and the slide surface is exposed to the atmosphere led to weak 
spotting and low signal intensities. It is assumed the ideal storage conditions for 
epoxysilane slides are in a vacuum and the poor performance of the ThermoFisher 
slides were due to inadequate preservation of the slide. However when the slides were 
analysed one week later, the intensity of the spots decreased further with time 
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suggesting the slide surface chemistry is not compatible with the antibody that was 
tested in this experiment. 
3.4.2.2: Aminosilane 
The aminosilane slide surface provides a solid covalent bond between the slide 
surface and the protein [218, 272] [273]. Aminosilane provides a solid all-round 
surface that performs well when used short-term. However the intensity levels 
decrease upon storage of the slides. It produces nice spot morphology and interacts 
well with PBS-Tre-Tw both short-term and long-term (despite a lack of intensity in 
the latter).   
An important aspect of the project is to have a sufficiently high level of intensity to 
incorporate the detection of very low abundance proteins in serum of those with 
irreversible lung disease and healthy controls. Aminosilane does not provide the best 
surface to enable this detection to occur. 
It is thought that this particular slide surface is more suited to the DNA microarrays, 
however these slides can be used in all conditions whether exposed to air or stored in 
vacuum. When processed fresh, for long term use this is not the slide surface that 
would be used for the remainder of the project. 
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3.4.2.3: Poly-L-Lysine 
This surface has been successful in DNA microarrays whereby it provides a positively 
charged surface to which negatively attached DNA binds to through electrostatic 
interactions [274, 275] [208]. Overall the intensity of slides increased when they were 
DQDO\VHGRQHZHHNODWHU7KLVSURFHVVRI³DJHLQJ´WKHVOLGHVKDVEHHQUHFRPPHQGHG
especially in cDNA microarray work [274, 276] [277] and this could be case in our 
investigation where an increase in intensity was observed with IgG1.  
Poly-L-lysine slides provide a platform for moderate to high levels of intensities and a 
nice spot morphology. The greatest disadvantage is that there is a high degree of auto-
fluorescence that could be misinterpreted as false-positive results. However this is 
also dependent on the type of coating buffer that is used on the surface and also the 
concentration of the capture antibody that is printed. As seen previously, PBS-Tre-Tw 
and PBS-Tre is compatible with the slide surface and the first 5 dilutions produce 
spots which are not autofluorescing compared to PBS-T or PBS-Glyc-Tw which 
suggests a combination of coating buffer at the correct concentration of capture 
antibody could provide a platform for measuring proteins in serum.  
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3.4.2.4: Nitrocellulose 
Nitrocellulose slides are regularly used in antibody microarrays [209, 278, 279]. 
Nitrocellulose works by providing a thin nitrocellulose coating that allows for a non-
covalent yet irreversible surface for the adhesion of molecules of interest [259]. In this 
investigation we have shown that in nitrocellulose slides, the level of signal intensity 
increases with time, like poly-L-lysine. However it has been noted that unlike the 
previous three slide surfaces at 250µg/ml of capture antibody, comet like spot 
morphology indicated that the slide was overloaded with too much antibody. 
Subsequent dilutions produced nice round spots and moderate intensities, in particular 
with PBS-Tre-Tw. The intensities from the nitrocellulose slides at 125µg/ml of 
capture antibody were comparable to the intensities from aminosilane. Should these 
slides be required for use on this type of antibody microarray platform, further 
optimisation will have to be performed. 
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3.4.3: Blocking Buffers 
Different types of blocking buffers can have a significant influence with antibody 
specificity, signal intensity and background levels [255] [280, 281]. To date, most 
microarray research focuses on using blocking buffers that reduce non-specific 
binding that can lead cross reactivity and poor signal intensities. As such the most 
common used blocking buffers in microarray research include BSA, horse serum as 
well as varying levels of low fat milk solutions [282] [283, 284]. 
Overall in this investigation, in terms of blocking buffers there is not much of a 
difference between 3% BSA Block and I-Block. Depending on the slide surface, one 
block buffer offered slightly higher levels of intensities than the other but this was 
marginal in many incidences. However it was noticed on poly-L-lysine slides that 
were stored in air for 1 week, only the 3% BSA Block produced visible spots that 
could be analysed as the I-Block, NAP and Milk were affected when the slide was 
exposed to air and thus did not block as effectively (results not shown). 
NAP and 5% milk block buffer led to high background and in certain cases smearing 
of the slides were noticed when scanned. This indicates insufficient blocking. Overall 
in terms of blocking buffers there are no differences in the blocking buffers and the 
intensity was more dependent on the slide surface than the blocking buffer but this 
will have to be tested across a wide range of proteins of different concentrations and 
abundances. Whilst the use of varying milk blocking buffers has been used successful 
in different types of antibodies microarrays, it was deemed incompatible with this 
poly-L-lysine slide surface. 
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In the future for most experiments using 3% BSA block and I Block on poly-L-lysine 
were effective, hence both will continued to be used . However looking forward when 
investigating serum and plasma the effect of the blocking buffers were investigated in 
greater depth, serum was much easier to block and generate a signal than plasma. 
Overall 3% BSA was the best blocking buffer that worked best on the poly-L-lysine 
surface and also with serum. Plasma proved more difficult with higher background. 
However if plasma samples were run, I-Block would be the choice of blocking buffer.  
I-Block (Tropix) is a purified version of casein that used as a blocking buffer in both 
western blots and in microarrays [285] [286]. I-Block has been recently been used a 
prominent blocking buffer in both reverse phase microarrays as well as lysate 
microarrays [287-289] [290]. I-Block has been used successfully in these antibody 
microarray experiments where low background levels which can be seen visually on 
the slide when scanned compared to other milk blocking buffers. 
The use of 3% BSA is not uncommon in blocking of antibody microarrays. A study 
by Rimini et al, showed that the blocking with 3% BSA block produced the lowest 
background signals compared to Superblock and 5% non-fat milk powder in the 
different sera that were tested [259]. The only difference between the blocking used in 
their study and the one used in our investigation is that they used 3% BSA in PBS-T 
whereas just PBS was used here. The data produced in this study, along with the work 
carried out in their study, which suggests that 3% BSA block produces one of the best 
S/N ratios.  
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3.4.4 Amplification 
One of the problems that were seen in the initial stages of optimisation was at the 
lowest end of the standard curves a distinct lack of sensitivity was seen. Knowing that 
potentially when measuring clinical samples there would be many low abundant 
cytokines, this presented a problem. Hence one way to overcome this problem was the 
use of amplification. This additional step is not unusual in antibody microarray as it 
has been used many years ago by Haab et al, [223] and Zhou, et al [291] and recently 
by Chen [292]. 
In this case tyramide amplification was used. The amplification works by when HRP 
enzyme (in the presence of a small amount of H202 on tyramide) causing activation 
and oxidation of biotinylated tyramide as extremely reactive intermediates and is 
thought to bind covalently to proteins at electron-rich amino acid residues such as 
tyrosine. This results in an increased amount of biotin that are present at sites of 
immune-reactivity, improving the sensitivity of signals leading to enhanced signal to 
noise ratios. Interestingly the effect of amplification also improves the level of 
background which almost halved. A possible explanation for this could be when using 
cy5 by itself without any amplification the PMT laser setting was set at 450 compared 
to 380-400 PMT with amplification to take in account the enhanced signals. With 
amplification there is an increase in signal intensity and this makes the background 
look weaker when it too has been raised compared to a weaker signal and background 
level without amplification.   
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3.4.5 Time Course 
Ideally a microarray assay has to be sensitive, accurate and precise. However at the 
same time it should be able to deliver results which are quicker than what is expected 
of an ELISA. A traditional sandwich ELISA takes up to 8 hrs, hence when designing 
this stage of the microarray protocol there was an emphasis to build a platform that 
could take almost half the time of a traditional ELISA. Initially the experimentation 
started using the same times as that of an ELISA. The average length of the time to 
perform the assay was continually halved. We noted that half the original time led to 
the best standard curves. Interestingly the strength of the curve would improve if the 
experimental length was halved. Leaving reagents on for longer periods of time could 
lead to unnecessarily structural changes that may reduce the efficiency of the 
microarray platform than enhance it. Additionally it has to be acknowledged that 
leaving the slide on for a longer period of time could expose it to evaporation which 
could also lead to the same problems.  
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3.4.6: Printing 
One of the major problems in printing large multi-cytokine microarrays is that long 
printing times lead to the increased likelihood of the spot drying over time. To 
overcome this problem, a study by MacBeath and Schreiber, used humidity inside the 
arrayer [293]. In addition to the correct print buffer, the key is to keep the spot as 
hydrated as possible during and after printing so that the proteins are not denatured. 
The different target heights and dwell times did not affect the spot shape or size. That 
was dependant on the printing buffer. The most important part of printing was the 
humidity. As the humidity was increased there were more spots that could be printed.  
3.4.7 Cy5 Detection 
There are multiple ways of obtaining a signal to a microarray experiment. The long 
term aim is to use a reagent that would provide a signal that could be detected and 
repeated over time. The use of cy5 enables slides once processed to be scanned 
repeatedly over a period of 2 months without any apparent drop in signal intensity. 
This, with a combination of the reagent used in the processing and the slide surface, 
provides a platform for repeated scanning. 
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3.5 Conclusion: 
In conclusion, multiple parameters were investigated when optimising the microarray 
platform from the choice of slide surface, to the optimal blocking buffer, the different 
settings on the microarrayer to print antibodies whilst also considering the need to use 
amplification to enhance the sensitivity of the platform. 
We have shown that PBS-Tre is the best coating buffer when printing a variety of 
different antibodies. We have also shown that poly-L-lysine slides are an ideal slide 
surface for antibody microarray use with consistent levels of signals intensities with 
time making them desirable when slides are printed and analysed both short and long-
term. Additionally the use of 3% BSA blocking buffers removes non-specific 
adsorption leading to enhanced S/N ratio and reduced background allowing for greater 
detection of low abundance cytokines in serum. The use of amplification allowed 
enhanced detection of these low abundance cytokines whilst improving both S/N and 
backgrounds levels. Moving forward these combination of parameters will be used to 
validate the microarray platform. Ultimately, the aim is to use this optimisation data to 
help evolve the microarray platform to become both accurate and precise when 
measuring cytokines in the sera of both healthy and COPD patients.  
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Chapter 4: Validation of an Antibody 
Microarray Platform 
4.0 Introduction 
The measurements of proteins or analytes in biological samples (serum, plasma, 
sputum etc.) are a key aspect of any bioanalytical method. However for an assay to be 
deemed suitable, a series of validatory tests have to be performed to prove it can be 
both accurate and reproducible. The validation of a method can be defined by the 
)'$ DV ³WKH SURFHVV E\ ZKLFK D PHWKRG LV WHVWHG E\ WKH GHYHORSHU RU XVHU IRU
reliability, accuracy and preFLVHQHVVIRULWVLQWHQGHGSXUSRVH´ [227]. Hence a variety 
of parameters have to be tested that satisfy the above definition. In the case of the 
validation of this antibody microarray the following parameters are tested; 
A) Limits of Detection, 
B) Limits of Quantification, 
C) Intra and Inter-assays, 
D) Spike Recovery experiments,  
E) Cross-reactivity, 
F) Direct comparison between Microarray and ELISA techniques. 
The six points of validation above will serve to provide a robust test into the nature of 
the antibody microarray technique and should allow one to decide whether it is a 
reliable method to ultimately measure multiple biological samples in COPD.  
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Hence the limits of detection (LOD) and lower and upper limits of quantification 
(LLoQ and ULoQ) are the first tests performed on this microarray platform. The LOD 
can be defined as lowest level of the analyte that can be detected but cannot be truly 
quantified [294-297]. Hence one can say that this approach serves to show how low 
the platform can measure an analyte but this value is both inaccurate and also 
imprecise. Hence the LLoQ and ULoQ have to be established when measuring 
biological samples. Both these limits can be defined as the lowest or highest 
concentration of an analyte that can be reliably measured on a platform such as an 
ELISA or microarray [227] [243] [294] [298]. This system can then discriminate and 
exclude values that fall above and below the limits of quantification.  
Interestingly in the field of validation and assay optimisation, there are disagreements 
about how best to measure the LOD and the LLoQ. One approach is to measure the 
LOD and use this to value to calculate the LoQ. Hence there is more than one 
experimental way to calculate the LLoQ. The first way centres on an approach used 
by Armbruster et al, whereby doubling the level of the LOD to calculate the LLoQ 
[243]. The alternative approach used in line with the FDA requirement for 
bioanalytical validation is to calculate the highest and lowest points of an assay that 
can be detected and quantified to an acceptable level of accuracy and precision [227]. 
However it is important to calculate the difference between both the LoD and LLoQ 
as these will help discriminate between the absence or presence of an analyte in a 
sample.  
Before the LLoQ can be determined it is important to define the parameters that are 
used to calculate this figure. Initially the limit of the blank (LoB) can be defined as the 
KLJKHVW ³DSSDUHQW´ VLJnal at a concentration that is found in multiple replicates of a 
sample that has no analytes (i.e. blank). Whilst the samples may contain no analyte is 
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it possible that it may give a signal that may or may not be similar to the signal 
obtained in the lowest concentration of an analyte. The LoB is calculated by 
measuring multiple replicates of a blank and calculating both the mean and the 
standard deviation (a). 
The LOD can be defined as the lowest concentration of analyte that can be measured 
and distinguished from the LoB. Although there are various versions of calculating 
this figure the traditional approach to estimating the limit of detection is defined as 
³'the concentration of the analyte giving a signal equal to the blank plus 3× the 
standard deviatioQRIWKHEODQNE´[243].  
Often the LLoQ can be equivalent to the LoD but often it is observed to be higher; 
however it cannot be lower than the LoD (c) [243]. 
a) LoB = Mean of Blank  
b) LOD= Blank + 3SD (Blank) 
c) LLoQ= 2 LoD 
Briefly, the LLoQ and ULoQ here are defined as the lowest and highest points that 
could be detected at an acceptable level of accuracy and precision. When testing 
standard curves for all 16 cytokines this was applied to calculate a value that is highly 
accurate and precise as defined from the FDA guidelines on bioanalytical method 
validation. 
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Accuracy can be defined as how close a measurement is to a true value and precision 
can be defined as the reproducibility of the values with regard to how close the values 
are to one another [238] [299]. This is often known as the coefficient of variation (CV 
%). Both the intra and inter-assays are key parameters in determining the performance 
and characteristic of the microarray platform. Additionally these parameters are used 
to calculate accuracy include spike recovery experiments. It is important to calculate 
the accuracy so to take into account how true the value is and if not calculate the level 
of inaccuracy. Both accuracy and precision can be calculated by analysing quality 
control (QC) samples at 3 concentrations (low, medium and high) which should 
represent the range of the standard curve.  
The level of accuracy from commercially available microarray kits range from 70-
130% dependent on the number of cytokines investigated and type of biological 
sample tested. Additionally precision (CV %) is often less than or equal to 20-30% 
dependent on the nature of the assay.  The efficiency of an analytical system depends 
upon high levels of accuracy and precision recorded over multiple test experiments. 
One of the biggest issues with microarray platforms when using a mixture of different 
antibodies and reagents is the problem of cross-reactivity. If cross-reactivity exists 
between different capture and detection antibodies, this will then limit the number of 
proteins that can be tested on an array. Cross reactivity between detection antibodies 
and capture antibodies as well as a non-specific analytes limits the number of proteins 
that can be used on a multiplexing platform.  
However it is not only antibodies alone that can lead to cross-reactivity. It is thought 
that other reagents in which antibodies are diluted could be involved as a source of 
interference in the assay [300] [301]. Non-specific binding may lead to a large 
background signal, therefore decreasing the sensitivity of the assay. However there are 
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reagents which may cause changes in proteins due to varying ionic strength, pH or 
hydrophobicity that may irreversibly change the structure of the protein leading to 
potential cross-reactivity and hence reducing the efficiency of the microarray platform 
[302]. A study by Pfleger et al, showed that use of different diluents in antibodies 
contribute significantly to both signal intensity and assay performance [303].   
Other factors in assay development, such as the temperature the microarray is run, the 
length of incubations, the number of wash steps and concentrations of the reagents, 
may all contribute to cross-reactivity and have to be optimised in order to improve the 
performance of the microarray. 
In this Chapter a direct comparison is made between ELISA and microarray. The 
antibody microarray is developed originally from the ELISA model for protein 
detection. Here the standard curves of both techniques are compared against one 
another to see the level of correlation. However this alone is not adequate to measure 
how comparable both techniques are so a selection of consenting healthy controls 
were recruited and serum measured for all 16 cytokines on the microarray and also on 
the ELISA. 
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4.2 Materials and Methods 
For the validation Chapter, poly-lysine slides were used. Due to the low level of 
sensitivity obtained, these slides were subject to amplification. Briefly, antibody 
duoset kits were purchased (R&D Systems, MN, USA) and printed on poly-L-lysine 
slides. Slides were processed immediately or after one week. Slides on the day of 
processing were taken from the vacuum and blocked for an hour with either I-Block 
or 3% BSA block buffer. Standards were made for all 16 cytokines (IL-8, IL-6, IL-1ȕ
TNF-Į ([RWD[LQ-1, Eotaxin-2, IFN-Ȗ 5$*( ,/-10, IL-4, IL-17, IL-23, MCP-1, 
VEGF and IP-10) DFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQVDQGGLOXWHGIROGDFURVV
dilutions and added at 50µl per well in 10 replicates for 45 mins. Additionally healthy 
human sera were added to the corresponding well on the slides. The slide was washed 
three times and 50µl of appropriately diluted biotinylated detection antibody was 
added to each block for 45 mins. Slides were subjected to tyramide amplification. 
Briefly, this was performed after the detection stage of the microarray process 
described above with the additional of 50µl of 1:1000 diluted streptavidin-HRP (Bio-
Rad, USA) in the dark. The slide was washed and 50µl of Bio-Rad Amplification 
Reagent was added for 10 mins in the dark. The slides were washed three times with 
20% DMSO-PBST and subsequently washed thrice with wash buffer. After washing, 
50µl of 1:1000 diluted streptavidin-conjugated cy5 (E-Biosciences, UK) was added 
and incubated at room temperature for 15 mins in the dark. The slide was washed 
three times and rinsed in ultra-pure water and centrifuged dry and scanned with the 
4200 AL microarray scanner at 635nm (Axon GenePix®). Fluorescence was 
quantified using the GenePix Pro Software (Axon GenePix®). The experiment was 
repeated at least twice. The median fluorescence of each spot was measured (minus 
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background) and the corrected fluorescence was used to calculate the average 
fluorescence signal across the standard detectable ranges.  
ELISAs were performed using the R&D systems duoset kits (listed in the previous 
VHFWLRQDQGXVHG LQ WKHPLFURDUUD\DVGHVFULEHGE\ WKHPDQXIDFWXUHU¶V LQVWUXFWLRQV
Briefly, plates were coated with 1-ȝJPORIFDSWXUHDQWLERG\DQGLQFXEDWHGRYHUQLJKW
at room temperature. The plates were washed 3 times with PBS-Tween 0.05% 
(Sigma) and blocked with Reagent Diluent (1% BSA in PBS) for 1 hour and washed 
three times. Standards were made in Reagent Diluent at the top concentration 
DFFRUGLQJ WR NLW LQVWUXFWLRQV DQG GLOXWHG  IROG DFURVV VHYHQ SRLQWV DW ȝO SHU
ZHOO LQ GXSOLFDWHV IRU  KUV 7KH SODWH ZDV ZDVKHG WKUHH WLPHV DQG ȝO RI
appropriately diluted biotinylated detection antibody was added to each well for 2 hrs. 
$IWHUZDVKLQJWKUHHWLPHVZLWKZDVKLQJEXIIHUȝORIGLOXWHGVWUHSWDYLGLQ-HRP was 
added and incubated at room temperature for 30 mins in the dark. Wells were washed 
three times and the enzyme substrate peroxidase chromogen was added. After 
LQFXEDWLRQIRUPLQVDWURRPWHPSHUDWXUHWKHUHDFWLRQZDVVWRSSHGE\DGGLQJȝO
of 0.18M H2SO4 per well and the absorbances were read at 450nm.  
To determine the precision of the microarray platform, intra- and inter assays were 
performed. Intra-assays were performed repeatedly over the same slide on the same 
day and inter-assays were performed over a period of three consecutive days. Up to 30 
healthy volunteers sera were collected and the 16 biomarkers were quantified. The 
mean of the replicates and the standard deviation was used to calculate the precision 
of the microarray methodology.  
PBS was also spiked to three know concentrations (750pg/ml, 188pg/ml and 24pg/ml) 
using recombinant protein standards for each of the 16 biomarkers and quantified 
using the standard curves generated from the microarrays. These three spikes were set 
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to be above and below the limits of quantification. Accuracy (%) was calculated based 
on the observed concentration measured against the expected concentration.  
To identify any effects that serum proteins may have on the assay system, sera from 
healthy donors were taken and cytokine levels were quantified for all 16 biomarkers. 
This serum was then spiked to the three known concentrations points mentioned 
above. The observed concentration was subtracted from background levels to 
calculate accuracy and precision. 
Finally to compare both ELISAs and microarrays, a group of healthy individuals were 
chosen and quantified for all 16 cytokines on the ELISA and microarray to determine 
the similarity between both methods.  
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4.3 Results 
4.3.1 Limits of Detection and Quantification 
The limits of detection and quantification were calculated first. This was done in three 
stages. The first was to calculate LOD. The LOD is defined as the lowest level of the 
analyte that can be detected but cannot be truly quantified [227]. This is calculated by 
drawing standard curves for all 16 biomarkers and using the curve to work out the 
standard deviation of the blank. Then the following equation is applied to calculate the 
LOD: 
LOD = 3SD (mean Blank) + mean Blank. 
For the limits of quantification, these were the lowest and highest points that could be 
GHWHFWHGDWDQDFFHSWDEOHOHYHORIDFFXUDF\DQGSUHFLVLRQ+HQFHDVHULHVRI³VSLNHV´
were run at the either end of the standard curves of the 16 biomarkers. The point 
where the precision fell below 20% was deemed to be LLoQ and 15% for the ULoQ 
as in line with FDA regulations for assay development.  
Table 12 illustrates the limits of detection and quantification for all 16 cytokines. This 
shows that with low abundance cytokines such as IL-6 and IL-8 the microarray system 
was able to measure signals as low as 1.5pg/ml, where in slightly higher abundant 
cytokines such as RAGE and eotaxin-2, the LLoQ was 5.9pg/ml. This shows the 
microarray platform can measure to a low level of sensitivity. 
Whilst the LOD is very low, often it is not chosen as the limit to measure proteins in 
biological samples. As these LOD values are very low, at these concentrations there is 
a higher degree of variability between samples. Additionally the ULoQ takes into 
account the high abundance cytokines in this 16 cytokine panel such as RAGE, 
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Eotaxin-2 and IL-23 and makes the necessary adjustments. Furthermore, in future 
studies, biological samples that fall above and below the LLoQ and ULoQ are 
included as follows: those that fall below the LLoQ are deemed to be undetectable 
(zero): and the ULoQ is the highest analyte concentration that can be quantified with 
acceptable precision and accuracy. 
The lower limit of detection is calculated as the concentration of biomarker required 
to give a signal that is equal to the background (blank) plus three times the SD of the 
blank [243] . The LLOQ can defined as twice the level of the LOD [243] or the lowest 
analyte concentration that can be quantified with acceptable precision and accuracy as 
in line with FDA regulations for assay development [227]. 
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Table 12: Shows the LOD, LLoQ and ULoQ for 16 cytokines. 
Cytokines Limits of Detection & Quantification 
 LOD (pg/ml) LLoQ (pg/ml) ULoQ (pg/ml) 
IL-8 0.535 1.5 750 
IL-6 0.683 1.5 750 
TNF-ɲ 1.126 1.5 750 
IL- ?ɴ 0.404 2.9 750 
VEGF 0.744 1.5 750 
EOTAXIN-1 1.863 2.9 750 
IFN-ɶ 0.108 2.9 750 
IL-17 0.445 5.9 750 
EOTAXIN-2 0.739 5.9 1900 
IP-10 0.458 5.9 750 
RAGE 0.968 5.9 1900 
MCP-1 0.284 5.9 750 
IL-4 0.6 2.9 750 
IL-10 0.503 2.9 750 
TGF-ɴ 0.398 2.9 750 
IL-23 0.612 5.9 1900 
 
Table 12 illustrates the LOD, LLoQ and ULoQ for all 16 cytokines on poly-L-lysine 
slides. The lower limit of detection is calculated as the concentration of biomarker 
required to give a signal that is equal to the background (blank) plus three times the 
standard deviation of the blank. The lower limit of quantification (LLOQ) is defined 
as twice the level of the LOD or the point where the CV, as a measure of precision, 
falls below 20% is deemed to be LLoQ in line with FDA regulations for assay 
development. 
The lower limit of detection varied from 0.284 to 1.9pg/ml for the 16 biomarkers 
investigated. The lower limit of quantification ranged between 1.5-5.9pg/ml and the 
upper limit of quantification between 750-1900pg/ml for the 16 biomarkers 
respectively. 
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4.3.2: Cross Reactivity 
Cross reactivity testing is an important validatory parameter in cytokine binding based 
assays such as ELISAs and in this case, the antibody microarray platform.  
Hence to determine if cross reactivity occurs in this microarray platform the following 
experiments were conducted; (I) A microarray panel was printed with a variety of 
capture antibodies and a single protein standard was added to which a complete 
cocktail of detection antibodies were added (Figure 46 & 47), and (II) a microarray 
panel was printed with a variety of capture antibodies and no protein standards were 
added and a complete cocktail of detection antibodies were added and processed as 
normal (Figure 48 & 49), and finally (III) a microarray panel was printed with a 
variety of capture antibodies and a cocktail of recombinant protein standards and a 
complete cocktail of detection antibodies with 1 antibody removed to detect if cross 
reactivity occurs between detection antibodies and specific cytokines (Figure 50 & 
51).  
No cross-reactivity was observed in all three experiments. In the first experiment a 
single protein standard was added to a combination of a full set of capture and 
detection antibodies and as expected only the protein that was added showed an 
observable signal (Figure 46 & 47). In the second experiment a full set of a selection 
capture antibodies were printed and added with the complimentary version of the 
detection antibodies without any protein standards and as expected no signals were 
detected (Figure 48 & 49). 
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The third experiment is the most decisive to show a lack of cross-reactivity. When all 
16 capture antibodies are printed and their protein standards added with all but one 
detection antibody all 15 spots show signals except for the set of spots that have no 
specific detection antibody. As an example, eotaxin-1 was not added and in Figure 50 
& 51 there was no signal observed, showing the microarray platform to be highly 
specific for the remaining 15 cytokines. 
 
Figure 46: Cross reactivity experiment 1; a complete selection of capture antibodies are 
added and only 1 protein standard is added with a complete cocktail of detection 
antibodies. 
As seen from the cartoon, a microarray panel was printed with a variety of different 
capture antibodies and a single protein standard (GCSF) was added to which a 
complete cocktail of detection antibodies were added including GCSF detection 
antibody and developed by streptavidin cy5 (A). This is reflected when the slide was 
scanned, as GCSF spots appear to be detected, whilst the remaining cytokines 
(GMCSF, TGF-ȕ,)1-Ȗ,/-2 and MIP-ȕWKDWZHUHDOVRSULQWHGZKHUHQRWGHWHFWHG
in the other panels, hence showing no cross-reactivity (B). 
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Figure 47: Cross reactivity experiment 1; A graphical representation of the experiment 
where a selection of capture antibodies are added and only 1 protein standard is added 
with a complete cocktail of detection antibodies. 
A graphical representation of the experiment is shown where a microarray panel was 
printed with a variety of different capture antibodies and a single protein standard 
(GCSF) was added to which a complete cocktail of detection antibodies were added 
including GCSF detection antibody. This is reflected when the slide was scanned, as 
GCSF spots appear to be detected, as shown by an increase in signal intensity whilst 
the reminder of the cytokines (GMCSF, TGF-ȕ ,)1-Ȗ ,/-2 and MIP-ȕ WKDWZHUH
also printed were not detected, as shown, where no signal intensity was observed.  
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Figure 48: Cross reactivity experiment; a complete selection of capture antibodies are 
added with no recombinant protein standards and a complete cocktail of detection 
antibodies. 
As seen from the cartoon, a microarray panel was printed with a variety of capture 
antibodies and no protein standards were added and a complete cocktail of detection 
antibodies were added and developed by streptavidin cy5 (A). This is reflected when 
the slide was scanned, when no spots were detected, except for a minimal amount of 
autoflourescence (B). 
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Figure 49: Cross reactivity experiment 2; a graphical representation of the experiment 
complete selection of capture antibodies are added with no protein standards and a 
complete cocktail of detection antibodies. 
A graphical representation of the experiment is shown where a microarray panel was 
printed with a variety of different capture antibodies and no recombinant protein 
standards were added to which a complete cocktail of detection antibodies were 
added. This is reflected when the slide was scanned, and no spots were detected as 
shown by trace levels of signal intensity for the six cytokines detected.  
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Figure 50: Cross reactivity experiment 3; 16 capture antibodies are printed and added with 
a complete set of 16 protein standards and with a 15 detection antibodies except for 
eotaxin-1 antibody 
As seen from the cartoon, a microarray panel was printed with a variety of capture 
antibodies (16) and a cocktail of recombinant protein standards (16) and a complete 
cocktail of detection antibodies with 1 antibody removed to detect if cross reactivity 
occurs between detection antibodies and specific cytokines (A). In this case eotaxin-1 
detection antibody was removed from the cocktail of detection antibodies. This is 
reflected when the slide was scanned, and spots are detected for all the remaining 15 
cytokines except for eotaxin-1 as highlighted in the white box where no spots are 
seen, indicating the microarray system does not display cross-reactivity (B).  
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Figure 51: Cross reactivity experiment 3; a graphical representation of the experiment 
where 16 capture antibodies are printed and added with a complete set of 16 protein 
standards and with a 15 detection antibodies except for eotaxin-1 antibody 
A graphical representation of the experiment is shown where a microarray panel was 
printed with a variety of capture antibodies (16) and a cocktail of recombinant protein 
standards (16) and a complete cocktail of detection antibodies with 1 antibody 
removed to detect if cross reactivity occurs between detection antibodies and specific 
cytokines. In this case eotaxin-1 detection antibody was removed from the cocktail of 
detection antibodies. This is reflected when the slide was scanned, and no signal is 
observed for eotaxin-1, whilst signals can be observed for all other 15 cytokines 
indicating there is no cross-reactivity in this microarray platform. 
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4.3.3 PBS and Serum Spike recovery 
PBS was also spiked to three known concentrations (750pg/ml, 188pg/ml and 
22pg/ml) using recombinant protein standards for each of the 16 biomarkers (IL-8, IL-
6, IL-ȕ 71)-Į ([RWD[LQ-1, Eotaxin-2, IFN-Ȗ 5$*( ,/-10, IL-4, IL-17, IL-23, 
MCP-1, VEGF and IP-10) and quantified using the standard curves generated from 
the microarrays. These three spikes were set to be above and below the limits of 
quantification. Accuracy (%) was calculated based on the observed concentration 
measured against the expected concentration. To identify any effects that serum 
proteins may have on the assay system, sera from healthy donors were taken and 
cytokine levels were quantified for all 16 biomarkers. This serum was then spiked to 
the three known concentration points mentioned above. The observed concentration 
was subtracted from background levels to calculate accuracy and precision (Figure 
52). 
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Figure 52: Microarray assay validation using PBS and serum samples spiked with known 
concentrations of cytokines. 
Sixteen cytokines were quantified in PBS (IL-8, IL-6, IL-1ȕ 71)-Į ([RWD[LQ-1, 
Eotaxin-2, IFN-Ȗ5$*(,/-10, IL-4, IL-17, IL-23, MCP-1, VEGF and IP-10). Three 
different known concentrations of cytokine (750 pg/ml, 188 pg/ml, 22 pg/ml) were 
then added to aliquots of PBS. The difference between blank PBS and spiked PBS 
was determined by the microarray assay (A).    
Additionally these sixteen cytokines were quantified in the serum of a healthy 
volunteer. Three different known concentrations of cytokine (750 pg/ml, 188 pg/ml, 
22 pg/ml) were then added to aliquots of the serum, and the concentration difference 
between the original and spiked serum samples was determined by microarray assay 
(B).  
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4.3.4 Target Concentration Spiked in PBS or Serum 
For all 16 biomarkers, PBS and serum spike recovery (accuracy and precision) were 
tested at three targeted concentrations; namely at 750pg/ml, 188pg/ml and 22pg/ml 
(Figure 53A). For all three targeted concentration points the observed concentration of 
all 16 cytokines (mean) was in line with the actual concentration spiked. As seen in 
Figs 53B/C, all biomarkers fall in the acceptance criteria for spike accuracy (80-
120DQGSUHFLVLRQ20%).  
If this is broken down into individual cytokines it can be seen in both serum and PBS 
spikes. For all three targeted concentration points the observed concentrations of all 
16 cytokines fall within the acceptable criteria in relation to the expected 
concentration (Figure 54A/B). Also in the accuracy and precision of all 16 cytokines 
the majority of the cytokines are within the acceptable parameters (Figure 55 & 56). 
However it has to be acknowledged that are certain cytokines that fall slightly below 
the acceptable levels. This occurs in the lower abundant cytokines such as IL-8, IL-6 
and IP-10 which were found in very low levels in healthy subjects and the variation at 
these lows levels have led to greater levels of inaccuracy and imprecision. However 
these values are comparable to those reported in Wood et al, [28], and Anderson et al, 
[29]. This shows that the microarray platform developed is both precise and accurate. 
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Figure 53: Accuracy and precision of cytokine concentration determination by microarray 
assay. 
Cytokine concentrations in spiked PBS and serum samples determined by microarray 
assay (mean± SD for 16 cytokines) (A). The actual concentrations are indicated by the 
dashed lines. (B) The percentage accuracy of cytokine concentration determination by 
microarray assay (mean ± SD for 16 cytokines) relative to the acceptable limits for 
variation in accuracy prescribed by the FDA. (C) The coefficient of variation of 
cytokine concentration determination by microarray assay (mean ± SD for 16 
cytokines) in spiked PBS and serum samples.  
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Figure 54: PBS and serum were spiked at three known concentration across all 16 
biomarkers (A & B). 
Cytokine concentrations in spiked PBS and spiked serum determined by microarray 
assay (mean± SD for 16 cytokines) (A + B). The actual concentrations are indicated 
by the solid lines. As seen from the figure, the observed concentrations from the spike 
experiments for both PBS and serum are close in relation to the actual concentration 
with the exception of low abundance cytokines such as IL-8 and IL-6.  
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Figure 55: The observed mean concentration was recorded and compared with the 
expected concentration to calculate the mean accuracy. 
The percentage accuracy of each of the 16 cytokines concentration determination by 
microarray assay (IL-8, IL-6, IL-ȕ 71)-Į ([RWD[LQ-1, Eotaxin-2, IFN-Ȗ 5$*(
IL-10, IL-4, IL-17, IL-23, MCP-1, VEGF and IP-10) relative to the acceptable limit 
for variation in accuracy prescribed by the FDA. As seen, with the exception of IL-8 
and IL-23 the remaining 14 cytokines would fall between the accuracy levels set 
between 80-120%.  
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Figure 56: The precision of the assay of all 16 cytokines are shown was calculated (A &B). 
The coefficient of variation each of the 16 cytokines concentration determination by 
microarray assay (IL-8, IL-6, IL-1ȕ 71)-Į ([RWD[LQ-1, Eotaxin-2, IFN-Ȗ 5$*(
IL-10, IL-4, IL-17, IL-23, MCP-1, VEGF and IP-10) relative to the acceptable limit 
for variation in accuracy prescribed by the FDA. However it was noted that in low 
abundance cytokines, such as IL-8 and IL-6 and IP-10, the accuracy and precision 
were lower than is considered acceptable. 
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4.3.5: Intra and Inter assay precision 
For the intra assay variation, 13 out of 16 biomarkers were within the acceptable 
limits for precision. However, a lower level of precision was achieved in the inter 
assay variation (11 out of 16 biomarkers within acceptable levels of precision) (Figure 
57A). This is probably due to the greater variation that occurs at the lowest 
concentration in the very low abundance cytokines in healthy sera (for example IL-
10). From the microarray assay data for the 16 cytokines on up to 30 healthy 
volunteer¶V sera (see section 4.3.6 below), the cytokines were split into three groups - 
low abundance cytokines with serum FRQFHQWUDWLRQVSJPO,/-1beta, IL-4, IL-6, 
IL-8, IL-10 and TNF-alpha), mid-abundance cytokines with concentrations 50-200 
pg/ml (VEGF, MCP-1, Eot-1, IFN-gamma, TGF-beta, IL-17) and high abundance 
F\WRNLQHV ZLWK FRQFHQWUDWLRQV   SJPO (RW-2, IL-23, IP-10 and RAGE). As 
expected there is a greater level of variation in the low abundance cytokines compared 
to the mid and high abundance cytokines as the level of CV% is higher in the former 
(Figures 57). The precision of the low, mid and high abundance groups was compared 
by Kruskal-Wallis test; there was no significant difference between the three groups 
for intra-assay CV, although the median CV for the low abundance group was on the 
limit for acceptable precision (CV ~20%) and the range of CVs was greatest for this 
group (Figure 57B). As anticipated, the inter-assay CVs were higher than the intra-
assay CVs, although the median CVs for the mid and high abundance cytokines again 
similar and well within the acceptable limit (Figure 57C). However, the median intra-
assay CV for the low abundance cytokines was above the acceptable limit of precision 
and was significantly higher than for either the mid or high abundance groups (as 
shown by a post-KRF'XQQ¶V0XOWLSOH&RPSDULVRQ7HVW)LJXUH 57C). 
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Figure 57: The intra- and inter-assay precision. 
(A) The intra- and inter-assay CV% for the quantification of 16 cytokines. (B) The 
intra-assay coefficient of variation for low, mid and high abundance cytokines. (C) 
The inter-assay coefficient of variation for low, mid and high abundance cytokines. 
7KH GDVKHG OLQHV UHSUHVHQW WKH DFFHSWDEOH OLPLW RI SUHFLVLRQ &9  7KH solid 
lines represent the median for each group. Significant differences between low, mid 
and high groups in (B) and (C) were determined by Kruskal-Wallis test with a post-
KRF'XQQ¶V0XOWLSOH Comparison test. The definition of low, mid and high abundance 
cytokines was based on the samples shown in Figure 53, giving the following cut-offs: 
low abundance <50 pg/ml; mid abundance 50-200 pg/ml; high abundance >200pg/ml. 
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4.3.6 Comparison of Microarray technology with 
ELISA 
The next stage was to compare between both ELISA and microarray methodology to 
see if the standard curves were positively correlated. When directly comparing 
methods, four cytokines (MIP-1ȕ 5DQWHV *0-CSF and M-CSF) were investigated 
and showed there were positive correlations between both the methods (using 
6SHDUPDQ¶V 5DQN FRUUHODWLRQ IRU HDFK F\WRNLQH showing that multiplex microarray 
WHFKQRORJ\ GRHV FRPSDUH ZHOO WR ³WUDGLWLRQDO´ (/,6$V (Figure 58A-D).  Both 
technologies show a strong degree of correlation which was statistically significant 
with regard to their respective standard curves with r values above 0.9865 for all 4 
cytokines tested. 
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Figure 58: A-D: This shows that multiplex microarray technology significantly correlates 
ǁŝƚŚƚŚĞ “ƚƌĂĚŝƚŝŽŶĂů ?>/^Ɛ ? 
SKRZV FRUUHODWLRQ EHWZHHQ LQGLYLGXDO ³WUDGLWLRQDO´ (/,6$V Q  DQG PXOWLSOH[
microarrays (n=10) of cytokines. The individual values each cytokine was plotted 
with microarray values on the Y-axis and ELISA values on the X-axis. The errors bars 
are calculated as SD. Note there is a strong correlation between all the 4 cytokines 
investigated (MIP-ȕ U   S 5DQWHV U  S *0&6F: 
U SDQG06&)U SUHVSHFWLYHO\  
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However the comparison of standard curves alone is insufficient to prove conclusively 
that both methods comparable. Ultimately another test was performed to see how 
similar two methods compare to one another as well as the quantification of clinical 
samples. Hence a comparison between the quantitative aspects of both methods was 
tested. Thirty sera was obtained from healthy individuals and quantified for all 16 
biomarkers using both microarray and ELISAs. The direct correlations are shown in 
Figure 59. This shows that across all 16 biomarkers there were no significant 
differences between techniques 3. Additionally Bland Altman plots 
were drawn to see if there was an agreement between techniques (Figure 60).  The 
level of bias is dictated by the thin dotted line either side of the zero. In the Bland-
Altman plot, with IL-8, TNF-Į and VEGF there is not so much deviation from the 
zero (as indicated by the bias line) (Figure 60). However with IL-ȕ there is a bias 
towards the microarray system and further indicates that when investigating very low 
abundance cytokines like IL-ȕ, the microarray technology has an advantage over an 
ELISA as it is able to detect more sensitively at low concentrations. 
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Figure 59: Correlation between microarray and ELISA techniques. 
Thirty sera were quantified by ELISA and microarray assay for 16 cytokines to see 
how well both techniques correlate to one another. The microarray technology was 
compared to traditional ELISA. Sera were obtained from 30 healthy individuals and 
quantified for all 16 cytokines using both microarray and ELISA. Across the 16 
biomarkers tested, there were no significant differences between techniques 
3) 
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Figure 60: Bland Altman graphs to show difference between two ELISAs and Microarrays. 
Bland Altman plots were drawn to see if there was an agreement between both 
ELISAs and microarrays. Bland Altman plots further highlight the agreement between 
these techniques since, for most cytokines, the bias in favour of one or other technique 
was negligible. However it was noticed that, for lower abundance cytokines such as 
IL-1ȕ', the microarray platform is slightly more sensitive than the ELISA.   
Chapter 4: Validation of an Antibody Microarray Platform 
 
 
~ 182 ~ 
 
Table 13 shows a summary of the values gathered from the variety of validatory 
experiments undertaken. In the vast majority of cytokines, the values fall well within 
the levels of accuracy and precision outlined by the FDA guidelines for bioanalytical 
method validation. The majority of exceptions arise often in the low abundant 
cytokines where at the lowest level there is variation when samples are repeated 
multiple times; ie intra and inter assays. This can now be compensated through the 
calculation of both the lower and upper limits of quantification. This allows users to 
decide whether those falling outside these limits are to be included when performing a 
large population study comparing multiple groups. 
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Table 13: Summary of the data from all the validatory tests. 
 
This includes ±intra, inter-assays, the limits of detection and quantification as well as 
the spiked experiments. Most of the values fall within the FDA derived guidelines for 
bioanalytical validation. Those that fall below the expected guidelines are discussed 
below.  
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4.4 Discussion  
At present there are no comprehensive guidelines for the validation of microarray 
protein biomarker studies. It is thus highly desirable that such criteria are established 
to ensure work can be standardized across research institutions [304] [305]. 
Consequently, for this study, the optimisation and validation of the microarray 
protocol was based upon the FDA guidelines for pharmacokinetic immunoassays. 
The limits of quantification are defined as the lowest and highest points in an assay 
that can be detected and quantified to an acceptable level of accuracy and precision. 
Both the LLoQ and ULoQ like the LOD are expressed as a concentration limit on the 
microarray platform. Therefore in association with the LoD/LLoQ established for all 
16 biomarkers, the microarray has the advantage of being able to detect the lowest 
concentrations. Whilst the LOD shown here is very low, often it is not chosen as the 
limit to measure proteins in biological samples, as at this concentration there is a 
higher degree of variability between samples and thus the LLoQ is chosen when using 
microarray technology as it is the lowest analyte concentration that can be quantified 
to an acceptable level with both accuracy and precision.  
A spike recovery test was conducted across 3 days to investigate the accuracy and 
precision of the methodology across both control samples (PBS) and biological 
samples (serum) for 16 biomarkers of interest. We show that, in the majority of 
biomarkers (14 out of 16), the accuracy is between 80-DQGWKHSUHFLVLRQ
CV, which is in accordance with data published in recent literature [126] [306] [307] 
[308].  Additionally inter- and intra-assays were both reproducible and precise with 11 
of the 16 cytokines falling within the aforementioned criteria. However it was noted 
that in low abundance cytokines, such as IL-8 and IL-10, the accuracy and precision 
were lower than is considered acceptable. This is due to greater calculated percentage 
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differences and as such should be reflected under different guidelines. Nevertheless, 
the biological and clinical relevance of very low serum levels of 
cytokines/chemokines has yet to be determined. 
Having shown that the majority of biomarker measurements fall within the FDA 
guidelines for pharmacokinetic immunoassays we then wanted to show that the assays 
were as reproducible and VHQVLWLYHDVWKH(/,6$WKH³JROGVWDQGDUG´RILPPXQRDVVD\
quantification [309] [310] . We show that when both ELISA and microarray were 
used to quantify a biomarker in serum there was no significant difference in the 
cytokine concentrations calculated. However, for some low abundance biomarkers, 
such as IL-1beta and IL-6, there is less agreement between techniques and this may be 
due to the lower sensitivity of the ELISA compared to the microarray, as in 
microarrays the standard curves were plotted 2 dilution points lower than in the 
ELISA. 
One caveat to the comparison between ELISA and microarray is that the microarray 
platform is measured by fluorescence intensity compared to that of the optical density 
used in an ELISA. Using fluorescence for detection gives the microarray a scale that 
is measurable over many 10,000s AU compared to the discrete 0-3 OD scale used in 
an ELISA. This clearly offers greater scope for the detection of biomarkers using 
microarrays. 
Currently there are many commercially available protein microarray platforms, 
however, the high cost of purchasing these kits makes it unattainable for most [299] 
[311]. The microarray protocol established here shows the stages required for 
optimisation that enables detection of multiple biomarkers at a lower running cost. 
This detection is not limited to the 16 biomarkers that are shown here but indeed can 
be expanded as required. 
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The in-house sandwich microarray workflow developed here demonstrates that 
multiple biomarkers can be quantified with relative ease, using reduced quantity of 
sample volume than required for ELISAs of equal biomarker number. 
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Chapter 5: Application of an Antibody 
Microarray as a Diagnostic Platform for COPD 
5.1 Introduction 
&23'LVGHILQHGDV³DSUHYHQWDEOHDQGWUHDWDEOHGLVHDVHVWDWHWKDWLVFKDUDFWHULVHGE\
airflow limitation that is not fully irreversible. The airflow limitation is progressive 
over time and is associated by an abnormal inflammatory response to noxious gaseous 
SDUWLFOHVLQSDUWLFXODUWKRVHIURPFLJDUHWWHIXPHV´[1, 312].  
The detection of early COPD in patients with respiratory disease is highly desirable. 
+RZHYHU GLDJQRVLQJ &23' LV GLIILFXOW DV WKHUH LV QR VLQJOH ³*2/' VWDQGDUG´
procedure available. Physical characteristics such as wheezing, chronic cough, 
breathlessness and sputum production have been implicated in the diagnosis of 
COPD. Additionally, other physical attributes such as use of accessory muscles, 
increased paradoxical abdominal movement and monitoring weight are used as 
predictors of disease outcome [313-316].  
Currently, the common measurements of physical symptoms of the disease include 
spirometric airflow tests, which measures FEV1 and FVC. FEV1 is defined as the 
volume of air a patient can expire in one second following a full intake of breath, 
whilst FVC can be defined as the total maximum volume of air that a patient can 
exhale following full inspiration [1, 317, 318]. If the ratio of FEV1/FVC falls below 
0.7, allied with a FEV1 <80%, the individual is defined as having COPD [319, 320]. 
However, spirometry alone may not suggest an individual may have COPD. Chest 
radiography may also aid in the differential diagnosis of COPD. Also pulse oximetry 
can be undertaken to calculate the saturation of oxygen that is present in an individual 
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at rest and at sleep to determine if he/she may have hypoxia, which is a common 
characteristic in COPD [321-325])LQDOO\DWHVWFDQEHSHUIRUPHGIRUĮ-antitrypsin 
deficiency, which is a hereditary genetic disorder caused by an abnormality in 
FKURPRVRPH$ ODFNRIĮ-antitrypsin production by the liver leads to a lack of 
control of neutrophil elastases in the lungs; leads to symptoms associated with 
emphysema. 
Hence, a system that would allow physicians to detect the different stages of the 
disease is highly desirable, but is presently unavailable [326-328]. It is vital to have a 
diagnostic platform, or combination of platforms, that would aid the diagnosis of 
sufferers more effectively, and help them improve their treatment according to the 
type of disease they have. 
The previous two chapters have shown the development/optimisation (Chapter 3), and 
the validation (Chapter 4), of a microarray platform.  This section focuses on applying 
this microarray platform to screen a selection of individuals that have COPD 
compared to non-smoking controls and smokers without symptoms of COPD. 
The microarray has been developed to measure up to 16 biomarkers simultaneously; 
all of these were measured to see if there are distinguishable patterns which could lead 
to improved understanding of the disease. An ultimate goal would be to be able to use 
WKHVHELRPDUNHUVLQWKHHDUO\GLDJQRVLVRI&23'GHYHORSPHQWLQµKHDOWK\¶VPRNHUV 
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5.2 Materials and Methods 
Briefly, antibody duoset kits were purchased (R&D Systems, MN, USA) and printed 
on poly-L-lysine slides. Slides were processed immediately or after one week. Slides 
on the day of processing were taken from the vacuum and blocked for an hour with 
either I-Block or 3% BSA block buffer. Standards were made for all 16 cytokines (IL-
8, IL-6, IL-ȕ71)-Į([RWD[LQ-1, Eotaxin-2, IFN-Ȗ5$*(,/-10, IL-4, IL-17, IL-
23, MCP-1, VEGF and IP-10) DFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQVDQGGLOXWHG
fold across 7 dilutions and added at 50µl per well in 10 replicates for 45 mins. 
Additionally healthy human sera and COPD human sera were added to the 
corresponding well on the slides. The slide was washed three times and 50µl of 
appropriately diluted biotinylated detection antibody was added to each block for 45 
mins. Slides were subjected to tyramide amplification. Briefly, this was performed 
after the detection stage of the microarray process described above with the additional 
of 50µl of 1:1000 diluted streptavidin-HRP (Bio-Rad, USA) in the dark. The slide was 
washed and 50µl of Bio-Rad Amplification Reagent was added for 10 mins in the 
dark. The slides were washed three times with 20% DMSO-PBST and subsequently 
washed thrice with wash buffer. After washing, 50µl of 1:1000 diluted streptavidin-
conjugated cy5 (E-Biosciences, UK) was added and incubated at room temperature 
for 15 mins in the dark. The slide was washed three times and rinsed in ultra-pure 
water and centrifuged dry and scanned with the 4200 AL microarray scanner at 
635nm (Axon GenePix®). Fluorescence was quantified using the GenePix Pro 
Software (Axon GenePix®). The experiment was repeated three times. The median 
fluorescence of each spot was measured (minus background) and the corrected 
fluorescence was used to calculate the average fluorescence signal across the standard 
detectable ranges.  
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5.3: Results 
5.3.1: The effect of COPD on cytokine levels in Non 
Smoking Controls, Smoking Controls and COPD 
individuals 
Sera from non-smoking controls, healthy smoking controls and COPD individuals 
were analysed on the microarray platform. As shown in Figures 61 and 62, there are 
no significant differences between groups for serum concentrations of most cytokines, 
except for eotaxin-2 and MCP-1, where there are significant differences between all 
WKUHHJURXSVS)LJXUHDQGS)LJXUH, respectively). However 
for other remaining cytokines (IL-8, IL-ȕ71)-Į ,/-6, IFN-Ȗ ,3-10, IL-4, IL-10, 
IL-23, IL-17, RAGE, eotaxin-1 TGF-ȕ DQG 9(*) WKHUH ZHUH QR VLJQLILFDQW
differences between all three groups.  
A line was drawn on all graphs at the 95 percentile of the healthy control group. 
Interestingly certain cytokines such as VEGF, MCP-1 and IL-23 showed values in 
both the healthy smoker group and COPD group to be well above the 95th percentile.  
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Figure 61: Differences in cytokine expressions in subjects with COPD, healthy smoking 
controls and non-smoking controls: IL-8, IL-6, IL-ɴĂŶĚdE&-ɲ ?-D, respectively). 
The difference in cytokine expression was investigated for the in those with COPD, 
healthy smoking controls and non-smoking controls in IL-8 (A), IL-6 (B), IL-ȕ&
and TNF-Į'UHVSHFWLYHO\Kruskal-Wallis tests were performed to compare all three 
SDWLHQW FRKRUWV DQG VXEVHTXHQWO\ 'XQQ¶V SRVW PXOWLSOH FRPSDULVRQV WHVWV EHWZHHQ
each subgroup which showed no significant differences between all three groups for 
each of the 4 cytokines. However in general the results were negative with no 
differences in groups seen. 
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Figure 62: Differences in cytokine expressions in subjects with COPD, healthy smoking 
controls and non-smoking controls: IFN-ɶ, IL-17, IL-4 and IL-10 (E-H, respectively). 
The difference in cytokine expression was investigated for the in those with COPD, 
healthy smoking controls and non-smoking controls in IFN-Ȗ(,/-17 (F), IL-4 (G) 
and IL-10 (H) respectively. Kruskal-Wallis tests were performed to compare all three 
SDWLHQW FRKRUWV DQG VXEVHTXHQWO\ 'XQQ¶V SRVW PXOWLSOH FRPSDULVRQV WHVWV EHWZHHQ
each subgroup which showed no significant differences between all three groups for 
each of the 4 cytokines. However in general the results were negative with no 
differences in groups seen. 
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Figure 63: Differences in cytokine expressions in subjects with COPD, healthy smoking 
controls and non-smoking controls: VEGF, Eotaxin-1, Eotaxin-2 and RAGE (I-L, respectively). 
The difference in cytokine expression was investigated for the in those with COPD, 
healthy smoking controls and non-smoking controls in  VEGF (I), eotaxin-1 (J), 
eotaxin-2 (K) and RAGE (L) respectively. Kruskal-Wallis tests were performed to 
compare all three patient cohorts DQGVXEVHTXHQWO\'XQQ¶VSRVWPXOWLSOHFRPSDULVRQV
tests between each subgroup which showed no significant differences between all 
three groups for VEGF (I), eotaxin-1 (J) and RAGE (L). However, in the case of 
eotaxin-2 (K), there is DVLJQLILFDQWGLIIHUHQFHEHWZHHQDOOWKUHHJURXSVSLQ
particular between the smoker control and COPD group when Mann Whitney tests 
ZHUHSHUIRUPHGSVKRZVDQLQFUHDVHLQHRWD[LQ-2 expression in the COPD 
group compared to the smoking controls.  
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Figure 64: Differences in cytokine expressions in subjects with COPD, healthy smoking 
controls and non-smoking controls: MCP-1, IP-10, TGF-ɴ and IL-23 (M-P, respectively). 
The difference in cytokine expression was investigated for the in those with COPD, 
healthy smoking controls and non-smoking controls in MCP (M), IP-10 (N), TGF-ȕ
(O) and IL-23 (P) respectively. Kruskal-Wallis tests were performed to compare all 
three patient cohorts DQG VXEVHTXHQWO\ 'XQQ¶V SRVW PXOWLSOH FRPSDULVRQV WHVWV
between each subgroup which showed no significant differences between all three 
groups for IP-10, TGF-beta and IL-23. In the case of MCP-1 (M) there is a significant 
difference between all three groups, in particular between the non-smoking control 
and COPD group when Mann :KLWQH\ WHVWV ZHUH SHUIRUPHG S144) shows an 
increase in MCP-1 expression in COPD compared to the non-smoking controls. 
 
Chapter 5: Application of an Antibody Microarray as a Diagnostic Platform for COPD 
 
 
~ 195 ~ 
 
5.3.2: The effect of smoking status on the likelihood of 
developing COPD 
The healthy smokers and COPD patients could be further subdivided into current 
smoking and ex-smoking groups to see whether the effect of smoking could possible 
indicate a pattern of how COPD may arise from those who are healthy smokers. As 
seen in Table 13, there were no significant differences between all 5 groups except in 
the case of MCP-1, Kruskal-Wallis tests were performed to compare all five patient 
FRKRUWV DQG VXEVHTXHQWO\ 'XQQ¶V SRVW PXOWLSOH FRPSDULVRQV WHVWV EHWZHHQ HDFK
subgroup, which showed there is a trend towards a progressive increase in this 
cytokine across all five groups from never-smokers to COPD current smokers. Mann 
Whitney tests performed showed a significant increase in MCP-1 between the healthy 
ex-smoking group and the COPD ex-VPRNLQJJURXSS 
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Table 14 Investigates the effect of smoking status of developing COPD in healthy non-
smoking individuals, ex healthy smokers, current healthy smokers, COPD ex-smokers 
and COPD current smokers 
Cytokine Kruskal-Wallis P Value 
IL-8 0.1460 
IL-6 0.5183 
IL-ȕ 0.7472 
TNF-Į 0.2854 
VGEF 0.5247 
Eotaxin-1 0.0997 
IFN-Ȗ 0.8544 
IL-17 0.9938 
Eotaxin-2 0.0854 
IP-10 0.04698 
RAGE 0.6311 
MCP-1 0.0120 
IL-4 0.6984 
IL-10 0.5870 
TGF-ȕ 0.5106 
IL-23 0.4545 
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Table 14 aims to show if there is a significant difference between the effects of 
smoking and the cessation of smoking in those who are healthy smokers and COPD 
patients. Kruskal-Wallis tests were performed to compare all five patient cohorts (in 
KHDOWK\LQGLYLGXDOVDQGVXEVHTXHQWO\'XQQ¶VSRVWPXOWLSOHFRPSDULVRQVWHVWVEHWZHHQ
each subgroup; ex healthy smokers, current healthy smokers, COPD ex-smokers and 
COPD current smokers) which showed no significant differences between all five 
groups in each of the 16 cytokines except for MCP-1 where there was a significant 
GLIIHUHQFH EHWZHHQ DOO JURXSV S :LWK 0&3-1 there was trend towards a 
progressive increase in MCP-1 across all five groups from non-smoking individuals to 
COPD current smokers (data not shown). 
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5.3.3: The correlation between cytokine expression and 
FEV% in those with COPD 
The FEV% predicted was initially evaluated to see if there was a relationship between 
this variable and the expression of cytokines. As can be seen in figures 65-69, the 
FRUUHODWLRQ EHWZHHQ WKHVH WZR YDULDEOHV ZHUH DQDO\VHG E\ 6SHDUPDQ¶V 5DQN
correlation, which showed no significant correlations for any of the 16 cytokines. 
Overall all 16 cytokines displayed negative results when FEV% correlation was 
investigated.  
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Figure 65: Correlation between FEV-1 predicted and cytokine concentration: IL-8, IL-6, IL-1ɴ 
and TNF-ɲ (A-D, respectively). 
6SHDUPDQ¶V 5DQN FRUUHODWLRQ WHVWs were performed to compare the relationship 
between the FEV-1% predicted against the concentration of the respective cytokines 
IL-8 (A), IL-6 (B), IL-1ȕ&DQG71)-Į'LQSDWLHQWVZLWK&23'which showed 
no significant correlations. In general all four cytokines showed negative results in 
correlation to FEV-1%pred. 
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Figure 66: Correlation between FEV-1 predicted and cytokine concentration: IFN-ɶ, IL-17, IL-
4, IL-10 (E-H, respectively). 
6SHDUPDQ¶V 5DQN FRUUHODWLRQ WHVWV ZHUH SHUIRUPHG WR FRPSDUH WKH UHODWLRQVKLS
between the FEV-1% predicted against the concentration of the respective cytokines, 
IFN-Ȗ(,/-17 (F), IL-4 (G), and IL-10 (H) in patients with COPD, which showed 
no significant correlations. In general all four cytokines showed negative results in 
correlation to FEV-1%pred. 
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Figure 67: Correlation between FEV-1 predicted and cytokine concentration: VEGF, Eotaxin-
1, Eotaxin-2 and RAGE (I-L, respectively). 
6SHDUPDQ¶V 5DQN FRUUHODWLRQ WHVWV ZHUH SHUIRUPHG WR FRPSDUH WKH UHODWLRQVKLS
between the FEV-1% predicted against the concentration of the respective cytokines, 
VEGF (I), Eotaxin-1 (J), Eotaxin-2 (K) and RAGE (L) in patients with COPD which 
showed no significant correlation for all four cytokines. In general all four cytokines 
showed negative results in correlation to FEV-1%pred. 
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Figure 68: Correlation between FEV-1 predicted and cytokine concentration: MCP-1, IP-10, 
TGF-Beta and IL-23 (M-P, respectively). 
6SHDUPDQ¶V 5DQN FRUUHODWLRQ WHVWV ZHUH SHUIRUPHG WR FRPSDUH WKH UHODWLRQVKLS
between the FEV-1% predicted against the concentration of the respective cytokines, 
MCP-1 (M), IP-10 (N), TGF-ȕ 2 DQG ,/-23 (P) in patients with COPD which 
showed no significant correlation in all 4 cytokines. In general all four cytokines 
showed negative results in correlation to FEV-1%pred. 
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5.3.4: The effect of gender on the cytokine expression in 
those with COPD 
The difference in gender were investigated between the 3 cohorts (healthy controls, 
smoking controls and COPD subjects) to see if there were significant differences 
between males and females amongst those who smoked and had COPD and those that 
smoked and did not have COPD. Kruskal-Wallis tests were performed and 
VXEVHTXHQWO\'XQQ¶VSRVWPXOWLSOHFRPSDULVRQVWHVWVEHWZHHQHDFKVXEJURXS; 
i) Male Healthy Non-Smokers, 
ii) Female Healthy Non-Smokers, 
iii) Male Healthy Smokers, 
iv) Female Healthy Smokers, 
v) Male COPD Subjects, 
vi) Female COPD Subjects 
However the results for all 16 cytokines (IL-8, IL-6, IL-ȕ71)-Į9(*)(RWD[LQ-1, 
Eotaxin-2, RAGE, MCP-1, IL-4, IL-10, TGF-ȕ,3-10, IFN-Ȗ,/-17 and IL-23) were 
all negative indicating in this study there is no difference between gender in this study 
(data not shown) 
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5.3.5: The GOLD stages of COPD 
COPD severity is divided into four categories according to international guidelines 
outlined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). This 
is often known as stage 1 (mild), stage 2 (moderate), stage 3 (severe) and stage 4 (very 
severe). This is based on the forced expiratory volume per second (FEV-1%) outlined 
in Table 1 (chapter 1). Hence graphs were plotted to show the mean concentration and 
standard deviation against the four stages of GOLD. As one might expect, there were 
variations between all samples in all groups. Additionally as the severity of COPD 
increases, inflammatory markers and growth factors also increase in expression. 
However in the graphs plotted (Figure 69-72) due to the unequal distribution of 
numbers in each group a general trend in all 16 biomarkers were not established. 
$GGLWLRQDOO\ D ³5()´ JURXS ZDV DGGHG WR WKH HDFK JUDSK 7KLV ZHUH WKH normal 
healthy controls, which served as a reference point to which the split COPD cohorts 
were compared. 
Finally the means of all the 16 cytokines for each GOLD stage was grouped to see 
whether there was a cumulative difference between groups. In Figure 73 it could be 
seen that the expression of cytokines was the lowest in stage 4 and highest in stages 
2/3. This may indicate that at GOLD stage 4 the immune response was suppressed as 
shown by the lowest expression of nearly all 16 cytokines.  Interestingly only the 
expression of IL-23 increased in GOLD stage 4. However one has to be cautious when 
making definitive assumptions from this data not knowing the medication those in the 
most severe group (stage 4) are undertaking. 
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Figure 69: Graph to show how the concentration of cytokine varies with the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) stage for IL-8, IL-6, IL-1ɴĂŶĚdE&-ɲ
respectively (A-D). 
All cytokines are expressed as mean concentration (pg/ml). Kruskal-Wallis test were 
performed DQG VXEVHTXHQWO\ 'XQQ¶V SRVW PXOWLSOH FRPSDULVRQV WHVWV EHWZHHQ HDFK
subgroup to compare all 5 groups across all 4 cytokines that showed no significant 
differences. A general trend seemed to show the level of cytokine concentration 
LQFUHDVLQJDVWKHVHYHULW\UDWLQJRI*2/'LQFUHDVHV$³5()´JURXSDUHKHDOWK\QRQ-
smoking control used as a comparison. Note at GOLD stage 4, the immune system 
could potentially be suppressed as indicated by low expressions of all 4 cytokines. 
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Figure 70: Graph to show how the concentration of cytokine varies with the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) stage for IFN-ɶ, IL-17, IL-4 and IL-10 
respectively (E-H).  
All cytokines are expressed as mean concentration (pg/ml). Kruskal-Wallis test were 
performed DQG VXEVHTXHQWO\ 'XQQ¶V SRVW PXOWLSOH FRPSDULVRQV WHVWV EHWZHHQ HDFK
subgroup to compare all 5 groups across all 4 cytokines that showed no significant 
differences. A general trend seemed to show the level of cytokine concentration 
LQFUHDVLQJDVWKHVHYHULW\UDWLQJRI*2/'LQFUHDVHV$³5()´JURXSDUHKHDOWK\QRQ-
smoking control used as a comparison. Note at GOLD stage 4, the immune system 
could potentially be suppressed as indicated by low expressions of all 4 cytokines. 
However it has to be acknowledged that there are 3 subjects in GOLD stage 4 and the 
medication they are on is unknown which could influence the data. 
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Figure 71: Graph to show how the concentration of cytokine varies with the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) stage for VEGF, Eotaxin-1, Eotaxin-2 
and RAGE respectively (I-L). 
All cytokines are expressed as mean concentration (pg/ml). Kruskal-Wallis test were 
performed DQG VXEVHTXHQWO\ 'XQQ¶V SRVW PXOWLSOH FRPSDULVRQV WHVWV EHWZHHQ HDFK
subgroup to compare all 5 groups across all 4 cytokines showed significant 
differences across all groups LQ5$*(SRQO\The immune system appears 
to be most active at stage 3 in the above cytokines, whilst at GOLD stage 4 the 
immune system seems suppressed as indicated by low expressions of all 4 cytokines. 
However it has to be acknowledged that there are 3 subjects in GOLD stage 4 and the 
medication they are on is unknown which could influence the data. 
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Figure 72: Graph to show how the concentration of cytokine varies with the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) stage for MCP-1, IP-10, TGF-beta and 
IL-23 respectively (M-P). 
All cytokines are expressed as mean concentration (pg/ml). Kruskal-Wallis test were 
performed DQG VXEVHTXHQWO\ 'XQQ¶V SRVW PXOWLSOH FRPSDULVRQV WHVWV EHWZHHQ HDFK
subgroup to compare all 5 groups across all 4 cytokines that showed significant 
differences all groups in MCP-SRQO\7he lowest expression of cytokines 
was observed at GOLD stage 4 as in line with the other 12 cytokines above except for 
IL-23 which is increased (P). However it has to be acknowledged that there are 3 
subjects in GOLD stage 4 and the medication they are on is unknown which could 
influence the data. 
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Figure 73: Dot plot to show the mean cytokine expression of all 16 cytokines across the 4 
stages of GOLD. 
As can be seen above the immune system is most active between stages 2 and 3 of 
GOLD. However at GOLD stage 4 where the FEV-1% drops less than 30%. It appears 
a potential explanation for this drop in the level of cytokines (with the exception of 
IL-23 which has increased expression at GOLD stage 4) could be that the immune 
system is suppressed significant compared to the other stages. However it has to be 
acknowledged that there are 3 subjects in GOLD stage 4 and the medication they are 
on is unknown which could influence the data which could negatively impact the 
nature of this finding.  
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5.3.6: Relationship between Age and FEV-1% 
The relationship between FEV-1 and age was investigated. Over time healthy 
individuals experience a reduction in FEV-1% and this is exacerbated in those with 
COPD and who smoke. However it seems to be no correlation between both variables 
in this study. This suggests both variables are independent of each other (Figure 74). 
Additionally the data was split to see if there was a difference between age/FEV-1 % 
compared to those who were current smokers and those who were ex-smokers. The 
data (not shown) shows that there is no correlation between COPD current and ex-
smokers in relation to age and FEV-1 predicted.  
 
Figure 74: The ƌĞůĂƚŝŽŶƐŚŝƉďĞƚǁĞĞŶ “ĂŐĞ ?ĂŶĚƉƌĞĚŝĐted FEV-1% in COPD individuals. 
There is no correlation between these two variables. Interestingly, the range of the 
COPD variables for age was between 46-84 and FEV-1 between 17-122%.  This 
indicates there is no relationship between the two variables suggesting both are 
independent of one another. 
 
 
Chapter 5: Application of an Antibody Microarray as a Diagnostic Platform for COPD 
 
 
~ 211 ~ 
 
5.3.7: The effect of Age on COPD 
An interesting aspect of this study was to investigate the impact of age on the 
progression of COPD. The ages of the COPD patients ranged from 46 to up 83 years 
(figures 84-87). As seen in Figure 87, only for IP-10 did age correlate significantly 
with serum concentration of the cytokines. There was an increase in IP-10 associated 
ZLWK DQ LQFUHDVH LQ DJH S $GGLWLRQDOO\ 9(*) VKRZHG D Wrend towards 
SRVLWLYHFRUUHODWLRQZLWKDJHS7KHUHPDLQGHURIWKHF\WRNLQHVWHVWHGVKRZHG
no significant correlations with age. 
 
Figure 75: ŽƌƌĞůĂƚŝŽŶďĞƚǁĞĞŶ “ĂŐĞ ?ĂŶĚĐǇƚŽŬŝŶĞĐŽŶĐĞŶƚƌĂƚŝŽŶ P/>-8, IL-6, IL-1ɴ and TNF-ɲ 
respectively (A-D, respectively. 
6SHDUPDQ¶V 5DQN FRUUHODWLRQ WHVWV ZHUH SHUIRUPHG WR FRPSDUH WKH UHODWLRQVKLS
between the ³DJH´ against the concentration of the respective cytokines; IL-8 (A), IL-
6 (B) IL-ȕ&DQG71)-Į' which showed no significant correlation in those with 
COPD. 
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Figure 76: ŽƌƌĞůĂƚŝŽŶďĞƚǁĞĞŶ “ĂŐĞ ?ĂŶĚĐǇƚŽŬŝŶĞĐŽŶĐĞŶƚƌĂƚŝŽŶ P/&E-ɶ, IL-17, IL-4 and IL-
10 (E-H, respectively). 
6SHDUPDQ¶V 5DQN FRUUHODWLRQ WHVWV ZHUH SHUIRUPHG WR FRPSDUH WKH UHODWLRQVKLS
between the ³DJH´ against the concentration of the respective cytokines; IFN-Ȗ (
IL-17 (F), IL-4 (G) and IL-10 (H) which showed no significant correlation in those 
with COPD. 
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Figure 77: ŽƌƌĞůĂƚŝŽŶďĞƚǁĞĞŶ “ĂŐĞ ?ĂŶĚĐǇƚŽŬŝŶĞĐŽŶĐĞŶƚƌĂƚŝŽŶ Ps'& ?ŽƚĂǆŝŶ-1, Eotaxin-
2 and RAGE (I-L, respectively). 
6SHDUPDQ¶V 5DQN FRUUHODWLRQ WHVWV ZHUH SHUIRUPHG WR FRPSDUH WKH UHODWLRQVKLS
between ³DJH´ and the concentration of the respective cytokines; eotaxin-1 (J), 
eotaxin02 (K) and RAGE (L) which showed no significant correlation. VEGF (I) 
concentration showed a trend towards a significant positive correlation with age 
(pLQWKRVHZLWK&23'  
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Figure 78 PŽƌƌĞůĂƚŝŽŶďĞƚǁĞĞŶ “ĂŐĞ ?ĂŶĚĐǇƚŽŬŝŶĞĐŽŶĐĞŶƚƌĂƚŝŽŶ PDW-1, IP-10, TGF-ɴ ?/>-
23 (M-P, respectively).  
6SHDUPDQ¶V 5DQN FRUUHODWLRQ WHVWV ZHUH SHUIRUPHG WR FRPSDUH WKH UHODWLRQVKLS
EHWZHHQ³DJH´and the concentration of the respective cytokines; MCP-1 (M), TGF-ȕ
(O) and IL-23 (P). IP-10 concentration showed a significant positive correlation with 
DJHSLQWKRVHZLWK&23' 
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5.3.8: Clustering of Microarray Data 
Due to the large sample size and the 16 biomarkers used, the data was analysed 
further in Multiple Experiment Viewer 4.7.4 (MEV). MEV is a Java tool that allows 
for complex proteomic data analysis. This was used to see if there were any new 
correlations or significant differences to the graphs previously shown in this chapters. 
An advantage of using MEV is that it avoids producing multiple graphs of the data 
when it can be represented as just one whole data set. This is shown in figure 87 
where a heat-map is drawn to show the expression of all 16 biomarkers and also to see 
visually the difference between all three patient cohorts.  
Interestingly when the heat-map is hierarchical clustered, the expression of the 16 
biomarkers is not dependant on the FEV-1 levels. Immediate differences in the 
cytokines patterns between patient cohorts are not seen in the heatmap (Figure 79A) 
however when the statistical analysis was undertaken on the heatmap both MCP-1 
SDQGHRWD[LQ-SVKRZHGDVLJQLILFDQWGLIIHUHQFHEHWZHHQDOO WKUHH
groups illustrated in Figure 79B which was in line with the results shown in section 
5.3.1. 
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Figure 79: Heat-map to show the expression of all 16 biomarkers across all the samples 
which are subdivided into the three patient cohorts. 
The heat-map above shows a hierarchical clustering of the levels of expression of the 
16 biomarkers studied in sera of COPD, healthy smoking (S) controls and healthy 
controls (NS). The multiple different proteins are outlined on the vertical axis, and the 
patient cohorts on the horizontal axis. Red and blue colours indicate high and low 
protein expression respectively (A). When Kruskal-Wallis test were performed to 
compare differences between all patient cohorts both MCP-SDQGHRWD[LQ-2 
S ZHUH GHHPHG VWDWLVWLFDOO\ VLJQLILFDQW % ZKLFK ZDV LQ OLQe with data 
produced in section 5.3.1. 
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5.3.9 False Discovery: 
Undertaking multiple Kruskal-Wallis tests and correlations also constitutes for 
multiple testing and therefore needs controlling to avoid the rise in false positive data. 
Hence this was preformed through J-Express Pro 2012 ± Build 119 which allows for 
IXUWKHUSURWHRPLFH[SUHVVLRQDQDO\VLV8VLQJWKLVVRIWZDUHWKH³VLJQLILFDQWDQDO\VLVRI
PLFURDUUD\V´RU³6$0´ZDVDPHWKRGFKRVHQWRFDOFXODWH WKHQXPEHURIJHQHV WKDW
are false positive. As both MCP-1 and eotaxin-2 both expressed significant between 
healthy non-smokers, healthy smoking controls and COPD patients, SAM was used to 
see if these were either true results or in fact false positive results.  
Table 15 below shows the results from SAM analysis. Interesting it has shown that 
only eotaxin-2 (highlighted in yellow) to be a truly positive result (FDR=0 and q 
value=0). MCP-1 (highlighted in orange) that was shown up early in Chapter 5 as 
being significant is shown to have a FDR and q-value of 25. Like p-values, q-values 
FDQEHDVVLJQHGRIFXWRIRUT7KHUHIRUHDVVHHQIURP7DEOH0&3-1 is 
GHILQHG DV EHLQJ IDOVH SRVLWLYH  DQG WKLV KDV WR EH DFNQRZOHGJHG ZKHQ
analysing the data. Therefore one can presume that eotaxin-2 is the only significant 
cytokine that could have a bearing on COPD from the data generated from this study.  
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Table 15: To show the ƐŝŐŶŝĨŝĐĂŶƚĂŶĂůǇƐŝƐŽĨŵŝĐƌŽĂƌƌĂǇƐ ?Žƌ “^D ?ŵĞƚŚŽĚƵƐĞĚƚŽ
discover false-positive results amongst all 16 cytokines 
Number: Cytokine: 
                                       
False Discovery  
Rate  (FRD): Q value: 
1 Eotaxin-2 0 0 
2 RAGE 37.5 25 
3 MCP-1 25 25 
4 IL-6 37.5 37.5 
5 VEGF 60 60 
6 IL-23 75 75 
7 Eotaxin-1 75 75 
8 IL-ȕ 93.75 75 
9 IL-10 91.667 75 
10 IP-10 82.5 75 
11 TGF-ȕ 88.636 75 
12 Il-17 87.5 75 
13 IFN-Ȗ 80.769 75 
14 IL-4 80.357 75 
15 IL-8 75 75 
16 TNF-Į 75 75 
 
Table 15 shows the use of the SAM method to discover false-positive data. Previously 
in Chapter 5, MCP- S DQG (RWD[LQ- S ZHUH GLVFRYHUHG WR EH
statistically significant when comparing healthy non-smoking controls, healthy 
smoking controls and COPD patients. When this data was analysed by SAM, which 
serves to assume each null hypothesis is true for each cytokine, it was shown that only 
eotaxin-2 can be regarded as a truly positive result. Like p-vales, q-values have a cut-
off point of 5% or 0.05 and therefore whilst MCP-1 was considered significant when 
analysed by Kruskal-Wallis testing, the repeated nature of performing that test across 
16 cytokines has led to a false positive result. Therefore is has to be acknowledged 
moving forward from the data in this study, the only eotaxin-2 is a significant 
cytokine and could play a role in the pathogenesis of COPD.  
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5.4 Discussion 
5.4.1 Biomarkers in COPD 
Our study shows that none of the 16 biomarkers completely correlates to all the 
factors outlined in the patient demographics. In general apart from eotaxin-2, the 
remaining of the data across the different variables were largely negative. Indeed 
when SAM analysis was performed on the dataset, only eotaxin-2 was shown to have 
truly positive data, meaning the significant data produced by MCP-1 has to be 
regarded as an obsolete. Therefore only eotaxin-2 can be considered as a cytokine 
which has significance in this study.  
However eotaxin-2 was not correlated significantly to FEV-1% despite being 
significant differences between the COPD group and both the smoking and non-
smoking control groups. Hence eotaxin-2 may be important biomarker in 
distinguishing between those that have COPD and those who are healthy smokers.  
Many of the inflammatory markers measured in COPD patients in this study, such as 
IL-6, IL-1ȕ and TNF-Į, were not significantly different to the healthy smoker 
controls. Similarly, it is known that IL-8 plays an important role in the recruitment of 
neutrophils to the site of inflammation; however in this study there were no significant 
differences in IL-8 levels between all 3 groups investigated.  
MCP-1 is a chemoattractant that is responsible for the recruitment of monocytes that 
can differentiate into macrophages. Currently there are few publications that directly 
implicate a role for MCP-1 in COPD. Liu et al, showed there to be an increase in the 
level of MCP-1 with low levels of FEV1% predicted in stable COPD patients [137]. 
However in this investigation no trend was seen between the FEV-1% and MCP-1 
concentrations. CCR2 is a receptor that is specific for MCP-1 that is present on all 
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monocytes, macrophages and T-lymphocytes [330, 331]. Increased MCP-1 levels in 
BAL fluid have been implicated in those with chronic bronchitis who smoke, 
suggesting that that this chemokine plays a role in the inflammatory process in 
association with cigarette smoke [332, 333].  
Similarly it is thought that MCP-1 is secreted by alveolar macrophages which are 
exposed to noxious particles present in cigarette smoke. This may enter the circulation 
of the pulmonary capillaries in and around the lungs that could contribute to higher 
levels of MCP-1 in the serum of those that have COPD compared to the healthy 
controls [144]. This suggests that analysing MCP-1 in serum is perhaps futile in 
comparison to investigating it in BAL fluid.  
Eotaxins, mainly compromising of eotaxin-1,-2 and -3, are strong chemoattractants for 
eosinophils. Usually this chemokine and its receptor are known to be associated in 
allergic reactions [334, 335]. It is postulated that eotaxins cause an influx of 
eosinophils into the bronchoalveolar lavage of those with asthma [336-339]. It has 
been reported that eosinophils can also influence other immune effector cells such as 
macrophages and T-lymphocytes [187] [340] [341]. However a mechanism for the 
role of eotaxins in COPD has yet to be postulated.  
In this study we have shown that, of all the 16 biomarkers investigated, eotaxin-2 
correlated significantly between the three patient cohorts. As mentioned in chapter 
one, as COPD is often described as a multicomponent disease including both 
emphysema and asthma, one can postulate that those whose have overlapping 
symptoms associated with asthma are represented in this study through the elevated 
expression of both eotaxin-1 and eotaxin-2 in the COPD cohort compared to the 
healthy smoking controls. Whilst it has never been proven that eotaxins have a 
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positive role in the pathogenesis of COPD, the results of this study indicate that these 
chemokines may play a role in the recruitment and activation of other immune 
effector cells such as macrophages which in turn play a role in the disease.  
It is worth noting the inflammatory cytokines such as IL-6, TNF-ĮDQG,/-ȕVKRZHG
no significant differences between these cytokines across the different patient 
subgroups which is contrary to results in the field that suggest that these three 
cytokines could play a role in the inflammatory processes in COPD. TNF-Į LQ 
particular is secreted by macrophages, mast cells and epithelial cells [342] [343] 
[344]. IL-ȕ LV NQRZQ WR DFWLvate macrophages in those with COPD which in turn 
contribute to the inflammatory process by release chemokines and activating the 
metalloproteinases [345]. IL-6 has been found to be elevated in the sputum and 
plasma of COPD patients who have known to have an exacerbation of the disease. IL-
6 is known to increase the inflammatory effect of COPD by releasing CRP from the 
liver [346]. 
Here we show that neither of these three inflammatory markers are elevated in this 
study, however, information is not available whether the COPD patients have had 
recent exacerbations prior to giving a blood sample. However going by results, it 
looks unlikely that the COPD patients would have had any exacerbations. 
Additionally it is unlikely that these exacerbations would be noticed in serum 
compared to BAL fluid. As a caveat it has to be acknowledged that information about 
the treatment that these COPD patients are no available which would have a 
significant bearing on the expression of these cytokines. 
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Interestingly WKH ERG\¶V UHVSRQVH WR DQ\ LQIODPPDWRU\ SURFHVVHV WKDW RFFXU LV WR
produce anti-inflammatory cytokines that could perhaps counteract the effect of 
inflammation that is present in COPD. To this end, this study included the 
measurement of IL-10 which is a known anti-inflammatory marker [347]. Specifically 
IL-10 has the ability to suppress TH1 cytokines such as TNF-Į DQG ,/-ȕ KHQFH
possibly the reason why the inflammatory cytokines where not as significantly 
different between the patient cohorts [348] [349]. However from the data in this study 
there was no significant increase in the expression of IL-10 in the COPD cohort 
compared to both the control cohorts.  
IL-17 is also known as IL17A. It is a glycosylated cytokines; approximately 25kDa in 
size that is produced by TH17 cells [350] [351, 352]. The role of IL-17 and the TH17 
cells in COPD are yet to be fully understood. Is it thought that IL-17 may play a role 
in the pathogenesis of COPD through the stimulation and chemokine production [108] 
[107] [353]. Specifically a role for IL-17A involves the production of chemokines 
such as IL-8 and GM-CSF which can lead to neutrophilic inflammation in COPD. In 
this study, no increase of serum IL-17 is was observed in the COPD cohort compared 
to the healthy smoker cohort. Additionally it is thought that IL-17 may a role in the 
production of metalloproteinases, in particular MMP-9 which contributes to epithelial 
tissue damage that ultimately leads to emphysema [105].  
As with IL-17, the exact role of IL-23 is not known. It is thought in mouse models 
involving cigarette smoke IL-23 induces the production of IFN-Ȗ DQG DOVR WKH
proliferation of memory T-cells [354] . However it is thought that IL-23 has a positive 
influence on the expression of IL-17. IL-23 is thought to induce TH17 cells to produce 
IL-17 working by a positive feedback system [355, 356]. In this investigation it can be 
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seen that both IL-17 and IL-23 are both up-regulated in the COPD cohort compared to 
the normal healthy cohort. Interestingly a large population of IL-23 is highly 
expressed as shown in the heatmap. A plausible explanation to this could be a 
polymorphism in the IL-23 gene which is better recognised in certain samples than 
others when using this particular duoset kit.  
In studies of severe COPD patients (without a history of asthma), bronchoscopy of 
airway smooth muscle has shown an increase in size compared to that of those whom 
didn¶t suffer from the disease [357] [358]. It is also thought that the expression of 
contractile proteins such as calponin and myosin are lower in COPD patients. This 
reduces the elasticity of lung fibres which induces airflow resistance [57]. It is 
believed that the growth factors such TGF-ȕ SOD\V D SLYRWDO UROH LQ LQFUHDVLQJ WKH
H[SUHVVLRQRI$60FRQWUDFWLOHSURWHLQVVXFKDVĮ-actin and calponin in patients with 
COPD compared to asymptomatic smokers [57].  
In subsequent studies it has been shown that there is an increase in the size of airway 
smooth muscle (ASM) in the peripheral airways of those who smoke and are 
diagnosed with COPD. Additionally there is a positive correlation in increased ASM 
and decreased FEV1 levels. This supports the growing assertion that airway smooth 
muscle remodelling may be accountable for chronic airflow limitation. It is 
hypothesised that cigarette smoke may be responsible for either the growth of ASM or 
specifically increasing ASM tones [57].   
In airway remodelling, mucosal thickening can augment the effect of mucosal 
restriction against elastic load. In a study in 2004, Baraldo and colleagues further 
supported the case that an increase in airflow limitation was in parallel with 
abnormalities that occur in airway remodelling of ASM cells. This resulted in a 
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thickening of the mucosal epithelial walls, which causes a narrowing of the airway 
lumen compared to normal airways [359].  However, in this study it can be seem that 
TGF-ȕ WKHUHZDVQRGLIIHUHQFHEHWZHHQ WKH WKUHHSDWLHQWFRKRUWVVXJJHVWLQJ LI WKHUH
was any airway remodelling in the lung there is no overspill into the pulmonary 
system as shown by the results.  
Interestingly the other growth factor in this biomarker study was VEGF. The actual 
role of VEGF and its receptors are not fully understood in COPD. In this study we 
have shown that expression of VEGF was not significantly increased in the COPD 
cohort compared to the both the healthy control cohorts. Additionally serum VEGF 
level correlated negatively with a decline in predicted FEV-1%. In a study by 
Kierszniewska-Stepien et al, it was shown that there was an increase in serum VEGF 
in those with mild COPD compared to healthy controls and there was a similar 
correlation with their FEV-1% predicted level. Additionally they reported there were 
no significant increases in serum VEGF in severe COPD patients. They suggest that 
alveolar damage that occurs due to emphysema may result in impaired VEGF 
production from lung epithelial cells in those with severe COPD [360].  
In addition to the measurement of standardised biomarkers in COPD, like those 
involved in inflammation and tissue remodelling, a new emphasis has been placed on 
discovering potential new biomarkers that could help distinguish those who have 
COPD from healthy controls. These biomarkers could help understand how the 
disease could progress compared to the standardised biomarkers. Hence for this 
investigation, the receptor for advanced glycation end-products (RAGE) was used as a 
potential novel biomarker. Work carried out in the field has shown that RAGE could 
influence a variety of different immune processes including cell/tissue injury as well 
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as being involved in oxidative stress and hypoxia which are two hallmarks of COPD 
[138, 165]. Work on murine models has shown that the treatment with sRAGE has 
shown to reverse the effect of inflammation. In humans it is thought that low levels of 
RAGE in blood may have a regulatory role in diseases such as rheumatoid arthritis 
and coronary heart disease, hence suggesting that low levels of this cytokine could be 
an indicator of poor inflammatory control [138, 139, 165]. Though it has been known 
that RAGE has been expressed in lung tissue of normal healthy controls, the exact role 
of this cytokine is not completely understood.  
Specifically in relation to RAGE in blood, a study by Smith et al showed that plasma 
sRAGE was significantly lower in stable COPD patients compared to healthy 
controls. They also noticed a significant positive correlation with FEV-1% predicted 
and plasma sRAGE [361]. In this investigation we have shown that there are no 
significant differences between the three patient subgroups investigated as well as 
WKHUHEHLQJQRVLJQLILFDQWFRUUHODWLRQVZLWKUHVSHFWWR³DJH´DQG)(9-1%.  
5.4.2: Gender differences in COPD  
Over many years, there has seen a rise in the number of women developing tobacco 
related diseases such as COPD and lung cancer [362] [363] [364] . Compared to men 
who have similar levels of airway obstruction women are reported to develop worse 
dyspnea and have poorer quality of life scores [365] [366]. Despite COPD being well 
studied, there seems to be a lack of knowledge about the gender differences between 
men and women in serum biomarkers in those with the disease. In this investigation 
we looked closely at the difference between the expression of 16 cytokines across 
both genders in the three patient cohorts.  
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No significant differences were observed in the expression of the biomarkers between 
sexes in all three groups. Overall, the data showed no skew favouring either gender 
apart from those mentioned above.  
However it has to be acknowledged that there are limitations in the present study. 
Ideally it would be beneficial to have exactly the same numbers of both females and 
males in each cohort. For all the 16 cytokines studied, there were more males than 
females, which may have skewed the data favouring male cytokine expression 
especially for VEGF (m=35, f=26). Additionally if information was available with 
regard to BODE, BMI and also smoking pack year history, further analyses could be 
performed in relation to gender and the expression of the 16 biomarkers. One can 
hypothesise at this stage that possibly the smoking pack year history could contribute 
to the higher expression of VEGF in males compared to females. A plausible 
mechanism for the role in VEGF could be directly related to the number of cigarettes 
that is smoked by an individual. Increased smoking could lead to impaired VEGF 
production that leads to airway obstruction and, ultimately, emphysema.  
5.4.3: Age differences in COPD  
In the third part of this study, the effect of age was investigated in relation to the 
expression of cytokines.  One of the earliest studies was conducted by CM Fletcher et 
al, which studied the FEV-1 % in a group of west London men to show the different 
stages of GOLD severity introduced by GOLD [367]. Their study showed that over a 
SHULRG RI  \HDUV RI DQ LQGLYLGXDO¶V OLIH )(9-1% falls irrespective of smoking. 
However their study noted that smoking did increase the drop in FEV-1%. However it 
was thought that, whilst the measurements such as FEV-1% and FVC% can be good 
indicators of airflow limitation, they fail to distinguish between airflow limitation 
caused by small airway obstruction and emphysema. Hence, in this study, the majority 
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of the cytokines in this microarray panel did not show a significant correlation with 
FEV-1% apart from IP-10. Only IP-10 showed a positively significant relationship 
with FEV-1% and age. IP-10 is a chemokine that is secreted by a variety of immune 
effector cells such as bronchial epithelial cells and neutrophils in response to both 
IFN-Ȗ DQG 71)-Į [368] [369] is known to be up-regulated in those who have an 
exacerbation in COPD compared to healthy controls [146]. However there is very 
little to show the relationship between the expression of this chemokine in relation to 
age in those with COPD. Additionally within the COPD samples, the direct 
relationship between age and FEV-1 showed there to be no correlation in the data. 
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Chapter 6: General Discussion, Future Work & 
Conclusion 
6.1 General Discussion 
There is increasing evidence that COPD is associated with prolonged systematic 
inflammation in both the airways and the lung. Previously ELISA work has shown 
that there are biomarkers, such as CRP, IL-8 and TNF-ĮWKDWVLJQLILFDQWO\LQFUHDVHG
in COPD patients compared to healthy smoking and non-smoking controls [342] [370] 
[371] [372]. However the ELISA methodology is limited by the ability to measure one 
protein in one sample at any one time. 
The main aim of this thesis was develop a microarray platform that would allow 
multiple biomarkers to be quantified. Initially a number of variables that can 
potentially affect the microarray ranging from printing buffers, blocking buffer, slide 
surface etc were examined (Chapter 3). Initially the print buffer was assessed in 
combination with different slide surfaces. It was imperative to have a print buffer that 
could hold the conformational shape of the capture antibody intact so the sandwich 
microarray process would function. Additionally the print buffer had to interact well 
with the chemically modified surfaces of the different slide types. Finally the 
combination of slide surface and print buffer would have to provide a high level of 
reproducibility and signal strength both short and long term.   
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In this stage of the investigation trehalose was diluted in PBS and printed on poly-L-
lysine slides was the best choice for this antibody microarray platform. Trehalose in 
particular is a naturally linked alpha disaccharide that forms a gel like surface on the 
slide and prevents the antibody from drying out and effectively holds them in position 
[212] [265] [267] [373]. Subsequent rehydration that occurs upon processing the 
slides allows the antibody to resume its reactivity when it binds to the detection 
antibody or protein of interest. 
Poly-L-lysine is not novel in terms of its use in microarrays. In particular this slide 
surface has been used readily in cDNA work [211] [214] [374]. Of all the slide 
surfaces tested, poly-L-lysine was the best type of slide surface for long term 
processing of the slide. A key aim when developing this project was to have a 
microarray platform that could process and quantify blood immediately and if 
required at a later date. The natural ageing of poly-L-lysine coated slides means that 
the strength of the signal is consistent over time and in parts the signal may in fact 
improve with time making it an ideal surface for running antibody microarrays [219] 
[275].  
One of the findings of our initial work with the generation of standard curves using 
normal sandwich ELISAs on the microarray was that at the lowest concentration of all 
16 cytokines tested there was a lack of sensitivity. A lot of research groups have had 
the same problem with sensitivity and resort to amplification to improve this issue. 
For example work by Zhou et al, used two-colour rolling-circle amplification to 
improve sensitivity in their serum antibody microarrays [291] without noticing any 
cross-reactivity. More recently Meany et al, have used tyramide signal amplification 
in their lectin microarrays [375]. This study used an opti-4CN amplification module 
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that is often used in western blots and lysate microarray as shown in a study by Chan 
et al, to amplify signals [376]. In our study amplification has a two-fold effect on the 
microarray slides; firstly the level of background is almost halved and secondly the 
signal to noise ratio is enhanced. An explanation for both could be amplification adds 
an extra layer to the antibody microarray process which could remove non-specific 
binding, increasing sensitivity and thus leading to less background and hence 
enhancing the signal around each spot printed. Additionally amplification did not lead 
to any cross reactivity.  
The choice of blocking buffer was then considered. It was shown that only 3% BSA 
and I-Block were effective on poly-L-lysine slide surfaces. 3% BSA may have 
contributed to a slightly higher level of background than I-Block but it was able to 
provide the best signal to noise ratio (S/N) which is was vital in being able to detect 
very low abundant cytokines.  
The main aim of the validation chapter (Chapter 4) was to run a series of experiments 
that would examine the robustness of the antibody microarray platform that was 
optimised in the previous chapter. The use of microarrays have been prevalent over 
the last decade with a lot of focus built on developing a platform that is both robust 
and accurate and satisfies the accepted criteria outlined by different assay 
developmental federations. However different research groups follow different 
acceptable criteria for their own microarray technology. Work carried out by 
Urbanoswa et al developed an antibody microarray platform that had accuracy level 
between 70-130% and precision levels as high as 30% [126]. These were at the time 
in accordance with the FDA for analytical method validation. However more recently 
these parameters set by the FDA for accuracy and precision seem to have been revised 
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to fit tighter criteria (accuracy 80- DQG SUHFLVLRQ  [227]. Interestingly, 
other companies, namely Affymetrix base their guidelines on the Luminex bead based 
assay, where they have accuracy levels between 70-130% and have precision levels 
 [377]. No universal level is in place for accuracy and precision for analytical 
method validation remains unclear. A consensus needs to be established whereby in 
microarray technology a set of criteria are followed that any research group or 
company wanting to undertake and develop such a platform can adhere to. By 
allowing research groups or companies to adopt their own approach to setting 
DFFHSWDEOHDFFXUDF\DQGSUHFLVLRQOHYHOVGRHVQ¶WRIIHUXQLYHUVDOVWDQGDUGL]DWLRQZLWK
regard to microarray quantification and validation. Ideally a quantitative microarray 
approach should have the parameters for accuracy as close to 100% as possible and 
the level of precision as low as possible. In this investigation we adopted an approach 
whereby the level of accuracy cumulatively of all 16 biomarkers to be between 80-
120% as in line with FDA regulations and tried to make sure that the level of 
precision was below 20%. However the problem that was identified and has to be 
accepted as a limitation in this study is, at the very lowest concentrations (below 
1pg/ml) for many cytokines there were higher than acceptable variations that occur in 
some sera. However to compensate for this lack of accuracy the lower limits of 
quantification were established. This enabled the study to reject and remove values 
which even though were quantified were actually below or above the accepted level of 
accuracy and precision for the assay. Hence the overall effect is to improve the 
microarray platform.  
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The two main objectives in this PhD were to firstly to develop an antibody microarray 
technology that would enable cytokines to be quantified in sera. This involved the 
optimisation and validation of the microarray technology. The second objective was to 
quantify biomarkers in serum samples from both COPD patients and healthy controls. 
The ultimate aim of this thesis was thus to use the microarray platform developed to 
produce a biomarker profile that can be used for diagnostic purposes. 
This study has shown that compared to traditionally sandwich ELISA, the microarray 
system that has been developed can be used to identify potential biomarkers that have 
been implicated in the pathogenesis of COPD. In addition clinical variables such as 
smoking history, age and FEV-1% predicted were compared to see if there were 
correlations between these parameters.  
The main aim of the COPD chapter (chapter 5) was to use to the microarray system to 
have sera quantify biomarkers for a selection of age-matched individuals that were 
either diagnosed as having COPD, were healthy smoking controls or non-smoking 
healthy controls. Within both the COPD and healthy smoking cohorts were current 
and ex-smokers. The results of this study showed that whilst certain inflammatory 
cytokines were not significantly more up-regulated in the COPD cohort compared to 
both the other two control cohorts. Only eotaxin-2 and MCP-1 showed significant 
differences between the three groups suggesting these were possibly key biomarkers 
in the disease. However one of the problems with multiple Kruskal-Wallis testing 
allows for potentially false positive results to be generated. When this was tested 
using the SAM method via J-Express Pro, this showed that only eotaxin-2 was only 
true result (FDR and q-value=0) and MCP-1 gave a false-positive result (FDR and q-
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value 7KLV WKHUHIRUH PHDQW WKDW WKH VLJQLILFDQW 0&3-1 result between the 3 
subgroups investigated was invalid.  
Interestingly it was observed that at GOLD stage 4 of the study there was a significant 
drop in the expression of 15 of the 16 biomarkers investigated. This suggested that at 
this stage of COPD, the immune system may potentially be immunosuppressed. It has 
to be acknowledged that with just three patients in GOLD stage 4 it would be difficult 
to make definitive assumptions about why these cytokines are decreased compared to 
the previous stages. Additionally it has to be acknowledged and discussed that the 
medication that the COPD patients were on were not available prior to analysis. It has 
to be taken into account that patients at GOLD stages 3 and 4 could be likely to be on 
a high dose of inhaled corticosteroids, which are immunosuppressive which would 
lead to drop in the 15 cytokines observed. However without the information available, 
this cannot be definitive to make such conclusions.  
Overall the data generated from this study were largely negative with the exception of 
eotaxin-2, which therefore unlikely to be much use for research and diagnosis of 
COPD. It therefore is worth considering whether serum itself may not be the best 
biological fluid that can be used when investigating COPD as much of pathogenesis 
of the disease occurs within the lungs and therefore using BAL fluid or induced 
sputum instead may become more beneficial. 
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6.2: Future Work 
There are a number of areas where the microarray work could be taken in the future. 
One of the problems that were encountered was the potential for antibodies in the 
duosets to lose sensitivity over time, reflected in the strength of the standard curve 
signal diminishing over time. Specifically this affects the bottom end of the standard 
curve meaning that much needed sensitivity to measure low abundant cytokines is no 
longer available, reducing the efficiency of the microarray platform. 
This problem was overcome in this study as most of the optimisation and validation 
were completed with a batch of cytokines kits purchased at the start of the 
investigation. A new set of kits were then purchased in during the last steps of the 
investigation and for running the COPD samples. In most laboratories the purchasing 
of multiple kits is often unattainable. Hence improving the shelf life of cytokine kits 
have to be addressed in order to prevent loss of signal over time. This issue was 
partially addressed when the second batch of cytokine kits were purchased. All 16 
cytokine kits were split in capture, detection and protein standard and almost all the 
contents were aliquoted into smaller storage tubes that can be frozen until use. 
However another problem that arose from the storing of the samples in the freezer 
came through the problem of multiple freeze-thaw cycles. If this occurs over at least 
four to five times, the signal strength starts to decrease over time suggesting that the 
antibody is suffering damage to its structure through multiple changes in temperature. 
To possibly address this problem it may be worth adding a cryopersative agent, such 
as trehalose, to the neat concentrations of antibodies that may prevent the issue of loss 
of signal over time or avoiding freeze-thawing if possible. One of the biggest 
strengths of the microarray is also one of its biggest weaknesses in that so little 
reagent is used, there needs to be a better way of storing antibodies and reagents that 
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can be used over many months. These kits are purchased to run approximately 20 
ELISAs per kit. As the microarrays in this investigation use only a fraction of these 
reagents during any one slide the requirement is to make a kit last over the 
recommended storage shelf life.  Hence cryopersative like trehalose will prevent the 
antibody from actually freezing and could thus extend the shelf life. If further time 
was available it would have been interesting to run a series of tests that could have 
shown whether this would work.  
Whilst the sandwich microarray platform established here was highly successful in 
being able to quantify cytokines in sera to a high level of accuracy and precision, the 
procedure lasts up to 5 hours including analysis. Additionally depending on the 
number of samples and cytokines test the analysis could take longer. Moving forward 
it is important that if this microarray technology is to be introduced to a greater 
clinical audience that a centralised computer programme may have to be developed to 
analyse the data much quicker. 
It may also be worth considering whether there could be a quicker qualitative 
approach whereby the strength of the signal of a spot could indicate whether someone 
has a low or high level of cytokine in blood. This would employ a type of reverse 
phase microarray system whereby sera would be directly printed on the slide surface 
instead of the capture antibody and directly detected using biotinylated secondary 
antibody that could be developed by fluorescence. Initial work had begun on this 
concept which showed that the printing of sera on poly-L-lysine slides were 
unsuitable and the addition of streptavidin cy5 was insufficient in developing a 
consistent signal. It was then shown that nitrocellulose slides allow the absorption of 
sera better to the surface than poly-L-lysine. Serum prints poorly on poly-L-lysine 
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slides, however on nitrocellulose there were indication that the spot morphology and 
consistency of spotting was better. Streptavidin infra-red was used instead of 
streptavidin cy5 which showed an improved level of sensitivity especially with the 
nitrocellulose slide compared with cy5 which leads to many background problems. 
The objective of running this reverse phase approach allows the whole process to be 
completed within 3 hrs once the sera have been printed on the slide. One can directly 
print sera from healthy individuals next to COPD or disease type individuals which 
would make it easier to see differences between both cohorts.  
Additionally, for the quantification of cytokines developed here, a 16 pad slide was 
used. For the reverse phase sera assay there is potential to use more pads on a slide 
which would allow for more detection antibodies to be tested. Whilst it is important to 
be able to quantify proteins in biological samples it is just as important to be able to 
pick out differences between different disease cohorts as soon as possible and this 
potential reverse phase sera microarray could potentially become a more faster 
approach to help diagnose multiple samples with further optimisation and validation.  
Whilst the use of this microarray platform has been useful in distinguishing between 
COPD, healthy smoking and non-smoking healthy cohorts in sera it would have been 
more informative if more biological samples could have been investigated. Other 
biological samples such as urine, bronchoalveolar lavage (BAL), plasma and cerebral 
spinal fluid were also tested on this microarray platform. One of the problems noticed 
with plasma compared to sera was that there was a higher level of background in 
plasma that could be reduced by using a different blocking buffer. However in BAL 
fluid, due to the scarcity of low abundant proteins, it made it slightly more difficult to 
quantify these 16 biomarkers. However it was noticed that compared to both plasma 
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and sera, BAL fluid produced some of the best background levels and subsequently 
these samples have been tried on a parallel project using this microarray technology. 
In the context of this project it would have been interesting if there were 
complimentary BAL, sputum or plasma samples that would have been available to the 
sera samples that were obtained in this study. As the sera are from the circulation in 
those with COPD, it does not reveal completely the mechanisms of change that are 
occurring at the sites of inflammation. For example a combination of BAL samples 
and lung biopsies would help provide a more in depth study of the pathogenesis of 
COPD. 
Furthermore, in this study, only three variables (age, sex and FEV-1%) were available 
as a tool for analysis. In previous COPD studies other variables such as BMI, BODE 
scale and smoking pack year history have also been used for additional purposes. For 
example with the availability of the smoking pack year history or the BODE scale, 
correlations could have been performed with the cytokine data to see if there a trend, 
in particular with MCP-1 and eotaxin-2 which were the most prominent of all the 16 
biomarkers.  
Additionally as mentioned in the previous chapters, the microarray study chooses to 
investigate 16 cytokines which were considered to be important in the pathogenesis of 
COPD. However as mentioned previously, this microarray platform is not just 
restricted to these 16 cytokines and if the resources were available there is the 
potential to look further and include many more cytokines. Cytokines not included in 
this study that have been included in Table 2 (Chapter 1) could be incorporated in any 
future work. Additionally over time one would expect novel cytokines to be 
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implicated in COPD and it is important that more, less common cytokines are 
investigated in this disease setting.  
Finally one of the biggest limitations of this microarray platform that needs to be 
addressed is the ability to measure high abundance cytokines with low abundant 
cytokines. When high abundance cytokines were incorporated with small cytokines, a 
dilution of the samples resulted in small abundant cytokines being diluted too much 
making them unquantifiable. Realistically it would be impossible to be able to 
quantify a high abundance cytokine such as CRP with a low abundant cytokine IL-
beta. Indeed this is the case in many leading microarray commercial companies which 
often try to limit their dynamic range where very large abundant cytokines are run on 
a different microarray platform to low abundant cytokines. The dynamic range for the 
16 biomarkers in this thesis is between 0-2000pg/ml. The potential may be to push 
this dynamic range up to 10,000pg/ml which would enable more cytokines that can be 
investigated. This would require further optimisation and validation.  
This microarray technology could have multiple implications in both research and 
management of those with COPD. At present there is no specific medication that is 
offered to those with COPD. In future the microarray technology could be used in a 
hospital setting where physicians could use the technology to monitor a drug 
treatment plan over a period of time. 
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6.3 Concluding Remarks 
In conclusion, this thesis has shown that an in-house antibody microarray system has 
been optimised and validated testing many parameters that allows for accurate and 
precise detection of up to 16 biomarkers thought to be involved in COPD. The 
investigation using the microarray technology on the COPD samples have shown that 
eotaxin-2 could potentially be an important biomarker of COPD in sera. They may 
work through the recruitment of immune effector cells into the lungs that secrete 
further cytokines and contribute to the inflammatory cascade that occurs in disease. 
Further future optimisation and validation would allow for more biomarkers to be 
tested on this antibody microarray that would allow this platform to be a useful 
diagnostic tool. This would enable this microarray system to be used in any disease 
setting.  
 
Bibliography 
 
~ 241 ~ 
 
Bibliography 
 
1. Mannino, D.M., Chronic obstructive pulmonary disease: definition and 
epidemiology. Respir Care, 2003. 48(12): p. 1185-91; discussion 1191-3. 
2. Mannino, D.M. and S. Braman, The epidemiology and economics of chronic 
obstructive pulmonary disease. Proc Am Thorac Soc, 2007. 4(7): p. 502-6. 
3. Barnes, P.J., Chronic obstructive pulmonary disease: a growing but neglected 
global epidemic. PLoS Med, 2007. 4(5): p. e112. 
4. Barnes, P.J., Mediators of chronic obstructive pulmonary disease. Pharmacol 
Rev, 2004. 56(4): p. 515-48. 
5. Cosio Piqueras, M.G. and M.G. Cosio, Disease of the airways in chronic 
obstructive pulmonary disease. Eur Respir J Suppl, 2001. 34: p. 41s-49s. 
6. Mannino, D.M. and A.S. Buist, Global burden of COPD: risk factors, 
prevalence, and future trends. Lancet, 2007. 370(9589): p. 765-73. 
7. Chapman, K.R., et al., Epidemiology and costs of chronic obstructive 
pulmonary disease. Eur Respir J, 2006. 27(1): p. 188-207. 
8. Jones, P.W., et al., Health-related quality of life in patients by COPD severity 
within primary care in Europe. Respir Med, 2011. 105(1): p. 57-66. 
9. Agusti, A.G., et al., Systemic effects of chronic obstructive pulmonary disease. 
Eur Respir J, 2003. 21(2): p. 347-60. 
10. Agusti, A., Systemic effects of chronic obstructive pulmonary disease: what 
we know and what we don't know (but should). Proc Am Thorac Soc, 2007. 
4(7): p. 522-5. 
11. Bourdin, A., et al., Recent advances in COPD: pathophysiology, respiratory 
physiology and clinical aspects, including comorbidities. Eur Respir Rev, 
2009. 18(114): p. 198-212. 
12. Rodriguez-Roisin, R., The airway pathophysiology of COPD: implications for 
treatment. COPD, 2005. 2(2): p. 253-62. 
13. Arne, M., et al., How often is diagnosis of COPD confirmed with spirometry? 
Respir Med, 2010. 104(4): p. 550-6. 
14. Joo, M.J., T.A. Lee, and K.B. Weiss, Geographic variation of spirometry use 
in newly diagnosed COPD. Chest, 2008. 134(1): p. 38-45. 
15. Poels, P.J., T.R. Schermer, and C. van Weel, Underuse of spirometry in the 
diagnosis of COPD. Monaldi Arch Chest Dis, 2005. 63(4): p. 234; author 
reply 234-5. 
16. Gorska, K., et al., Comparison of cellular and biochemical markers of airway 
inflammation in patients with mild-to-moderate asthma and chronic 
obstructive pulmonary disease: an induced sputum and bronchoalveolar 
lavage fluid study. J Physiol Pharmacol, 2008. 59 Suppl 6: p. 271-83. 
17. Gorska, K., et al., Eosinophilic airway inflammation in chronic obstructive 
pulmonary disease and asthma. J Physiol Pharmacol, 2008. 59 Suppl 6: p. 
261-70. 
18. Guerra, S., Asthma and chronic obstructive pulmonary disease. Curr Opin 
Allergy Clin Immunol, 2009. 9(5): p. 409-16. 
19. Wood, A.M. and R.A. Stockley, The genetics of chronic obstructive 
pulmonary disease. Respir Res, 2006. 7: p. 130. 
20. Briggs, D.D., Jr., Chronic obstructive pulmonary disease overview: 
prevalence, pathogenesis, and treatment. J Manag Care Pharm, 2004. 10(4 
Suppl): p. S3-10. 
Bibliography 
 
~ 242 ~ 
 
21. Shapiro, S.D. and E.P. Ingenito, The pathogenesis of chronic obstructive 
pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol 
Biol, 2005. 32(5): p. 367-72. 
22. Miller, A., et al., Dual-energy X-ray absorptiometry is the method of choice to 
assess body composition in COPD. Respirology, 2009. 14(3): p. 411-8. 
23. Dewan, N.A., COPD exacerbations: to X-ray or not to X-ray. Chest, 2002. 
122(4): p. 1118-21. 
24. Waatevik, M., et al., Different COPD disease characteristics are related to 
different outcomes in the 6-minute walk test. COPD, 2012. 9(3): p. 227-34. 
25. Brown, C.D. and R.A. Wise, Field tests of exercise in COPD: the six-minute 
walk test and the shuttle walk test. COPD, 2007. 4(3): p. 217-23. 
26. Chiba, H. and S. Abe, [The environmental risk factors for COPD--tobacco 
smoke, air pollution, chemicals]. Nihon Rinsho, 2003. 61(12): p. 2101-6. 
27. Criner, G.J. and B.R. Celli, Advanced COPD: pathogenesis, evaluation, and 
treatment. Semin Respir Crit Care Med, 2010. 31(3): p. 255. 
28. Alifano, M., et al., Treatment of COPD: from pharmacological to 
instrumental therapies. Eur Respir Rev, 2010. 19(115): p. 7-23. 
29. Usmani, O.S., Unravelling the small airways: structure-function-treatment 
relationships in asthma and COPD. Respiration, 2012. 84(1): p. 1-3. 
30. Hoshino, T., R. Toda, and H. Aizawa, Pharmacological treatment in asthma 
and COPD. Allergol Int, 2009. 58(3): p. 341-6. 
31. Berger, W.E. and D.C. Cline, Asthma and COPD: definitions, epidemiology, 
and treatment guidelines. Postgrad Med, 2005. 118(6 Suppl Acute): p. 2-8. 
32. Telenga, E.D., et al., Inhaled corticosteroids in chronic obstructive pulmonary 
disease: a review. Expert Opin Pharmacother. 11(3): p. 405-21. 
33. Cosio, B.G., et al., Theophylline restores histone deacetylase activity and 
steroid responses in COPD macrophages. J Exp Med, 2004. 200(5): p. 689-
95. 
34. Barnes, P.J., Theophylline for COPD. Thorax, 2006. 61(9): p. 742-4. 
35. Schweiger, T.A. and M. Zdanowicz, Systemic corticosteroids in the treatment 
of acute exacerbations of chronic obstructive pulmonary disease. Am J Health 
Syst Pharm. 67(13): p. 1061-9. 
36. Gan, W.Q., S.F. Man, and D.D. Sin, Effects of inhaled corticosteroids on 
sputum cell counts in stable chronic obstructive pulmonary disease: a 
systematic review and a meta-analysis. BMC Pulm Med, 2005. 5: p. 3. 
37. Fens, N., et al., Exhaled breath profiling enables discrimination of chronic 
obstructive pulmonary disease and asthma. Am J Respir Crit Care Med, 2009. 
180(11): p. 1076-82. 
38. Barnes, P.J., ABC of chronic obstructive pulmonary disease. Future 
treatments. BMJ, 2006. 333(7561): p. 246-8. 
39. Bergren, D.R., Environmental tobacco smoke exposure and airway 
hyperresponsiveness. Inflamm Allergy Drug Targets, 2009. 8(5): p. 340-7. 
40. Gompertz, S., et al., Relationship between airway inflammation and the 
frequency of exacerbations in patients with smoking related COPD. Thorax, 
2001. 56(1): p. 36-41. 
41. Martin, P., H. Glasgow, and J. Patterson, Chronic obstructive pulmonary 
disease (COPD): smoking remains the most important cause. N Z Med J, 
2005. 118(1213): p. U1409. 
42. Kaminsky, D.A. and T.W. Marcy, COPD and smoking cessation motivation. 
Chest, 2004. 125(5): p. 1958; author reply 1958-9. 
43. Zaher, C., et al., Smoking-related diseases: the importance of COPD. Int J 
Tuberc Lung Dis, 2004. 8(12): p. 1423-8. 
Bibliography 
 
~ 243 ~ 
 
44. Churg, A., M. Cosio, and J.L. Wright, Mechanisms of cigarette smoke-
induced COPD: insights from animal models. Am J Physiol Lung Cell Mol 
Physiol, 2008. 294(4): p. L612-31. 
45. Kent, L., et al., Cigarette smoke extract induced cytokine and chemokine gene 
expression changes in COPD macrophages. Cytokine, 2008. 42(2): p. 205-16. 
46. Suzuki, M., et al., Decreased airway expression of vascular endothelial 
growth factor in cigarette smoke-induced emphysema in mice and COPD 
patients. Inhal Toxicol, 2008. 20(3): p. 349-59. 
47. Loukides, S., P. Bakakos, and K. Kostikas, Oxidative stress in patients with 
COPD. Curr Drug Targets, 2011. 12(4): p. 469-77. 
48. Joppa, P., et al., Oxidative stress in patients with COPD and pulmonary 
hypertension. Wien Klin Wochenschr, 2007. 119(13-14): p. 428-34. 
49. Kinnula, V.L. and M. Myllarniemi, Oxidant-antioxidant imbalance as a 
potential contributor to the progression of human pulmonary fibrosis. 
Antioxid Redox Signal, 2008. 10(4): p. 727-38. 
50. Kinnula, V.L. and J.D. Crapo, Smoking and COPD-mechanisms and 
prevention. COPD, 2009. 6(4): p. 231-3. 
51. Tantucci, C. and D. Modina, Lung function decline in COPD. Int J Chron 
Obstruct Pulmon Dis, 2012. 7: p. 95-9. 
52. Barnes, P.J., Histone deacetylase-2 and airway disease. Ther Adv Respir Dis, 
2009. 3(5): p. 235-43. 
53. Cavalcante, A.G. and P.F. de Bruin, The role of oxidative stress in COPD: 
current concepts and perspectives. J Bras Pneumol, 2009. 35(12): p. 1227-37. 
54. Bhowmik, A., Histone deacetylase activity and COPD. N Engl J Med, 2005. 
353(5): p. 528-9; author reply 528-9. 
55. Barnes, P.J., Reduced histone deacetylase in COPD: clinical implications. 
Chest, 2006. 129(1): p. 151-5. 
56. St-Laurent, J., et al., Influence of smoking on airway inflammation and 
remodelling in asthma. Clin Exp Allergy, 2008. 38(10): p. 1582-9. 
57. Chung, K.F., The role of airway smooth muscle in the pathogenesis of airway 
wall remodeling in chronic obstructive pulmonary disease. Proc Am Thorac 
Soc, 2005. 2(4): p. 347-54; discussion 371-2. 
58. Chung, K.F., Inflammatory mediators in chronic obstructive pulmonary 
disease. Curr Drug Targets Inflamm Allergy, 2005. 4(6): p. 619-25. 
59. Menezes, A.M. and P.C. Hallal, Role of passive smoking on COPD risk in 
non-smokers. Lancet, 2007. 370(9589): p. 716-7. 
60. Van Overveld, F.J., et al., Differences in responses upon corticosteroid 
therapy between smoking and non-smoking patients with COPD. J Physiol 
Pharmacol, 2006. 57 Suppl 4: p. 273-82. 
61. Camp, P.G., D.E. O'Donnell, and D.S. Postma, Chronic obstructive 
pulmonary disease in men and women: myths and reality. Proc Am Thorac 
Soc, 2009. 6(6): p. 535-8. 
62. Sertogullarindan, B., et al., Frequency of pulmonary hypertension in patients 
with COPD due to biomass smoke and tobacco smoke. Int J Med Sci, 2012. 
9(6): p. 406-12. 
63. Salvi, S. and P.J. Barnes, Is exposure to biomass smoke the biggest risk factor 
for COPD globally? Chest, 2010. 138(1): p. 3-6. 
64. Ekici, A., et al., Obstructive airway diseases in women exposed to biomass 
smoke. Environ Res, 2005. 99(1): p. 93-8. 
65. Fullerton, D.G., N. Bruce, and S.B. Gordon, Indoor air pollution from 
biomass fuel smoke is a major health concern in the developing world. Trans 
R Soc Trop Med Hyg, 2008. 102(9): p. 843-51. 
Bibliography 
 
~ 244 ~ 
 
66. Po, J., Respiratory disease associated with solid biomass fuel exposure in 
rural women and children ; a systemic review and meta-analysis. Am J Respir 
Crit Care Med, 2009. 179(A4740). 
67. Regalado, J., et al., The effect of biomass burning on respiratory symptoms 
and lung function in rural Mexican women. Am J Respir Crit Care Med, 
2006. 174(8): p. 901-5. 
68. Moran-Mendoza, O., et al., Wood smoke-associated lung disease: a clinical, 
functional, radiological and pathological description. Int J Tuberc Lung Dis, 
2008. 12(9): p. 1092-8. 
69. Blanc, P.D. and K. Toren, Occupation in chronic obstructive pulmonary 
disease and chronic bronchitis: an update. Int J Tuberc Lung Dis, 2007. 
11(3): p. 251-7. 
70. Rodriguez, E., et al., Impact of occupational exposure on severity of COPD. 
Chest, 2008. 134(6): p. 1237-43. 
71. Blanc, P.D., et al., Occupational exposures and the risk of COPD: dusty 
trades revisited. Thorax, 2009. 64(1): p. 6-12. 
72. Boschetto, P., et al., Chronic obstructive pulmonary disease (COPD) and 
occupational exposures. J Occup Med Toxicol, 2006. 1: p. 11. 
73. Ramirez-Venegas, A., et al., Survival of patients with chronic obstructive 
pulmonary disease due to biomass smoke and tobacco. Am J Respir Crit Care 
Med, 2006. 173(4): p. 393-7. 
74. Zhou, Y., et al., COPD in Chinese nonsmokers. Eur Respir J, 2009. 33(3): p. 
509-18. 
75. Steinkamp, G., [COPD, the systemic disease: nutrition - an underestimated 
and unresolved problem]. Pneumologie, 2003. 57(11): p. 681-9. 
76. Wouters, E.F., et al., Systemic and local inflammation in asthma and chronic 
obstructive pulmonary disease: is there a connection? Proc Am Thorac Soc, 
2009. 6(8): p. 638-47. 
77. Jeffery, P.K., Remodeling and inflammation of bronchi in asthma and chronic 
obstructive pulmonary disease. Proc Am Thorac Soc, 2004. 1(3): p. 176-83. 
78. Borger, P., et al., Beyond the Immune System: The Role of Resident Cells in 
Asthma and COPD. J Allergy (Cairo), 2012. 2012: p. 968039. 
79. Maeno, T., [The role of CD8+ T cells in the pathogenesis of COPD]. Nihon 
Kokyuki Gakkai Zasshi, 2008. 46(3): p. 268-9. 
80. Morissette, M.C., J. Parent, and J. Milot, Perforin, granzyme B, and FasL 
expression by peripheral blood T lymphocytes in emphysema. Respir Res, 
2007. 8: p. 62. 
81. Paats, M.S., et al., Systemic CD4+ and CD8+ T-cell cytokine profiles 
correlate with GOLD stage in stable COPD. Eur Respir J, 2012. 40(2): p. 
330-7. 
82. Tetley, T.D., Macrophages and the pathogenesis of COPD. Chest, 2002. 
121(5 Suppl): p. 156S-159S. 
83. Barnes, P.J., Alveolar macrophages in chronic obstructive pulmonary disease 
(COPD). Cell Mol Biol (Noisy-le-grand), 2004. 50 Online Pub: p. OL627-
37. 
84. Olesiejuk, R., K. Danielak-Rybka, and B. Wojnarowicz-Dmitruk, 
[Emphysema connected with Alpha-1 anti-trypsin deficiency]. Pneumonol 
Alergol Pol, 2003. 71(7-8): p. 344-8. 
85. Miravitlles, M., Alpha1-anti-trypsin deficiency: epidemiology and incidence. 
Respir Med, 2002. 96(3): p. 205. 
86. Jeffery, P.K., Remodeling in asthma and chronic obstructive lung disease. 
Am J Respir Crit Care Med, 2001. 164(10 Pt 2): p. S28-38. 
Bibliography 
 
~ 245 ~ 
 
87. Ilumets, H., et al., Transient elevation of neutrophil proteinases in induced 
sputum during COPD exacerbation. Scand J Clin Lab Invest, 2008. 68(7): p. 
618-23. 
88. Demedts, I.K., et al., Role of apoptosis in the pathogenesis of COPD and 
pulmonary emphysema. Respir Res, 2006. 7: p. 53. 
89. Urbanowicz, R.A., et al., Altered effector function of peripheral cytotoxic 
cells in COPD. Respir Res, 2009. 10: p. 53. 
90. Tosiek, M.J., et al., CD4+CD25+Foxp3+ regulatory T cells are dispensable 
for controlling CD8+ T cell-mediated lung inflammation. J Immunol, 2011. 
186(11): p. 6106-18. 
91. Saetta, M., et al., Increased proportion of CD8+ T-lymphocytes in the 
paratracheal lymph nodes of smokers with mild COPD. Sarcoidosis Vasc 
Diffuse Lung Dis, 2003. 20(1): p. 28-32. 
92. Huang, H., et al., CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory 
response, tumor localization and therapy by targeted delivery of interleukin 2 
via acquired pMHC I complexes. Immunology, 2007. 120(2): p. 148-59. 
93. Lim, S.C., et al., Apoptosis of T lymphocytes isolated from peripheral blood of 
patients with acute exacerbation of chronic obstructive pulmonary disease. 
Yonsei Medical Journal, 2011. 52(4): p. 581-7. 
94. Rufino, R., et al., Quantitative assessment of elastic fibers in chronic 
obstructive pulmonary disease. J Bras Pneumol, 2007. 33(5): p. 502-9. 
95. Urbanowicz, R.A., et al., Enhanced effector function of cytotoxic cells in the 
induced sputum of COPD patients. Respir Res, 2010. 11: p. 76. 
96. Gupta, J., et al., T lymphocyte subset profile and serum alpha-1-antitrypsin in 
pathogenesis of chronic obstructive pulmonary disease. Clin Exp Immunol, 
2007. 149(3): p. 463-9. 
97. Plumb, J., et al., Increased T-regulatory cells within lymphocyte follicles in 
moderate COPD. Eur Respir J, 2009. 34(1): p. 89-94. 
98. Barcelo, B., et al., Phenotypic characterisation of T-lymphocytes in COPD: 
abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco 
smoking. Eur Respir J, 2008. 31(3): p. 555-62. 
99. Smyth, L.J., et al., CD4-regulatory cells in COPD patients. Chest, 2007. 
132(1): p. 156-63. 
100. Demoor, T., et al., Increased T-regulatory cells in lungs and draining lymph 
nodes in a murine model of COPD. Eur Respir J, 2010. 35(3): p. 688-9. 
101. Castellani, M.L., et al., IL-35, an anti-inflammatory cytokine which expands 
CD4+CD25+ Treg Cells. J Biol Regul Homeost Agents, 2010. 24(2): p. 131-
5. 
102. Qiu, S.L., et al., [CD(4)(+)Foxp3(+) regulatory T cells in inflammation and 
emphysema after smoking cessation in rats]. Zhonghua Jie He He Hu Xi Za 
Zhi, 2010. 33(9): p. 688-92. 
103. Roos-Engstrand, E., et al., Expansion of CD4+CD25+ helper T cells without 
regulatory function in smoking and COPD. Respir Res, 2011. 12: p. 74. 
104. Chen, K., et al., IL-17RA is required for CCL2 expression, macrophage 
recruitment, and emphysema in response to cigarette smoke. PLoS One, 2011. 
6(5): p. e20333. 
105. Alcorn, J.F., C.R. Crowe, and J.K. Kolls, TH17 cells in asthma and COPD. 
Annu Rev Physiol, 2010. 72: p. 495-516. 
106. Hong, S.C. and S.H. Lee, Role of th17 cell and autoimmunity in chronic 
obstructive pulmonary disease. Immune Netw, 2010. 10(4): p. 109-14. 
Bibliography 
 
~ 246 ~ 
 
107. Zhang, X., et al., Increased interleukin (IL)-8 and decreased IL-17 production 
in chronic obstructive pulmonary disease (COPD) provoked by cigarette 
smoke. Cytokine, 2011. 56(3): p. 717-25. 
108. Pridgeon, C., et al., Regulation of IL-17 in chronic inflammation in the human 
lung. Clin Sci (Lond), 2011. 120(12): p. 515-24. 
109. Ling Ye, X.W., Meiling Jin, Role of Airway Epithelial Cells in Development 
of Chronic Obstructive Pulmonary Disease. Journal of Epithelial Biology and 
Pharmacology, 2009. 2: p. 44-50. 
110. Reynolds, P.R., M.G. Cosio, and J.R. Hoidal, Cigarette smoke-induced Egr-1 
upregulates proinflammatory cytokines in pulmonary epithelial cells. Am J 
Respir Cell Mol Biol, 2006. 35(3): p. 314-9. 
111. Wang, I.J., C.Y. Wu, and F.R. Hu, Effect of proinflammatory cytokines on the 
human MUC5AC promoter activity in vitro and in vivo. Clin Ophthalmol, 
2007. 1(1): p. 71-7. 
112. McManus, T.E., et al., Acute and latent adenovirus in COPD. Respir Med, 
2007. 101(10): p. 2084-90. 
113. Gandhi, A., et al., Factors associated with symptomatic rhinovirus infection in 
patients with COPD. J Clin Virol, 2012. 
114. Glader, P., et al., Cigarette smoke extract modulates respiratory defence 
mechanisms through effects on T-cells and airway epithelial cells. Respir 
Med, 2006. 100(5): p. 818-27. 
115. Comer, D.M., et al., Airway epithelial cell apoptosis and inflammation in 
COPD, smokers and nonsmokers. Eur Respir J, 2013. 41(5): p. 1058-67. 
116. Puchelle, E., et al., Airway epithelial repair, regeneration, and remodeling 
after injury in chronic obstructive pulmonary disease. Proc Am Thorac Soc, 
2006. 3(8): p. 726-33. 
117. Li, W., Y. Xu, and Z. Zhang, Activity of matrix metalloproteinase in airway 
epithelial cells of COPD patients. J Huazhong Univ Sci Technolog Med Sci, 
2005. 25(2): p. 151-4. 
118. Sethi, S., et al., Airway bacterial concentrations and exacerbations of chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med, 2007. 176(4): p. 
356-61. 
119. Working, G., Biomarkers Definitions Working G. Biomarkers and surrogate 
endpoints: preferred definitions and conceptual framework. Clinical 
pharmacology and therapeutics. 2001. 69(3): p. 89-95. 
120. Sin, D.D. and J. Vestbo, Biomarkers in chronic obstructive pulmonary 
disease. Proc Am Thorac Soc, 2009. 6(6): p. 543-5. 
121. Rosenberg, S.R. and R. Kalhan, Biomarkers in chronic obstructive pulmonary 
disease. Transl Res, 2012. 159(4): p. 228-37. 
122. Martinez, F.J., et al., Sex differences in severe pulmonary emphysema. Am J 
Respir Crit Care Med, 2007. 176(3): p. 243-52. 
123. Nicholas, B.L., C.D. O'Connor, and R. Djukanovic, From proteomics to 
prescription-the search for COPD biomarkers. COPD, 2009. 6(4): p. 298-
303. 
124. Taylor, D.R. and I.D. Pavord, Biomarkers in the assessment and management 
of airways diseases. Postgrad Med J, 2008. 84(998): p. 628-34; quiz 633. 
125. Frangogiannis, N.G., Biomarkers: hopes and challenges in the path from 
discovery to clinical practice. Transl Res, 2012. 159(4): p. 197-204. 
126. Urbanowska, T., et al., Protein microarray platform for the multiplex analysis 
of biomarkers in human sera. J Immunol Methods, 2006. 316(1-2): p. 1-7. 
Bibliography 
 
~ 247 ~ 
 
127. Higashimoto, Y., et al., Serum biomarkers as predictors of lung function 
decline in chronic obstructive pulmonary disease. Respir Med, 2009. 103(8): 
p. 1231-8. 
128. Richens, J.L., et al., Systems biology coupled with label-free high-throughput 
detection as a novel approach for diagnosis of chronic obstructive pulmonary 
disease. Respir Res, 2009. 10: p. 29. 
129. Pinto-Plata, V., et al., Profiling serum biomarkers in patients with COPD: 
associations with clinical parameters. Thorax, 2007. 62(7): p. 595-601. 
130. Vestbo, J., et al., Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate End-points (ECLIPSE). Eur Respir J, 2008. 31(4): p. 869-73. 
131. Agusti, A., et al., Characterisation of COPD heterogeneity in the ECLIPSE 
cohort. Respir Res, 2010. 11: p. 122. 
132. Garcia-Rio, F., et al., Systemic inflammation in chronic obstructive pulmonary 
disease: a population-based study. Respir Res, 2010. 11: p. 63. 
133. Ropcke, S., et al., Repeatability of and relationship between potential COPD 
biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and 
induced sputum. PLoS One, 2012. 7(10): p. e46207. 
134. Pinto-Plata, V., et al., Inflammatory and repair serum biomarker pattern. 
Association to clinical outcomes in COPD. Respir Res, 2012. 13: p. 71. 
135. Di Stefano, A., et al., T helper type 17-related cytokine expression is 
increased in the bronchial mucosa of stable chronic obstructive pulmonary 
disease patients. Clin Exp Immunol, 2009. 157(2): p. 316-24. 
136. Gasse, P., et al., IL-1 and IL-23 mediate early IL-17A production in 
pulmonary inflammation leading to late fibrosis. PLoS One, 2011. 6(8): p. 
e23185. 
137. Liu, S.F., et al., Correlation between serum biomarkers and BODE index in 
patients with stable COPD. Respirology, 2009. 14(7): p. 999-1004. 
138. Sukkar, M.B., et al., Soluble RAGE is deficient in neutrophilic asthma and 
COPD. Eur Respir J, 2012. 39(3): p. 721-9. 
139. Young, R.P., B.A. Hay, and R.J. Hopkins, Does RAGE protect smokers from 
COPD? Eur Respir J, 2011. 38(3): p. 743-4; author reply 744. 
140. Nadigel, J., et al., IL-8 production in response to cigarette smoke is decreased 
in epithelial cells from COPD patients. Pulm Pharmacol Ther, 2013. 
141. Gao, J. and B. Zhan, The effects of Ang-1, IL-8 and TGF-beta1 on the 
pathogenesis of COPD. Mol Med Rep, 2012. 6(5): p. 1155-9. 
142. D'Armiento, J.M., et al., Eosinophil and T cell markers predict functional 
decline in COPD patients. Respir Res, 2009. 10: p. 113. 
143. Fujimoto, K., et al., Airway inflammation during stable and acutely 
exacerbated chronic obstructive pulmonary disease. Eur Respir J, 2005. 
25(4): p. 640-6. 
144. Traves, S.L., et al., Increased levels of the chemokines GROalpha and MCP-1 
in sputum samples from patients with COPD. Thorax, 2002. 57(7): p. 590-5. 
145. Aaron, S.D., et al., Multi analyte profiling and variability of inflammatory 
markers in blood and induced sputum in patients with stable COPD. Respir 
Res, 2010. 11: p. 41. 
146. Quint, J.K., et al., Serum IP-10 as a biomarker of human rhinovirus infection 
at exacerbation of COPD. Chest, 2010. 137(4): p. 812-22. 
147. Quint, J.K. and J.A. Wedzicha, The neutrophil in chronic obstructive 
pulmonary disease. J Allergy Clin Immunol, 2007. 119(5): p. 1065-71. 
148. Lappalainen, U., et al., Interleukin-1beta causes pulmonary inflammation, 
emphysema, and airway remodeling in the adult murine lung. Am J Respir 
Cell Mol Biol, 2005. 32(4): p. 311-8. 
Bibliography 
 
~ 248 ~ 
 
149. Pauwels, N.S., et al., Role of IL-1alpha and the Nlrp3/caspase-1/IL-1beta axis 
in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J, 
2011. 38(5): p. 1019-28. 
150. Rupp, J., et al., Imbalanced secretion of IL-1beta and IL-1RA in Chlamydia 
pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J, 
2003. 22(2): p. 274-9. 
151. Ishii, T., et al., Neither IL-1beta, IL-1 receptor antagonist, nor TNF-alpha 
polymorphisms are associated with susceptibility to COPD. Respir Med, 
2000. 94(9): p. 847-51. 
152. Eagan, T.M., et al., TNF-alpha is associated with loss of lean body mass only 
in already cachectic COPD patients. Respir Res, 2012. 13(1): p. 48. 
153. Deveci, Y., et al., [Serum ghrelin, IL-6 and TNF-alpha levels in patients with 
chronic obstructive pulmonary disease.]. Tuberk Toraks, 2010. 58(2): p. 162-
72. 
154. Daldegan, M.B., M.M. Teixeira, and A. Talvani, Concentration of CCL11, 
CXCL8 and TNF-alpha in sputum and plasma of patients undergoing asthma 
or chronic obstructive pulmonary disease exacerbation. Braz J Med Biol Res, 
2005. 38(9): p. 1359-65. 
155. Basyigit, I., et al., [Body mass index and serum and sputum TNF-alpha levels 
relation in asthma and COPD]. Tuberk Toraks, 2004. 52(3): p. 256-61. 
156. Cordoba-Lanus, E., et al., Association of IL-6 gene polymorphisms and COPD 
in a Spanish population. Respir Med, 2008. 102(12): p. 1805-11. 
157. Grubek-Jaworska, H., et al., IL-6 and IL-13 in induced sputum of COPD and 
asthma patients: correlation with respiratory tests. Respiration, 2012. 84(2): 
p. 101-7. 
158. Vogiatzis, I., et al., Effects of rehabilitative exercise on peripheral muscle 
TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD. Thorax, 
2007. 62(11): p. 950-6. 
159. Hodge, S., et al., Interleukin-4 and tumour necrosis factor-alpha inhibit 
transforming growth factor-beta production in a human bronchial epithelial 
cell line: possible relevance to inflammatory mechanisms in chronic 
obstructive pulmonary disease. Respirology, 2001. 6(3): p. 205-11. 
160. Zhu, J., et al., Plasma cells and IL-4 in chronic bronchitis and chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med, 2007. 175(11): p. 
1125-33. 
161. Imaoka, H., et al., Interleukin-18 production and pulmonary function in 
COPD. Eur Respir J, 2008. 31(2): p. 287-97. 
162. Hardaker, E.L., et al., Regulation of TNF-alpha- and IFN-gamma-induced 
CXCL10 expression: participation of the airway smooth muscle in the 
pulmonary inflammatory response in chronic obstructive pulmonary disease. 
FASEB J, 2004. 18(1): p. 191-3. 
163. Torvinen, M., H. Campwala, and I. Kilty, The role of IFN-gamma in 
regulation of IFN-gamma-inducible protein 10 (IP-10) expression in lung 
epithelial cell and peripheral blood mononuclear cell co-cultures. Respir Res, 
2007. 8: p. 80. 
164. Boutou, A.K., et al., Levels of inflammatory mediators in chronic obstructive 
pulmonary disease patients with anemia of chronic disease: a case-control 
study. QJM, 2012. 105(7): p. 657-63. 
165. Wu, L., et al., Advanced glycation end products and its receptor (RAGE) are 
increased in patients with COPD. Respir Med, 2011. 105(3): p. 329-36. 
Bibliography 
 
~ 249 ~ 
 
166. Wu, Q., et al., IL-23-dependent IL-17 production is essential in neutrophil 
recruitment and activity in mouse lung defense against respiratory 
Mycoplasma pneumoniae infection. Microbes Infect, 2007. 9(1): p. 78-86. 
167. Zhang, L., et al., Expression of Interleukin (IL)-10, IL-17A and IL-22 in 
Serum and Sputum of Stable Chronic Obstructive Pulmonary Disease 
Patients. COPD, 2013. 
168. Demeo, D.L., et al., IL10 polymorphisms are associated with airflow 
obstruction in severe alpha1-antitrypsin deficiency. Am J Respir Cell Mol 
Biol, 2008. 38(1): p. 114-20. 
169. Ceyhan, B.B., F.Y. Enc, and S. Sahin, IL-2 and IL-10 levels in induced 
sputum and serum samples of asthmatics. J Investig Allergol Clin Immunol, 
2004. 14(1): p. 80-5. 
170. Mak, J.C., et al., Elevated plasma TGF-beta1 levels in patients with chronic 
obstructive pulmonary disease. Respir Med, 2009. 103(7): p. 1083-9. 
171. Pavlisa, G., et al., Serum levels of VEGF and bFGF in hypoxic patients with 
exacerbated COPD. Eur Cytokine Netw, 2010. 21(2): p. 92-8. 
172. Chung, K.F., Cytokines in chronic obstructive pulmonary disease. Eur Respir 
J Suppl, 2001. 34: p. 50s-59s. 
173. Tomaki, M., et al., Decreased expression of antioxidant enzymes and 
increased expression of chemokines in COPD lung. Pulm Pharmacol Ther, 
2007. 20(5): p. 596-605. 
174. Seifart, C., et al., TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter 
polymorphisms in patients with chronic obstructive pulmonary disease. 
Tissue Antigens, 2005. 65(1): p. 93-100. 
175. Ferroni, P., et al., Rebuttal to circulating IL-6 levels in chronic obstructive 
pulmonary disease. Thromb Haemost, 2001. 85(2): p. 373. 
176. Hannink, J.D., et al., Non-invasive ventilation abolishes the IL-6 response to 
exercise in muscle-wasted COPD patients: A pilot study. Scand J Med Sci 
Sports, 2012. 
177. Lin, J.C., et al., Mechanism of cigarette smoke-induced kinin B(1) receptor 
expression in rat airways. Peptides, 2010. 31(10): p. 1940-5. 
178. Antoniu, S.A., Challenges in targeting TNF alpha in asthma and COPD. Curr 
Opin Investig Drugs, 2009. 10(5): p. 404-6. 
179. Karadag, F., et al., Biomarkers of systemic inflammation in stable and 
exacerbation phases of COPD. Lung, 2008. 186(6): p. 403-9. 
180. Ogawa, Y., E.A. Duru, and B.T. Ameredes, Role of IL-10 in the resolution of 
airway inflammation. Curr Mol Med, 2008. 8(5): p. 437-45. 
181. Barnes, P.J., The cytokine network in asthma and chronic obstructive 
pulmonary disease. J Clin Invest, 2008. 118(11): p. 3546-56. 
182. Kang, M.J., et al., IL-18 induces emphysema and airway and vascular 
remodeling via IFN-gamma, IL-17A, and IL-13. Am J Respir Crit Care Med, 
2012. 185(11): p. 1205-17. 
183. Kang, M.J., et al., IFN-gamma-dependent DNA injury and/or apoptosis are 
critical in cigarette smoke-induced murine emphysema. Proc Am Thorac Soc, 
2006. 3(6): p. 517-8. 
184. Barczyk, A., et al., Cytokine production by bronchoalveolar lavage T 
lymphocytes in chronic obstructive pulmonary disease. J Allergy Clin 
Immunol, 2006. 117(6): p. 1484-92. 
185. Siva, R., et al., Eosinophilic airway inflammation and exacerbations of 
COPD: a randomised controlled trial. Eur Respir J, 2007. 29(5): p. 906-13. 
186. Saha, S. and C.E. Brightling, Eosinophilic airway inflammation in COPD. Int 
J Chron Obstruct Pulmon Dis, 2006. 1(1): p. 39-47. 
Bibliography 
 
~ 250 ~ 
 
187. Jahnz-Ro yk, K., T. Plusa, and J. Mierzejewska, Eotaxin in serum of patients 
with asthma or chronic obstructive pulmonary disease: relationship with 
eosinophil cationic protein and lung function. Mediators Inflamm, 2000. 9(3-
4): p. 175-9. 
188. Qiu, Y., et al., Biopsy neutrophilia, neutrophil chemokine and receptor gene 
expression in severe exacerbations of chronic obstructive pulmonary disease. 
Am J Respir Crit Care Med, 2003. 168(8): p. 968-75. 
189. Noguera, A., et al., Enhanced neutrophil response in chronic obstructive 
pulmonary disease. Thorax, 2001. 56(6): p. 432-7. 
190. Profita, M., et al., Chronic obstructive pulmonary disease and neutrophil 
infiltration: role of cigarette smoke and cyclooxygenase products. Am J 
Physiol Lung Cell Mol Physiol, 2010. 298(2): p. L261-9. 
191. Hollander, C., et al., Serum and bronchial lavage fluid concentrations of IL-8, 
SLPI, sCD14 and sICAM-1 in patients with COPD and asthma. Respir Med, 
2007. 101(9): p. 1947-53. 
192. Eickmeier, O., et al., Sputum biomarker profiles in cystic fibrosis (CF) and 
chronic obstructive pulmonary disease (COPD) and association between 
pulmonary function. Cytokine, 2010. 50(2): p. 152-7. 
193. Minton, K., T cell signalling: Balancing regulatory and self-reactive T cells. 
Nat Rev Immunol, 2012. 12(10): p. 685. 
194. Bordon, Y., T cell signalling: heavy metal rocks T cells. Nat Rev Immunol, 
2011. 11(5): p. 300-1. 
195. Wilkinson, B., H. Wang, and C.E. Rudd, Positive and negative adaptors in T-
cell signalling. Immunology, 2004. 111(4): p. 368-74. 
196. Greenlee, K.J., Z. Werb, and F. Kheradmand, Matrix metalloproteinases in 
lung: multiple, multifarious, and multifaceted. Physiol Rev, 2007. 87(1): p. 
69-98. 
197. Polosukhin, V.V., et al., Hypoxia-inducible factor-1 signalling promotes 
goblet cell hyperplasia in airway epithelium. J Pathol, 2011. 224(2): p. 203-
11. 
198. Marillier, R.G., et al., IL-4/IL-13 independent goblet cell hyperplasia in 
experimental helminth infections. Bmc Immunology, 2008. 9: p. 11. 
199. Horsnell, W.G., et al., Delayed goblet cell hyperplasia, acetylcholine receptor 
expression, and worm expulsion in SMC-specific IL-4Ralpha-deficient mice. 
PLoS Pathog, 2007. 3(1): p. e1. 
200. Makris, D., Tc2 response at the onset of COPD exacerbations. CHEST, 2008. 
134(3): p. 483-8. 
201. Costa, C., et al., CXCR3 and CCR5 chemokines in induced sputum from 
patients with COPD. Chest, 2008. 133(1): p. 26-33. 
202. Islam, L.N. and P.C. Wilkinson, Chemotactic factor-induced polarization, 
receptor redistribution, and locomotion of human blood monocytes. 
Immunology, 1988. 64(3): p. 501-7. 
203. Konigshoff, M., N. Kneidinger, and O. Eickelberg, TGF-beta signaling in 
COPD: deciphering genetic and cellular susceptibilities for future therapeutic 
regimen. Swiss Med Wkly, 2009. 139(39-40): p. 554-63. 
204. Santibanez, J.F., M. Quintanilla, and C. Bernabeu, TGF-beta/TGF-beta 
receptor system and its role in physiological and pathological conditions. 
Clin Sci (Lond), 2011. 121(6): p. 233-51. 
205. Filippi, C.M., et al., Transforming growth factor-beta suppresses the 
activation of CD8+ T-cells when naive but promotes their survival and 
function once antigen experienced: a two-faced impact on autoimmunity. 
Diabetes, 2008. 57(10): p. 2684-92. 
Bibliography 
 
~ 251 ~ 
 
206. Kubiczkova, L., et al., TGF-beta -- an excellent servant but a bad master. J 
Transl Med, 2012. 10(1): p. 183. 
207. Carlsson, A., et al., Serum proteome profiling of metastatic breast cancer 
using recombinant antibody microarrays. European Journal of Cancer, 2008. 
44(3): p. 472-480. 
208. Yu, X., et al., Protein microarrays: effective tools for the study of 
inflammatory diseases. Methods Mol Biol, 2009. 577: p. 199-214. 
209. Ingvarsson, J., et al., Detection of pancreatic cancer using antibody 
microarray-based serum protein profiling. Proteomics, 2008. 8(11): p. 2211-
9. 
210. Orchekowski, R., et al., Antibody microarray profiling reveals individual and 
combined serum proteins associated with pancreatic cancer. Cancer Res, 
2005. 65(23): p. 11193-202. 
211. Angenendt, P., et al., Toward optimized antibody microarrays: a comparison 
of current microarray support materials. Anal Biochem, 2002. 309(2): p. 
253-60. 
212. Wu, P. and D.W. Grainger, Toward immobilized antibody microarray 
optimization: print buffer and storage condition comparisons on 
performance. Biomedical Sciences Instrumentation, Vol 40, 2004. 449: p. 
243-248. 
213. Lee, C.S. and B.G. Kim, Improvement of protein stability in protein 
microarrays. Biotechnology Letters, 2002. 24(10): p. 839-844. 
214. Seurynck-Servoss, S.L., et al., Evaluation of surface chemistries for antibody 
microarrays. Analytical Biochemistry, 2007. 371(1): p. 105-115. 
215. Sobek, J., C. Aquino, and R. Schlapbach, Quality considerations and 
selection of surface chemistry for glass-based DNA, peptide, antibody, 
carbohydrate, and small molecule microarrays. Methods Mol Biol, 2007. 
382: p. 17-31. 
216. Altman, N., Replication, variation and normalisation in microarray 
experiments. Appl Bioinformatics, 2005. 4(1): p. 33-44. 
217. Hessner, M.J., et al., Immobilized probe and glass surface chemistry as 
variables in microarray fabrication. BMC Genomics, 2004. 5(1): p. 53. 
218. Servoss, S.L., et al., High-throughput analysis of serum antigens using 
sandwich ELISAs on microarrays. Methods Mol Biol, 2009. 520: p. 143-50. 
219. Olle, E.W., et al., Comparison of antibody array substrates and the use of 
glycerol to normalize spot morphology. Exp Mol Pathol, 2005. 79(3): p. 206-
9. 
220. Lee, Y., et al., Micropatterned assembly of silica nanoparticles for a protein 
microarray with enhanced detection sensitivity. Biomed Microdevices, 2010. 
12(3): p. 457-64. 
221. Wingren, C. and C.A. Borrebaeck, Antibody microarray analysis of directly 
labelled complex proteomes. Current Opinion in Biotechnology, 2008. 19(1): 
p. 55-61. 
222. Mo, X.Y., et al., The effects of different sample labelling methods on signal 
intensities of a 60-mer diagnostic microarray. J Virol Methods, 2006. 134(1-
2): p. 36-40. 
223. Haab, B.B., Methods and applications of antibody microarrays in cancer 
research. Proteomics, 2003. 3(11): p. 2116-22. 
224. Espina, V., et al., Protein microarray detection strategies: focus on direct 
detection technologies. J Immunol Methods, 2004. 290(1-2): p. 121-33. 
Bibliography 
 
~ 252 ~ 
 
225. Karsten, S.L., et al., An evaluation of tyramide signal amplification and 
archived fixed and frozen tissue in microarray gene expression analysis. 
Nucleic Acids Res, 2002. 30(2): p. E4. 
226. Bansal, S. and A. DeStefano, Key elements of bioanalytical method validation 
for small molecules. AAPS J, 2007. 9(1): p. E109-14. 
227. Administration, F.a.D., Guidance for Industry: Bioanalytical Method 
Validation. www.fda.gov/downloads/Drugs/.../Guidances/ucm070107.pdf, 
2001. 
228. Smolec, J., et al., Bioanalytical method validation for macromolecules in 
support of pharmacokinetic studies. Pharm Res, 2005. 22(9): p. 1425-31. 
229. James, C.A., M. Breda, and E. Frigerio, Bioanalytical method validation: a 
risk-based approach? J Pharm Biomed Anal, 2004. 35(4): p. 887-93. 
230. Shah, V.P., et al., Bioanalytical method validation--a revisit with a decade of 
progress. Pharm Res, 2000. 17(12): p. 1551-7. 
231. Smith, G., Review of the 2008 European Medicines Agency concept paper on 
bioanalytical method validation. Bioanalysis, 2009. 1(5): p. 877-81. 
232. Jacobson, R.H., Validation of serological assays for diagnosis of infectious 
diseases. Rev Sci Tech, 1998. 17(2): p. 469-526. 
233. Boterman, M., et al., Recommendations on the interpretation of the new 
European Medicines Agency Guideline on Bioanalytical Method Validation 
by Global CRO Council for Bioanalysis (GCC). Bioanalysis, 2012. 4(6): p. 
651-60. 
234. Srinivas, N.R., Bioanalytical assay validation parameters re-visited: 
perspectives on stability studies. Biomedical Chromatography, 2009. 23(10): 
p. 1031-3. 
235. Kricka, L.J. and S.R. Master, Validation and quality control of protein 
microarray-based analytical methods. Mol Biotechnol, 2008. 38(1): p. 19-31. 
236. Kandasamy, K., et al., Bioanalytical method development, validation and 
quantification of flupirtine maleate in rat plasma by liquid chromatography-
tandem mass spectrometry. Arzneimittelforschung, 2011. 61(12): p. 693-9. 
237. Xue, Y.J., et al., An integrated bioanalytical method development and 
validation approach: case studies. Biomedical Chromatography, 2012. 
26(10): p. 1215-27. 
238. Gonzalez, A.G., M.A. Herrador, and A.G. Asuero, Intra-laboratory 
assessment of method accuracy (trueness and precision) by using validation 
standards. Talanta, 2010. 82(5): p. 1995-8. 
239. Bayley, D.L., et al., Validation of assays for inflammatory mediators in 
exhaled breath condensate. Eur Respir J, 2008. 31(5): p. 943-8. 
240. Tignon, M., et al., Development and inter-laboratory validation study of an 
improved new real-time PCR assay with internal control for detection and 
laboratory diagnosis of African swine fever virus. J Virol Methods, 2011. 
178(1-2): p. 161-70. 
241. Binsaeed, A.A., et al., A validation study comparing the sensitivity and 
specificity of the new Dr. KSU H1N1 RT-PCR kit with real-time RT-PCR for 
diagnosing influenza A (H1N1). Annals of Saudi Medicine, 2011. 31(4): p. 
351-5. 
242. Vessman, J., Selectivity or specificity? Validation of analytical methods from 
the perspective of an analytical chemist in the pharmaceutical industry. J 
Pharm Biomed Anal, 1996. 14(8-10): p. 867-9. 
243. Armbruster, D.A. and T. Pry, Limit of blank, limit of detection and limit of 
quantitation. Clin Biochem Rev, 2008. 29 Suppl 1: p. S49-52. 
Bibliography 
 
~ 253 ~ 
 
244. Choi, D.H., et al., Validation of a method for predicting the precision, limit of 
detection and range of quantitation in competitive ELISA. Anal Sci, 2007. 
23(2): p. 215-8. 
245. Anderson, M., et al., Evaluation of Multiplex Immunoassay Results. Genetic 
Engineering & Biotechnology News, 2011. 31(8): p. 24-25. 
246. Fang, L., et al., Estimating area under the curve and relative exposure in a 
pharmacokinetic study with data below quantification limit. J Biopharm Stat, 
2011. 21(1): p. 66-76. 
247. Guo, Y., O. Harel, and R.J. Little, How well quantified is the limit of 
quantification? Epidemiology, 2010. 21 Suppl 4: p. S10-6. 
248. Bergstrand, M. and M.O. Karlsson, Handling data below the limit of 
quantification in mixed effect models. AAPS J, 2009. 11(2): p. 371-80. 
249. Wang, X., S. Ghosh, and S.W. Guo, Quantitative quality control in 
microarray image processing and data acquisition. Nucleic Acids Res, 2001. 
29(15): p. E75-5. 
250. Petrov, A.S., S, Microarray Image Processing and Quality Control. Journal 
of VLSI Signal Processing, 2004. 38: p. 211-226. 
251. Koutsokera, A., et al., Systemic biomarkers in exacerbations of COPD: the 
evolving clinical challenge. Chest, 2012. 141(2): p. 396-405. 
252. Al-shair, K., et al., Biomarkers of systemic inflammation and depression and 
fatigue in moderate clinically stable COPD. Respir Res, 2011. 12: p. 3. 
253. Cazzola, M. and G. Novelli, Biomarkers in COPD. Pulm Pharmacol Ther, 
2010. 23(6): p. 493-500. 
254. Gong, P., G.M. Harbers, and D.W. Grainger, Multi-technique comparison of 
immobilized and hybridized oligonucleotide surface density on commercial 
amine-reactive microarray slides. Anal Chem, 2006. 78(7): p. 2342-51. 
255. Lv, L.L., et al., Construction of an antibody microarray based on agarose-
coated slides. Electrophoresis, 2007. 28(3): p. 406-13. 
256. Cretich, M., et al., High sensitivity protein assays on microarray silicon 
slides. Anal Chem, 2009. 81(13): p. 5197-203. 
257. Darr, C.M., et al., A comparative evaluation of microarray slides as 
substrates for the development of protease assay biosensors. Exp Mol Pathol, 
2011. 91(3): p. 714-7. 
258. Moran-Mirabal, J.M., et al., Controlling microarray spot morphology with 
polymer liftoff arrays. Anal Chem, 2007. 79(3): p. 1109-14. 
259. Rimini, R., et al., Validation of serum protein profiles by a dual antibody 
array approach. J Proteomics, 2009. 73(2): p. 252-66. 
260. Metwalli, E., et al., Surface characterizations of mono-, di-, and tri-
aminosilane treated glass substrates. J Colloid Interface Sci, 2006. 298(2): p. 
825-31. 
261. Wu, Q.H., et al., [Oligonucleotide microarray preparation using enhanced 
poly-L-lysine glass slides]. Di Yi Jun Yi Da Xue Xue Bao, 2004. 24(11): p. 
1236-41. 
262. Liu, Y., et al., Neoglycolipid-based oligosaccharide microarray system: 
preparation of NGLs and their noncovalent immobilization on nitrocellulose-
coated glass slides for microarray analyses. Methods Mol Biol, 2012. 808: p. 
117-36. 
263. Subramaniam, R., et al., A multivalent Mannheimia-Bibersteinia vaccine 
protects bighorn sheep against Mannheimia haemolytica challenge. Clin 
Vaccine Immunol, 2011. 18(10): p. 1689-94. 
Bibliography 
 
~ 254 ~ 
 
264. Price, K.E., N.G. Greene, and A. Camilli, Export requirements of 
pneumolysin in Streptococcus pneumoniae. J Bacteriol, 2012. 194(14): p. 
3651-60. 
265. Wu, P. and D.W. Grainger, Comparison of hydroxylated print additives on 
antibody microarray performance. J Proteome Res, 2006. 5(11): p. 2956-65. 
266. Preininger, C., et al., Optimizing processing parameters for signal 
enhancement of oligonucleotide and protein arrays on ARChip Epoxy. 
Bioelectrochemistry, 2005. 67(2): p. 155-62. 
267. Momose, Y., et al., Comparative analysis of transcriptional responses to the 
cryoprotectants, dimethyl sulfoxide and trehalose, which confer tolerance to 
freeze-thaw stress in Saccharomyces cerevisiae. Cryobiology, 2010. 60(3): p. 
245-61. 
268. Sauer, U., L. Bodrossy, and C. Preininger, Evaluation of substrate 
performance for a microbial diagnostic microarray using a four parameter 
ranking. Anal Chim Acta, 2009. 632(2): p. 240-6. 
269. Yu, L., et al., High-performance UV-curable epoxy resin-based microarray 
and microfluidic immunoassay devices. Biosens Bioelectron, 2009. 24(10): p. 
2997-3002. 
270. Giraud, G., et al., Fluorescence lifetime imaging of quantum dot labeled DNA 
microarrays. Int J Mol Sci, 2009. 10(4): p. 1930-41. 
271. Jia, M., et al., Development of a sensitive microarray immunoassay for the 
quantitative analysis of neuropeptide Y. Anal Chem, 2012. 84(15): p. 6508-
14. 
272. Pollack, J.R., DNA microarray technology. Introduction. Methods Mol Biol, 
2009. 556: p. 1-6. 
273. Sip, M., et al., Detection of viral infections by an oligonucleotide microarray. 
J Virol Methods, 2010. 165(1): p. 64-70. 
274. Redkar, R.J., et al., Signal and sensitivity enhancement through optical 
interference coating for DNA and protein microarray applications. J Biomol 
Tech, 2006. 17(2): p. 122-30. 
275. Balboni, I., et al., Evaluation of microarray surfaces and arraying parameters 
for autoantibody profiling. Proteomics, 2008. 8(17): p. 3443-9. 
276. Kimura, N., et al., Site-specific, covalent attachment of poly(dT)-modified 
peptides to solid surfaces for microarrays. Bioconjug Chem, 2007. 18(6): p. 
1778-85. 
277. Tomizaki, K.Y., K. Usui, and H. Mihara, Protein-protein interactions and 
selection: array-based techniques for screening disease-associated 
biomarkers in predictive/early diagnosis. FEBS J, 2010. 277(9): p. 1996-
2005. 
278. Garcia, B.H., 2nd, et al., Antibody microarray analysis of inflammatory 
mediator release by human leukemia T-cells and human non small cell lung 
cancer cells. J Biomol Tech, 2007. 18(4): p. 245-51. 
279. Bohm, D., et al., Antibody microarray analysis of the serum proteome in 
primary breast cancer patients. Cancer Biol Ther, 2011. 12(9): p. 772-9. 
280. Kusnezow, W., et al., Antibody microarrays: an evaluation of production 
parameters. Proteomics, 2003. 3(3): p. 254-64. 
281. Cho, E.J., et al., Optimization of aptamer microarray technology for multiple 
protein targets. Anal Chim Acta, 2006. 564(1): p. 82-90. 
282. Karoonuthaisiri, N., et al., Development of antibody array for simultaneous 
detection of foodborne pathogens. Biosens Bioelectron, 2009. 24(6): p. 1641-
8. 
Bibliography 
 
~ 255 ~ 
 
283. Kuno, A., et al., Focused differential glycan analysis with the platform 
antibody-assisted lectin profiling for glycan-related biomarker verification. 
Mol Cell Proteomics, 2009. 8(1): p. 99-108. 
284. Lian, W., et al., Sensitive detection of multiplex toxins using antibody 
microarray. Anal Biochem, 2010. 401(2): p. 271-9. 
285. Longo, C., et al., A novel biomarker harvesting nanotechnology identifies Bak 
as a candidate melanoma biomarker in serum. Exp Dermatol, 2011. 20(1): p. 
29-34. 
286. Signore, M. and K.A. Reeder, Antibody validation by Western blotting. 
Methods Mol Biol, 2012. 823: p. 139-55. 
287. Aguilar-Mahecha, A., et al., Development of reverse phase protein 
microarrays for the validation of clusterin, a mid-abundant blood biomarker. 
Proteome Sci, 2009. 7: p. 15. 
288. Espina, V., et al., Reverse phase protein microarrays for monitoring 
biological responses. Methods Mol Biol, 2007. 383: p. 321-36. 
289. Gallagher, R.I., et al., Reverse phase protein microarrays: fluorometric and 
colorimetric detection. Methods Mol Biol, 2011. 723: p. 275-301. 
290. Pierobon, M., et al., Reverse-phase protein microarrays. Methods Mol Biol, 
2012. 823: p. 215-35. 
291. Zhou, H., et al., Two-color, rolling-circle amplification on antibody 
microarrays for sensitive, multiplexed serum-protein measurements. Genome 
Biol, 2004. 5(4): p. R28. 
292. Chen, Q., et al., Amplified in breast cancer 1 enhances human 
cholangiocarcinoma growth and chemoresistance by simultaneous activation 
of Akt and Nrf2 pathways. Hepatology, 2012. 55(6): p. 1820-9. 
293. MacBeath, G. and S.L. Schreiber, Printing proteins as microarrays for high-
throughput function determination. Science, 2000. 289(5485): p. 1760-3. 
294. Iwaki, K. and Y. Hayashi, [Method for estimating the precision and detection 
limit for ELISA]. Nihon Yakurigaku Zasshi, 2009. 134(4): p. 207-11. 
295. van den Heuvel, E., Estimation of the limit of detection for quantal response 
bioassays. Pharm Stat, 2011. 10(3): p. 203-12. 
296. Huang, S., T. Wang, and M. Yang, The Evaluation of Statistical Methods for 
Estimating the Lower Limit of Detection. Assay Drug Dev Technol, 2012. 
297. Longford, N.T., Handling the limit of detection by extrapolation. Stat Med, 
2012. 31(26): p. 3133-46. 
298. Xue, Y.J., et al., An integrated bioanalytical method development and 
validation approach: case studies. Biomed Chromatogr, 2012. 26(10): p. 
1215-27. 
299. JG, W., Protein Microarrays: Reduced Autoflourescence and improved LOD. 
ENG Life Sci, 2010. 10(2): p. 103-108. 
300. Kricka, L.J., Interferences in immunoassay--still a threat. Clin Chem, 2000. 
46(8 Pt 1): p. 1037-8. 
301. Martins, T.B., et al., Heterophile antibody interference in a multiplexed 
fluorescent microsphere immunoassay for quantitation of cytokines in human 
serum. Clin Diagn Lab Immunol, 2004. 11(2): p. 325-9. 
302. Tate, J. and G. Ward, Interferences in immunoassay. Clin Biochem Rev, 
2004. 25(2): p. 105-20. 
303. Pfleger, C., N. Schloot, and F. ter Veld, Effect of serum content and diluent 
selection on assay sensitivity and signal intensity in multiplex bead-based 
immunoassays. J Immunol Methods, 2008. 329(1-2): p. 214-8. 
Bibliography 
 
~ 256 ~ 
 
304. Valentin, M.A., et al., Validation of immunoassay for protein biomarkers: 
bioanalytical study plan implementation to support pre-clinical and clinical 
studies. J Pharm Biomed Anal, 2011. 55(5): p. 869-77. 
305. Ellington, A.A., et al., Measurement and quality control issues in multiplex 
protein assays: a case study. Clin Chem, 2009. 55(6): p. 1092-9. 
306. Wood, B.A., et al., Microsphere immunoassay for the detection of cytokines in 
domestic cat (Felis catus) plasma: elevated IL-12/23 in acute feline 
immunodeficiency virus infections. Vet Immunol Immunopathol, 2012. 145(3-
4): p. 604-10. 
307. Binnicker, M.J., D.J. Jespersen, and J.A. Harring, Evaluation of three 
multiplex flow immunoassays compared to an enzyme immunoassay for the 
detection and differentiation of IgG class antibodies to herpes simplex virus 
types 1 and 2. Clin Vaccine Immunol, 2010. 17(2): p. 253-7. 
308. Dietrich, H., et al., Safety, tolerability, and pharmacokinetics of a single dose 
of pasireotide long-acting release in healthy volunteers: a single-center Phase 
I study. Eur J Endocrinol, 2012. 166(5): p. 821-8. 
309. Elshal, M.F. and J.P. McCoy, Multiplex bead array assays: performance 
evaluation and comparison of sensitivity to ELISA. Methods, 2006. 38(4): p. 
317-23. 
310. Leng, S.X., et al., ELISA and multiplex technologies for cytokine 
measurement in inflammation and aging research. J Gerontol A Biol Sci Med 
Sci, 2008. 63(8): p. 879-84. 
311. Knight, P.R., et al., Development of a sensitive microarray immunoassay and 
comparison with standard enzyme-linked immunoassay for cytokine analysis. 
Shock, 2004. 21(1): p. 26-30. 
312. Viegi, G., et al., Definition, epidemiology and natural history of COPD. Eur 
Respir J, 2007. 30(5): p. 993-1013. 
313. Espinosa de los Monteros, M.J., et al., Variability of respiratory symptoms in 
severe COPD. Arch Bronconeumol, 2012. 48(1): p. 3-7. 
314. Tashkin, D.P., et al., Lung function and respiratory symptoms in a 1-year 
randomized smoking cessation trial of varenicline in COPD patients. Respir 
Med, 2011. 105(11): p. 1682-90. 
315. Agusti, A., et al., Night-time symptoms: a forgotten dimension of COPD. Eur 
Respir Rev, 2011. 20(121): p. 183-94. 
316. Voll-Aanerud, M., et al., Respiratory symptoms in adults are related to 
impaired quality of life, regardless of asthma and COPD: results from the 
European community respiratory health survey. Health Qual Life Outcomes, 
2010. 8: p. 107. 
317. Celli, B.R., et al., Predictors of Survival in COPD: more than just the FEV1. 
Respir Med, 2008. 102 Suppl 1: p. S27-35. 
318. van Dijk, W.D. and T.R. Schermer, Change in FEV1 over time in COPD. N 
Engl J Med, 2011. 365(26): p. 2540; author reply 2541. 
319. Celli, B.R. and R.J. Halbert, Point: should we abandon FEV(1)/FVC <0.70 to 
detect airway obstruction? No. Chest, 2010. 138(5): p. 1037-40. 
320. Mohamed Hoesein, F.A., P. Zanen, and J.W. Lammers, Lower limit of normal 
or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review. Respir 
Med, 2011. 105(6): p. 907-15. 
321. Kent, B.D., P.D. Mitchell, and W.T. McNicholas, Hypoxemia in patients with 
COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulmon 
Dis, 2011. 6: p. 199-208. 
Bibliography 
 
~ 257 ~ 
 
322. Krieger, A.C., et al., Respiratory disturbance during sleep in COPD patients 
without daytime hypoxemia. Int J Chron Obstruct Pulmon Dis, 2007. 2(4): p. 
609-15. 
323. Vonk-Noordegraaf, A., et al., Early changes of cardiac structure and function 
in COPD patients with mild hypoxemia. Chest, 2005. 127(6): p. 1898-903. 
324. Sabit, R., et al., The effects of hypoxia on markers of coagulation and systemic 
inflammation in patients with COPD. Chest, 2010. 138(1): p. 47-51. 
325. Burtscher, M., et al., Intermittent hypoxia increases exercise tolerance in 
patients at risk for or with mild COPD. Respir Physiol Neurobiol, 2009. 
165(1): p. 97-103. 
326. Blasi, F. and E.E. Guffanti, Chronic obstructive pulmonary disease in the 
elderly: identifying the knowledge gaps to support research and clinical 
practice guidelines. Curr Opin Pulm Med, 2011. 17 Suppl 1: p. S55. 
327. Incalzi, R.A., et al., From Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) guidelines to current clinical practice : an overview of the 
pharmacological therapy of stable chronic obstructive pulmonary disorder. 
Drugs Aging, 2006. 23(5): p. 411-20. 
328. Pierson, D.J., Clinical practice guidelines for chronic obstructive pulmonary 
disease: a review and comparison of current resources. Respir Care, 2006. 
51(3): p. 277-88. 
329. Tusher, V.G., R. Tibshirani, and G. Chu, Significance analysis of microarrays 
applied to the ionizing radiation response. Proc Natl Acad Sci U S A, 2001. 
98(9): p. 5116-21. 
330. Jee, Y., et al., Upregulation of monocyte chemotactic protein-1 and CC 
chemokine receptor 2 in the central nervous system is closely associated with 
relapse of autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol, 
2002. 128(1-2): p. 49-57. 
331. Deshmane, S.L., et al., Monocyte chemoattractant protein-1 (MCP-1): an 
overview. J Interferon Cytokine Res, 2009. 29(6): p. 313-26. 
332. de Boer, W.I., et al., Monocyte chemoattractant protein 1, interleukin 8, and 
chronic airways inflammation in COPD. J Pathol, 2000. 190(5): p. 619-26. 
333. Tanino, M., et al., Increased levels of interleukin-8 in BAL fluid from smokers 
susceptible to pulmonary emphysema. Thorax, 2002. 57(5): p. 405-11. 
334. Matsuura, H., et al., Elevation of plasma eotaxin levels in children with food 
allergy. Nihon Rinsho Meneki Gakkai Kaishi, 2009. 32(3): p. 180-5. 
335. Williams, T.J. and P.J. Jose, Role of eotaxin and related CC chemokines in 
allergy and asthma. Chem Immunol, 2000. 78: p. 166-77. 
336. Zietkowski, Z., et al., Eotaxin-1 in exhaled breath condensate of stable and 
unstable asthma patients. Respir Res, 2010. 11: p. 110. 
337. Krisiukeniene, A., et al., Smoking affects eotaxin levels in asthma patients. J 
Asthma, 2009. 46(5): p. 470-6. 
338. Paplinska, M., H. Grubek-Jaworska, and R. Chazan, [Role of eotaxin in the 
pathophysiology of asthma]. Pneumonol Alergol Pol, 2007. 75(2): p. 180-5. 
339. Hemelaers, L. and R. Louis, [Eotaxin: an important chemokine in asthma]. 
Rev Med Liege, 2006. 61(4): p. 223-6. 
340. Sabroe, I., et al., Differential regulation of eosinophil chemokine signaling via 
CCR3 and non-CCR3 pathways. J Immunol, 1999. 162(5): p. 2946-55. 
341. Ferland, C., et al., IL-16 activates plasminogen-plasmin system and promotes 
human eosinophil migration into extracellular matrix via CCR3-chemokine-
mediated signaling and by modulating CD4 eosinophil expression. J 
Immunol, 2004. 173(7): p. 4417-24. 
Bibliography 
 
~ 258 ~ 
 
342. Petrescu, F., S.C. Voican, and I. Silosi, Tumor necrosis factor-alpha serum 
levels in healthy smokers and nonsmokers. Int J Chron Obstruct Pulmon Dis, 
2010. 5: p. 217-22. 
343. Franciosi, L.G., et al., Markers of exacerbation severity in chronic obstructive 
pulmonary disease. Respir Res, 2006. 7: p. 74. 
344. Pitsiou, G., et al., Tumor necrosis factor-alpha serum levels, weight loss and 
tissue oxygenation in chronic obstructive pulmonary disease. Respir Med, 
2002. 96(8): p. 594-8. 
345. Singh, B., S. Arora, and V. Khanna, Association of severity of COPD with IgE 
and interleukin-1 beta. Monaldi Arch Chest Dis, 2010. 73(2): p. 86-7. 
346. He, J.Q., et al., Associations of IL6 polymorphisms with lung function decline 
and COPD. Thorax, 2009. 64(8): p. 698-704. 
347. Sharma, G., N.A. Hanania, and Y.M. Shim, The aging immune system and its 
relationship to the development of chronic obstructive pulmonary disease. 
Proc Am Thorac Soc, 2009. 6(7): p. 573-80. 
348. Akdis, C.A. and K. Blaser, Mechanisms of interleukin-10-mediated immune 
suppression. Immunology, 2001. 103(2): p. 131-6. 
349. Taylor, A., et al., Mechanisms of immune suppression by interleukin-10 and 
transforming growth factor-beta: the role of T regulatory cells. Immunology, 
2006. 117(4): p. 433-42. 
350. Doe, C., et al., Expression of the T helper 17-associated cytokines IL-17A and 
IL-17F in asthma and COPD. Chest, 2010. 138(5): p. 1140-7. 
351. Miossec, P., IL-17 and Th17 cells in human inflammatory diseases. Microbes 
Infect, 2009. 11(5): p. 625-30. 
352. Korn, T., et al., IL-17 and Th17 Cells. Annu Rev Immunol, 2009. 27: p. 485-
517. 
353. Zhang, J., et al., Increased expression of CD4(+)IL-17(+) cells in the lung 
tissue of patients with stable chronic obstructive pulmonary disease (COPD) 
and smokers. Int Immunopharmacol, 2013. 15(1): p. 58-66. 
354. Oppmann, B., et al., Novel p19 protein engages IL-12p40 to form a cytokine, 
IL-23, with biological activities similar as well as distinct from IL-12. 
Immunity, 2000. 13(5): p. 715-25. 
355. Hirahara, K., et al., Signal transduction pathways and transcriptional 
regulation in Th17 cell differentiation. Cytokine Growth Factor Rev, 2010. 
21(6): p. 425-34. 
356. Ivanov, II, L. Zhou, and D.R. Littman, Transcriptional regulation of Th17 cell 
differentiation. Semin Immunol, 2007. 19(6): p. 409-17. 
357. Gosens, R., et al., Muscarinic receptor signaling in the pathophysiology of 
asthma and COPD. Respir Res, 2006. 7: p. 73. 
358. Pera, T., et al., Cigarette smoke and lipopolysaccharide induce a proliferative 
airway smooth muscle phenotype. Respir Res, 2010. 11: p. 48. 
359. Baraldo, S., et al., Neutrophilic infiltration within the airway smooth muscle 
in patients with COPD. Thorax, 2004. 59(4): p. 308-12. 
360. Kierszniewska-Stepien, D., et al., Serum vascular endothelial growth factor 
and its receptor level in patients with chronic obstructive pulmonary disease. 
Eur Cytokine Netw, 2006. 17(1): p. 75-9. 
361. Smith, D.J., et al., Reduced soluble receptor for advanced glycation end-
products in COPD. Eur Respir J, 2011. 37(3): p. 516-22. 
362. Greaves, L.J. and L.A. Richardson, Tobacco use, women, gender, and chronic 
obstructive pulmonary disease: are the connections being adequately made? 
Proc Am Thorac Soc, 2007. 4(8): p. 675-9. 
Bibliography 
 
~ 259 ~ 
 
363. Rahmanian, S.D., P.T. Diaz, and M.E. Wewers, Tobacco use and cessation 
among women: research and treatment-related issues. J Womens Health 
(Larchmt), 2011. 20(3): p. 349-57. 
364. Punturieri, A., et al., Lung cancer and chronic obstructive pulmonary disease: 
needs and opportunities for integrated research. J Natl Cancer Inst, 2009. 
101(8): p. 554-9. 
365. Rosi, E. and G. Scano, Cigarette smoking and dyspnea perception. Tob Induc 
Dis, 2004. 2(1): p. 35-42. 
366. Celli, B., et al., Sex differences in mortality and clinical expressions of 
patients with chronic obstructive pulmonary disease. The TORCH experience. 
Am J Respir Crit Care Med, 2011. 183(3): p. 317-22. 
367. Fletcher, C.P., R, The natural history of chronic bronchitis and emphysema. 
New York: Oxford, 1976. Pr. 
368. Barnes, P.J. and M.G. Cosio, Characterization of T lymphocytes in chronic 
obstructive pulmonary disease. PLoS Med, 2004. 1(1): p. e20. 
369. Spurrell, J.C., et al., Human airway epithelial cells produce IP-10 (CXCL10) 
in vitro and in vivo upon rhinovirus infection. Am J Physiol Lung Cell Mol 
Physiol, 2005. 289(1): p. L85-95. 
370. Tanni, S.E., et al., Smoking status and tumor necrosis factor-alpha mediated 
systemic inflammation in COPD patients. J Inflamm (Lond), 2010. 7: p. 29. 
371. Dentener, M.A., et al., Differences in local versus systemic TNFalpha 
production in COPD: inhibitory effect of hyaluronan on LPS induced blood 
cell TNFalpha release. Thorax, 2006. 61(6): p. 478-84. 
372. Sarioglu, N., et al., Relationship between BODE index, quality of life and 
inflammatory cytokines in COPD patients. Multidiscip Respir Med, 2010. 
5(2): p. 84-91. 
373. Kusnezow, W., et al., Antibody microarray-based profiling of complex 
specimens: systematic evaluation of labeling strategies. Proteomics, 2007. 
7(11): p. 1786-99. 
374. Miller, J.C., et al., Antibody microarray profiling of human prostate cancer 
sera: antibody screening and identification of potential biomarkers. 
Proteomics, 2003. 3(1): p. 56-63. 
375. Meany, D.L., et al., Tyramide signal amplification for antibody-overlay lectin 
microarray: a strategy to improve the sensitivity of targeted glycan profiling. 
J Proteome Res, 2011. 10(3): p. 1425-31. 
376. Chan, S.M., et al., Protein microarrays for multiplex analysis of signal 
transduction pathways. Nat Med, 2004. 10(12): p. 1390-6. 
377. Affymetrix, I., Assay Qualifications. 
http://www.panomics.com/products/luninex-assays/index.php?id=product_64, 
2012. 
 
 
